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Atopy is a disorder with strong familial tendency, starting usually in childhood or 
adolescence when patients become sensitized and produce IgE antibodies in response to 
ordinary allergens. However, the complex mechanisms of inheritance, from genetic 
predisposition of atopy to atopic (allergic) diseases, are still incompletely understood. 
Many candidate genes have been identified using positional cloning and/or candidate 
gene techniques. Recent data suggest that the pathogenesis of atopic diseases is complex 
and might be caused by gene-gene and/or gene-environmental interactions.  
 
This study aimed to investigate the association between candidate gene polymorphisms 
and atopic phenotypes in the Singapore population of Chinese (n=331), Malay (n=51) 
and Asian Indian (n=101) ethnic backgrounds. Further, transcriptional activity of some 
polymorphisms was investigated using a reporter gene assay system, in order to 
determine whether these polymorphisms affect candidate gene function. 
 
In this study, we were able to detect the polymorphisms on the CD14 promoter at 
positions -159, -550, -1145, and -1359; the IL-4 promoter at -590; the IL-18 5’ non-
trancription region at positions -137, +113 and +127; and the β2-adrenergic receptor 
(B2AR) at the amino acid positions 16 and 27 (Arg16Gly and Gln27Glu) in all three 
ethnic groups. There was strong linkage disequilibrium in the CD14 and IL-18 
polymorphisms. In the Chinese, a novel polymorphism (CD14/-550) was identified, 
however, the two commonly reported polymorphisms on Toll-like receptor 4 (TLR-4) at 
the amino acid positions 299 and 399 (Asp299Gly and Thr399Ile) were not observed. 
 viii
The results showed that there exist obvious ethnic differences in the allele frequencies of 
the various polymorphisms on candidate genes, such as: TLR-4, IL-4 and B2AR. No 
association was observed between all polymorphisms evaluated and atopy-related 
phenotypes, e.g. total IgE (tIgE) levels and allergic rhinitis and asthma, except 
association between CD14 polymorphisms and allergic asthma in Malays. 
 
The influence of polymorphisms on CD14 promoter and IL-18 5’ non-trancription region 
on transcriptional activity were investigated by reporter assay in different cell-lines 
(THP-1, U937, HepG2 and HeLa). The results showed that polymorphisms on the CD14 
promoter did not show any obvious effects on its transcriptional activity. On the contrary, 
polymorphisms on the IL-18 5’ non-trancription region were found to influence 
transcription activity.  
 
This study reports no association between some reported polymorphisms of candidate 
genes in patients with atopy and allergic diseases in Singapore population. One could 
argue that it is due to the possible difference in the study population, this clearly indicate 
that predisposition to atopy is influenced by complex immune processes, including 
interactions of multiple genes, interactions of environmental and genetic factors and 
population heterogeneity. Future studies would be needed to identify the key genes for 
atopic phenotypes and to investigate the interactions between genetic and environmental 
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 CHAPTER 1 
INTRODUCTION 
 
Atopic diseases represent a global health problem due to their increasing high prevalence, 
especially in industrialized countries. Although environmental factors play important 
roles, there is a strong genetic predisposition in the development of atopy and atopic 
diseases (Mackay and Rosen, 2001; Arshad, 2002; Marshall, 2004). 
 
1.1 Definition of atopy and atopic diseases  
1.1.1 Atopy 
Allergy is an inappropriate and harmful response to a normally harmless substance and is 
usually caused by proteins, called allergens, including pollens, dust mites, animal dander, 
food and so on. Atopy is a kind of allergy which refers to an inherited predisposition to 
produce IgE antibodies (Arshad, 2002). The term “atopy” comes from the Greek word 
Atopos which means “out of place”. Atopy is thus defined as a personal or familial 
tendency to produce IgE antibodies in response to low doses of allergens, usually proteins, 
and to develop typical symptoms such as asthma, rhinoconjunctivitis or eczema 
(Johansson et al., 2001; Roitt and Delves, 2001). Although these allergens target different 
organs, in most patients they are characterized by elevated total IgE levels. At least 25-
30% of the population is atopic (Arshad, 2002). But the existence of atopy may or may 
not lead to development of atopic diseases including asthma, allergic rhinitis, and atopic 
dermatitis. Genes and environment factors both play an important role in development of 
these diseases.  
 2 
 
According to the definition from “Revised Nomenclature of Allergy for Global Use” 
made by the World Allergy Organization in October 2003, the term, atopy, should be 
revised to describe the genetic predisposition to become Ig-E sensitized to allergens 
commonly occurring in the environment, and cannot be used until an IgE sensitization 
has been documented by IgE-antibodies in serum or by a positive skin prick test 
Johansson et al., 2004). In our study, we defined the atopy according to the   specific 
serum IgE (sIgE) to five common antigens, namely Bermuda grass (G2), Aspergillus 
fumigatus (M3), Blatella germanica (Cockroach) (I16), Dermatophagoides pteronyssinus 
(house dust mite) (D1) and Dermatophagoides farinea (house dust mite)  (D2). Subjects 
were classified into atopic and non-atopc groups on the basis of serum specific IgE (sIgE) 
levels. Subjects with sIgE levels equal or more than 0.35 ku/l to at least one of the 
inhalant allergens belonged to the atopic group, and the others belonged to the non-atopic 
group.  
 
In one word, atopy was defined as a positive skin prick test (SPT) or a positive serum 
specific IgE (equal or more than 0.35U/ml) to at least one of the common inhalant 
allergens tested. 
 
1.1.2 Allergic rhinitis 
Allergic rhinitis is associated with an excessive generation of specific IgE and 
characterized by one or more of the following symptoms: anterior nasal symptoms of 
pruritus, sneeze, discharge and stuffiness, and an associated loss of sense of smell and 
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inability to taste. These symptoms may be present for part of the year or throughout the 
year (Bradley and Mccuskey, 1997; Howarth, 1999).  
There are two basic forms of allergic rhinitis: seasonal and perennial. Seasonal allergic 
rhinitis, also known as hay fever, is triggered by allergy to pollens, including trees in 
spring, grasses in summer and weeds in fall. As to perennial rhinitis (year-round), the 
triggers include indoor allergens such as mold, house dust mite, cockroach and animal 
dander. The symptoms are the same as those of seasonal allergic rhinitis but are 
experienced throughout the year (Roecken et al., 2004). Allergic rhinitis can occur at any 
age and affects approximately 20% of the young population (Bradley and Mccluskey, 
1997). 
In one word, rhinitis was defined as the occurrence of two or more symptoms (nasal 
obstruction, rhinorrhea, sneezing and itchy nose) on most days during the past year 
(Bousquet et al., 2001). Allergic rhinitis was defined if atopy coexisted.  
1.1.3 Allergic asthma 
The condition termed asthma is difficult to define satisfactorily. The difficulty arises 
from poor understanding of its causes, pathophysiology, and also a lack of a specific 
marker of the disease. Asthma is currently defined as a “chronic inflammatory disorder of 
the airways in which many cells and cellular elements play a role, in particular mast cells, 
eosinophils, T-lymphocytes, macrophages, neutrophils and epithelial cells.” Asthma is 
characterized by a reversible airflow obstruction and airway inflammation, persistent 
airway hyperreactivity and airway remodeling (National Institutes of Health, 1997). For 
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susceptible individuals, this inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in early morning. 
The diagnosis of asthma is based on typical clinical features and pulmonary function 
testings (Bradley and Mccluskey, 1997; Arshad, 2002).  
Asthma may be roughly divided into atopic and non-atopic asthma. Although there is 
considerable overlap, childhood asthma is usually associated with atopy whereas adult-
onset asthma often arises in non-atopic individuals (Bradley and Mccluskey, 1997). The 
prevalence of asthma in childhood has been reported to be up to 40% in developed 
countries but as low as 3% in developing countries (Chung and Adcock, 2001). 
In one word, asthma was defined a history of paroxysmal attacks of breathlessness 
commonly associated with a tightness of the chest, wheezing, and asthma previously 
confirmed by a physician. Allergic asthma was defined if patients also had atopy 
(Johansson et al, 2004). 
1.1.4 Atopic dermatitis 
Atopic dermatitis, also called eczema, is a chronically relapsing inflammatory skin 
disease. It is characterized by itching, leading to scratching and excoriations. It was 
reported that as many as 50-75% of patients with eczema in early childhood would 
develop allergic rhinitis or asthma (Mygind et al., 1997). In our study, since we lacked 
information on subjects’ history of atopic dermatitis, we did not study the association 
between eczema and candidate genes.   . 
1.1.5 Relationship between atopy and atopic diseases 
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The relationship between atopic diseases and atopy is complicated. Both are inherited and 
possibly have the same susceptibility genes involved (Arshad, 2002). For example, atopy 
often precedes asthma and increases the risk of developing asthma 10-20 times (Holgate, 
1999).  
 
There are also close associations among atopic diseases.  For example, 75% of asthmatics 
have rhinitis and 20% to 40% of rhinitis patient suffer from asthma (Palma-Carlos et al., 
2001). In another epidemiological study, rhinitis was reported to occur in up to 80% of 
patients with asthma (Leynaert et al., 1999). Allergic rhinitis and allergic asthma are 
common respiratory diseases that often coexist and the allergic mechanisms in the two 
diseases have similar patterns. Both of them are associated with raised levels of IgE 
(Sherrill et al., 1999) and the concept of “one airway, one disease” has arisen.  
 
However not all rhinitis patients develop asthma and not all asthma patients with rhinitis, 
there are some difference between the two conditions. The first is about exposure to 
allergens: the nose being more exposed than the lower airways. The second is structural 
difference between the nasal and bronchial mucosa: the former has a large vascular 
supply whereas the latter has a smooth muscle. Airway smooth muscle is of paramount 
importance in asthma owing to its contractile properties, and it may also contribute to the 
expression and secretion of pro-inflammatory mediators and cytokines (Bousquet et al., 
2003). An initiative in collaboration with WHO termed Allergic Rhinitis and its Impact 
on Asthma (ARIA) has been developed to assess the relationship between asthma and 
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rhinitis (Bousquet et al., 2001). In this project, we studied disease candidate genes for 
allergic rhinitis and asthma together. 
 
1.2 Pathophysiology and immunology of atopy 
 
1.2.1 Basic concepts in immunology  
The word ‘immunity’ comes from the Latin term ‘immunis’, meaning ‘exempt’, which 
refers to all the mechanisms used by the body to protect against environmental agents. In 
vertebrates, immunity is divided into two major categories: innate immunity and acquired 
immunity (Benjamini et al., 2000;  Roitt and Delves, 2001).  
 
1.2.1.1 Innate immunity 
Innate immunity is present from birth and is relatively nonspecific. Many important 
nonspecific factors take part in innate immunity, including various physical barriers, 
chemical barriers and cellular components. For example: physical barriers first prevent 
the microorganisms from accessing the body, complements facilitate phagocytosis, and 
phagocytic cells kill microorganisms (Benjamini et al., 2000; Roitt and Delves, 2001).  
 
1.2.1.2 Acquired immunity  
Acquired immunity is more specialized than innate immunity. It is mediated by 
lymphocytes and characterized by antigen-specificity and memory. There are two 
branches of acquired immunity: humoral immunity and cellular immunity. Humoral 
immunity is mediated by serum antibodies which are the proteins secreted by the B cell. 
Cellular immunity consists of the T lymphocytes. There are several subpopulations of T 
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cells, e.g. T helper cells and T cytotoxic cells, which perform different functions 
(Benjamini et al., 2000; Roitt and Delves, 2001).  
 
1.2.2 Hypersensitivity  
However, under some circumstances, immune responses may produce damaging effects 
and such conditions are known as hypersensitivity or allergic reactions. Usually, 
hypersensitivity reactions are divided into the following five types: 
Type I: IgE-mediated reactions 
Type II: Cytotoxic reactions 
Type III: Immune complex reactions 
Type IV: Cell-mediated immunity reaction 
Type V: Stimulatory hypersensitivity 
Atopy and atopic diseases are mainly related to IgE-mediated reactions. There are 
harmful immune responses that may produce tissue injury and cause allergic diseases, 
including asthma, allergic rhinitis and eczema (Benjamini et al., 2000; Roitt and Delves, 
2001;).  
 
1.2.3 Pathophysiology of atopic diseases 
There are many various antigens in our living environment, such as grass pollens, house-
dust mites and animal dander. In general, the immune system just mounts a low-grade 
immunologic reaction and produces allergen-specific IgG1 and IgG4 in non-atopic 
person (Kemeny et al., 1989; Kay, 2001). By contrast, the condition will be completely 
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different if the person has predisposition to atopy. The pathophysiology of atopic diseases 
is described in the following four steps.  
 
1.2.3.1 Antigen presentation 
Acquired immunity is particularly important in atopic diseases. Allergens which enter the 
airway are processed by antigen presenting cells (APCs), e.g. dendritic cells, B cells and 
mononuclear phagocytes. The dendritic cells then move to the regional lymph nodes, 
where they act as APC to the B and T cells. Association of APC and T cells first involves 
non-specific binding through adhesion molecules, such as: intercellular adhesion 
molecule (ICAM) and lymphocyte function-associated antigen (LFA) interaction. In 
order to recognize the peptide antigen, T cell has receptors which are complementary to 
antigen-MHC complex and hence bind to it. The binding stimulates the antigen-
presenting cell to secrete interleukins required for T cell activation and performance. 
Before activated T cells set to work, they need B7 and CD28 as co-stimulatory molecules. 
Without co-stimulation, activated T cells fall into a state of unresponsiveness known as 
anergy. Overall, antigen presentation can be split into four stages: adhesion, antigen-
specific activation, co-stimulation and cytokine signaling (Roitt and Delves, 2001; Busse 
and Lemanske, 2001). 
 
1.2.3.2 T cell precursor differentiate into Th1 and Th2 
When antigen is presented to T cell, T cell precursor will differentiate into T helper type 
1 (Th1) or T helper type 2 (Th2) based on interactions with the microenvironment. In the 
presence of interleukin 12 (IL-12), interleukin 18 (IL-18), or i
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differentiates into Th1 cells. This evolution is mediated by a mechanism that depends on 
signal transducer and activator of transcription-1 (STAT-1) and the T-bet transcription 
factor. Whereas, in the presence of interleukin 4 (IL-4) (which comes from IgE-activated 
mast cells or DCs), or interleukin 13 (IL-13), Th2 cells are formed. This is a complex 
process that involves STAT-6–mediated signal transduction and the activation of a 
variety of transcription factors, including GATA-3, nuclear factor of activated T cells-c 
(NFATc), and c-maf (Roitt and Delves, 2001; Kay, 2001; Maddox and Schwartz, 2002).  
 
Typical human Th1 cytokines include IFN-γ, Tumor necross factor-β (TNF-β) and 
interleukin 2 (IL-2) and these Th1 cells promote the production of IgG 2α opsonizing and 
complement-fixing antibodies, macrophage activation, antibody-dependent cell-mediated 
cytotoxicity and delay-type hypersensitivity. Th2 are typified by the production of IL-4, 
IL-5, IL-6, IL-9, IL-10 and IL-13. These cells provide optimal help for humoral immune 
responses, including IgG1 and IgE isotype switching and mucosal immunity, stimulation 
of mast cell and eosinophil growth and differentiation and IgA synthesis. Thus, Th1 cells 
are associated with cell-mediated inflammatory reactions while Th2 cells associated with 
strong antibody and allergic reactions (Roitt and Delves, 2001). Therefore, the balance 
between Th1 and Th2 may be important in affecting the level of IgE which is essential 
for atopic diseases. 
 
1.2.3.3 Production of allergen-specific IgE antibodies 
Th2 type cytokines, such as IL-4 and IL-13, are important signals for differentiation of B 
cells to IgE-producing plasma cells (Kay, 2001; Hamelmann et al., 2002). This IgE is 
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released into the blood and quickly binds to either the high-affinity IgE receptors (FcεRI) 
on mast cells and Basophils or low-affinity IgE receptors (FCεRII or CD23) on 
lymphocytes, eosinophils, platelets and macrophages (Busse and Lemanske, 2001). 
 
1.2.3.4 IgE –mediated mast-cell activation and clinical manifestation 
Re-exposure of allergens leads to the binding of the specific allergen to IgE-FcεRI 
complexes on mast cells. This activates the signaling cascades and causes the release of 
preformed granules containing histamine, trypatase, chymase, eicosanoids, free radicals 
and preformed Th2-like cytokines. These granules are the mediators for the early IgE-
mediated reactions (Busse and Lemanske, 2001).  
 
On the other hand, the release of the inflammatory cytokines leads to the “late phase 
reaction”, which primarily involves the recruitment and activation of eosinophils, Th2 
cells, macrophages and neutrophils (Rothenberg, 1998). Once the late phase is initiated, 
eosinophages become one of the major mediators of chronic inflammation in allergic 
asthma (Maddox and Schwartz, 2002). 
 
In addition, interleukin 5 (IL-5) is the cytokine primarily responsible for the eosinophil 
differentiation. Once in the airways, eosinophils can release toxic granules that cause 
direct tissue damage, smooth muscle contraction and increased vascular permeability, and 
ultimately lead to the recruitment of more eosinophils and Th2 cells to airways (Maddox 
and Schwartz, 2002). 
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All these toxic granules released from mast cells or eosinophils in different tissues or 
organs in human induce different clinical manifestations of allergy, including: asthma, 
allergic rhinitis and atopic eczema. The summary of the whole pathophysiology of atopic 
diseases is shown in Figure 1. 
 
 
Figure 1: Summary of pathophysiology on atopic diseases. The four main steps include 
antigen presentation, Th1 and Th2 differentiation, IgE production and granules release. 
 
1.2.4 Candidate genes implicated in the pathophysiology of atopy 
Several candidate genes are believed to be implicated in the pathophysiology of atopic 
diseases. Mutation of the genes might affect the atopy-related phenotypes. The possible 
disease candidate genes can be divided into six categories: (1) Major histocompatibility 
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complex class II which affects effective presentation of allergens to T cells; (2) Cytokines 
which influence the balance of Th1 and Th2, including IL-4, IL-13, IL-12, IL-18, IFN-γ 
and so on; (3) Lipopolysaccharides (LPS) related factors, e.g. cluster of differentiation 14 
(CD14) and Toll-like receptor 4 (TLR4); (4) Specific receptors which may change  
affinity, e.g. T cell receptor, high-affinity IgE receptor, IL-4 receptor and β2-adrenergic 
receptor (β2AR); (5) Variations in IgE itself, e.g., IgE heavy-chain variants. (6) Others 
which are related with inflammation, e.g., Tumor necrosis factor α (TNF α), signal 
transducers and activators of transcription 6 (STAT-6) (Figure 1; Table 1 at the end of 
Chapter 1). 
 
1.3 Genetics of atopy 
Each human cell contains 46 (23 pairs of) chromosomes, including 22 pairs of autosomal 
chromosomes and two sex-specific chromosomes, X and Y (female XX and male XY). The 
haploid human genome consists approximately of 3×10
9 
base pairs. Only 3% to 10% of 
human genetic material codes for the estimated 40,000 human genes. Mutation in DNA 
sequence occurs once every 1900 bp or so (Sachidanandam et al., 2001). Mutations 
occurring in more than 1% of the population are called polymorphisms. Polymorphisms 
form the basis of human diversity, including human responses to environmental stimuli 
(Adkinson et al., 2003).  
 
Without any doubt, atopy is related to inheritance. It is also considered as a polygenic 
disease as several genes may be involved. Polymorphisms in the DNA sequences of genes 
may alter gene function. The genetics of atopy includes the following three aspects:  (1) 
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polygenic inheritance --- several genes may predispose the development of atopic diseases; 
(2) genetic heterogeneity --- different combinations of genes in different individuals; (3) 
environmental factors --- environment is necessary for expression of the disease phenotype 
(FitzGerald et al., 2001). In the following section, basic concepts in genetics and methods 
for studying genetic contribution to atopic diseases are presented and association studies on 
candidate genes in atopic diseases are summarized.  
 
1.3.1 Basic concepts in genetics used in the study 
1.3.1.1 Glossary of genetic terms  
Glossary of genetic terms used in this study is shown in the following (Lodish et al., 2000; 





In this study, we analysed polymorphisms on the promoters of candidate genes. Control 
of gene expression can be regulated at several levels: transcription, RNA process, RNA 
transport, mRNA degradation, translation and posttranslation by protein phosphorylation. 
The most common and important gene regulation is at the level of transcription (Wray 
GA, 2003; Johansson SG, 2003). Promoters are usually defined as those sequence 
 Allele: Allele is one of several alternative forms of a gene occupying a given locus on a chromosome. 
 
Candidate gene: A gene that has been implicated in causing or contributing to the development of a particular 
disease. 
 
 Gene: An individual unit of heredity. Gene is the segment of DNA involved in producing a polypeptide chain; it 
includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences 
(introns) between individual coding segments (exons). 
 
 Genome: Total genetic information carried by a cell or organism. 
 
 Genotype: Genotype is the genetic constitution of an organism. It also refers to the observed alleles at a genetic 
locus of an individual.  
 
 Haplotype: Hapotype is the particular combination of alleles in a defined region of some chromosome, in effect the 
genotype in miniature. In other words, Haplotype is the linear, ordered arrangement of alleles on a chromosome. 
 
 Heterozygote: A diploid organism with two distinguishable alleles at a particular locus. 
 
 Homozygote: A diploid organism with two identical alleles at a particular locus. 
 
 Linkage: Linkage describes the tendency of genes to be inherited together as a result of their location on the same 
chromosome; measured by percent recombination between loci. 
 
Linkage disequilibrium: Linkage disequilibrium describes a situation in which some combinations of genetic 
markers occur more or less frequently in the population than would be expected from their distance apart. It implies 
that a group of markers has been inherited coordinately. It can result from reduced recombination in the region or 
from a founder effect, in which there has been insufficient item to reach equilibrium since one of the markers was 
introduced into the population. 
 
 Mutation: mutation describes any change in the sequence of genomic DNA. 
 
 Phenotype: Phenotype is the appearance or other characteristics of an organism, resulting from the interaction of its 
genetic constitution with the environment. 
 
 Polymorphisms: polymorphism refers to the simultaneous occurrence in the population of genomes showing allelic 
variations. Loci at which there are two or more alleles that are each present at a frequency of at least 1% in the 
population. 
 
  Promoter: Promoter is a region of DNA involved in binding of RNA polymerase to initiate transcription. 
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elements 5’- of the gene that fix the site of transcription initiation and control mRNA 
quantity and sometimes tissue specificity. A promoter may extend for several kilobases, 
however, the important elements usually seem to be in the region about 300-400 bp of 
upstream from the transcription start site (King et al., 1992). A promoter is a specific 
sequence of nucleotides on the gene that informs the RNA polymerase where to begin 
transcribing. Transcription requires the interaction of RNA polymerase with promoter 
DNA. To incite transcription, the transcriptional factors on the promoter are required for 
the stabilization of binding of RNA polymerase to the promoter. Most of these 
transcription factors contain structural motifs, such as zinc finger or leucine zipper. 
Mutation in any one of the structural motifs may increase or decrease the risk of 
development for genetic diseases (King et al., 1992). 
 
1.3.2 Approaches to study the genetic components of atopy 
Familial concordance of atopy and atopic diseases could be explained by shared 
environment as well as shared genes. Several genetic epidemiology approaches are 
helpful in searching for genetic component in atopic diseases. Family study and twin 
study are useful steps in determining whether atopy and atopic diseases have genetic 
components, and segregation analysis is useful to determine the mode of inheritance. 
Currently, many family and twin studies have shown genetic predispositionin atopy and 
other atopic disorders. However, the mode of inheritance and contributing genes are 
unknown. 
1.3.2.1 Family study 
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Although familial aggregation of a disorder could be caused by either common 
environment within a family or genetic components, the genetic background of asthma 
and atopy can be derived using the prevalence of asthma or other atopic diseases in the 
general population and first-degree relatives of affected individuals (FitzGerald et al., 
2001). Many studies have shown that genetic factors influence the development of atopy 
and atopic diseases. For example: as early as 1976, Kauffman et al. showed that if neither 
parent had atopy,  the risk of atopy was 0-20%, if one of parents had atopy, the risk of 
atopy was 30-50% and if both parents had atopy, the risk of atopy increased to 60-100% 
(Kauffman and Frick,1976). Another study demonstrated a prevalence of 13% in first-
degree relatives of asthmatics and in contrast only 4% in the control group (Sibald et al., 
1980). These studies implied that atopy and asthma do cluster in families.  
 
1.3.2.2 Twin study 
Another method to determine whether familial aggregation is due to common genetic or 
common environmental factors is to compare the concordance rates of disease in 
monozygotic (MZ) and dizygotic (DZ) twin pairs. MZ twin pairs are genetically identical 
and DZ pairs are genetically like any pair of siblings. A higher concordance rate in MZ 
than in DZ twin pairs indicates that a significant part of the familial aggregation is due to 
genetic factors, and equal rates of concordance indicate the familial aggregation is 
determined largely be environmental factors (King et al., 1992). However, this method is 
based on the assumption that twins have shared common environment (Hall, 1996).  
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Twin studies provide useful information in the assessment of the contribution of genetic 
factors in atopic diseases. Many twin studies have demonstrated that atopic-related 
phenotypes, e.g. IgE, asthma and atopy, are under strong genetic control (Hopp et al., 
1984; Nieminen et al., 1991). For example, in 1984, Hopp RJ studied 61 pairs of MZ and 
46 pairs of DZ twins and reported that the intrapair correlation coefficient for IgE levels 
was 82% in MZ twins and 52% in DZ twins (Hopp et al., 1984). The twin studies indicate 
that between 30-50% of the risk of developing asthma and 60% of the risk of high total 
IgE may be due to genetic factors (King et al., 1992; Hall, 1996). Twin study also has 
shown a significant genetic component in the development of hay fever. The MZ twin 
pairs (probandwise concordance rate=60.3%, 95% CI =52-68%) were significantly more 
concordant for hay fever than were DZ twin pairs (31.5%, 95% CI=26-36%) (Rasanen et 
al., 1998). 
 
1.3.2.3 Segregation analysis 
Phenotypes with evidence for a genetic component are ofter further investigated by using 
segregation analysis. The mode of inheritance can be studied in family settings by means 
of segregation analysis. Segregation analysis is used to analyze the pattern of inheritance 
of a disorder by observing how the disease is distributed within families (Holgate and 
Halloway, 2002). Although many modes of inheritance of atopic diseases, e.g. dominant, 
recessive, co-dominant, polygenic models, have been demonstrated (Blumenthal et al., 
1981; Meyers et al., 1991; Martinez et al., 1994; Cook and Van der Veer, 1996), the 
model of inheritance for atopy and atopic diseases is still conflicting and unclear. 
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1.3.3 General strategies for defining susceptibility genes 
Atopic diseases are a complex disease, and many genes could be involved in the 
pathologic procedure. Identifying susceptibility genes for atopy has proved to be a 
diffcult task. There are a few approaches have been used in the search for the genes 
involved in atopic diseases, e.g. linakge anaysis, positional cloning, candidate genes and 
so on (Xu et al.1998; Rannala, 2001; Sudbery, 2002; Whittaker, 2003). All methods have 
their own respective advantages and disadvantages in identifying susceptibility genes for 
atopy, and successful identification of susceptibility genes for atopy is likely to depend 
on a combination of different methods.  
 
1.3.3.1 Linkage analysis 
Genetic linkage is a powful method to help to elucidate the genetic mechanisms for atopy 
and to find chromosomal locations for susceptibility genes. At present, there are two 
major categories of linkage analysis: one is parametric linkage analysis and the other one 
is non-parametric linkage analysis, also called allele-sharing methods (Ligget SB, 1997; 
Sudbery, 2002). Parametric linkage analysis requires the genetic model to be tested in 
which parameters for the mode of transmission, dominance, allele frequency ans so on, 
are specified. It is the most powerful means of mapping a susceptibility gene, but it only 
works when the genetic model is correct. In the complex disease, parameters analysis can 
be used for mapping the genes responsible for a subset of cases caused by alleles with a 
large effect segregating in a Mendelian fashion (Sudbery 2002). Unlike parametric 
linkage analysis, non-parametric analysis is not based on a specific disease model. It tests 
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whether the inheritance pattern of markers for a chromosome region is consistent with 
random Mendelian segregation (Ligget SB, 1997).  
 
1.3.3.2 Positional genetics approach 
 
One approach to identifying disease-causing genes involves searching the entire genome 
with a technique termed positional cloning (John et al., 2003). It is a process where 
linkage is established between diseases-associated phenotypes and highly polymorphic 
genetic markers, with increasing levels of precision for searching susceptibility genes 
without any prior knowledge of its function (Barnes et al., 2000). Identification of such a 
closely linked marker is then followed by “Chromosomal walking” until the exact 
mutation gene is found. Ofter candidate genes can be identified in this region, and their 
roles in the genetics of allergy can be determined (John et al., 2003). However, this 
approach has the disadvantage that the power to detect linkage in complex genetic 
diseases is very limited, and several thousand two-generation families may be necessary 
to detect a linkage to a gene which affects 10% of the subjects with disease (Moffatt and 
Cookson, 1998).  
 
1.3.3.3 Candidate gene approach 
 
Candidate gene approach refers to identification of polymorphisms within a gene of 
known function that influences atopic diseases (Anderson and Cookson, 1999). The 
choice of candidate gene itself requires knowledge of the biological relevance and the 
molecular basis of the diseases. In association studies, a particular gene is examined for 
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its variance in predicted frequency in population with and without the suspected 
syndrome. This method can confirm candidates but it ignores the contributions of other 
unknown and unbiased loci that may be important (Nieters et al., 2004). Recently, the 
structure of the human genome has been broken into haplotype block; these haplotype 
blocks can be incorporated into the association studies to enhance the power of genetic 
analysis (Nieters et al., 2004). 
 
Positive association may occur under three circumstances. (1) The allele is contributing to 
the phenotype. (2) There exists a population (ethnic) admixture. In order to avoid this 
admixture, we could divide the study subjects into ethnic groups. (3) Alleles are in 
linkage disequilibrium (Holgate and Holloway, 1999). That means that association may 
be found even if the polymorphisms do not alter the function of a gene due to linkage 
disequilibrium (Moffatt and Cookson, 1998). Although the candidate gene approach may 
have false positive association, it is still a useful method to identify the susceptibility 
genes for atopy and atopic diseases.     
 
1.4 Procedure in genetic research: susceptibility genes 
Genetic research for susceptibility gene of atopic diseases can be summarized as the 
following steps (Koppelman et al., 2001).  
 
1) The definition of atopic diseases. In genetics study, the right definition is especially 
important. If the definition well reflects gene functions, the opportunity for successfully 
finding susceptibility genes for atopic diseases may increase. Before that, to standardize 
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the recruitment of the study population, assessment of environmental factors and clear 
definition of the phenotypes are all very important, which will be useful for decreasing 
the inconsistent results in association studies.  
 
2) Determination of genetic contribution to atopic diseases. Familial studies and twin 
studies can dissect genetic and environmental contribution to atopic diseases.  
 
3) Identification of chromosomal regions. The typical method to identify chromosomal 
regions that may contain susceptibility genes for atopic diseases is through linkage 
analysis.  
 
4) Identification of susceptibility genes. Positional cloning and candidate genes provide 
the chance for successful identification of susceptibility genes.  
 
5) Functional assessment of susceptibility genes. The functional role of susceptibility 
genes can be assessed in various methods including animal models (e.g. a knock out or 
transgenic mouse), in vitro models (e.g. reporter system to study promoter function or a 
cell system); or in vivo models.  
 
6) Determination of the relationship between susceptibility genes and environment. Once 
susceptibility genes known, the interaction with the environment could be investigated. 




Figure 2. Flowchart of genetic research in atopy and atopic diseases: right columns give 
some explanations to each step. (Wiesch et al., 1999; Koppelman et al., 2001) 
 
In our study, we concentrated on step (4) and (5). On the one hand, we used association 
study to test candidate genes in Singapore population in vivo. On the other hand, we used 
functional study to further confirm their functions in vitro.  
 
1.5 Summary of candidate genes on atopy 
There are two clues for searching candidate genes for atopy. One is linkage study which 
identifys a region of the genome where a susceptibility allele is located. Examination of 
the region then identifies a likely candidate. The other is nature of the disease will suggest 
 
1. Subjects (Define atopic disease) To choose the right definition is  
especially important  
2. Determine the genetic Component     
 twin study &Family studies 
Twin studies and segregation analyses 
separate the relative contribution of genes  
and environment to atopic disease.  
3. Identify chromosomal regions that 
contain disease genes 
Linkage analysis performed to scan  
the genome for the locations of the 
 major genes regulating atopic diseases.  
4. Identify candidate genes  Candidate genes 
      Positional candidate genes 
5. Determine functional relevance of 
   polymorphisms in candidate genes 
Two aspects of research in gene function. 
 (In vivo and in vitro) 
6. Assess role of SNPs in disease gene 
             in interaction with the environment               
Useful for understanding, prevention 
 and therapy for atopic diseases 
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possible candidate genes. Recent advances in understanding of the molecular biology of 
atopy have suggested a number of plausible candidate genes for atopic diseases. Many 
studies were carried out to search susceptibility genes for atopy and atopic diseases by 
combining linkage study and candidate genes strategies.  
 
1.5.1 Susceptibility regions  
 
As early as 1989, Cookson et al. first found the linkage of atopy to the chromosome 
11q13 marker D11S97 in a limited sample of seven extended families (Cookson et al., 
1989). 
 
In 1994, Marsh et al. used sib-pair analysis of 170 individuals from 11 Amish families, 
revealed evidence for linkage of five markers in chromosome 5q31.1 with a gene 
controlling total serum immunoglobulin E (IgE) concentration (Marsh et al., 1994).  
 
In 1996, a genome-wide screen for asthma was conducted on chromosome 4q, 6, 7, 11q, 
13q and 16 by Daniels’ group in the United Kingdom. Their results demonstrated the 
extent and the complexity of the genetic predisposition to asthma (Daniels et al., 1996) 
 
In 1998, Hizawa et al. conducted a genome-wide search for genes influencing Der p-
specific IgE antibody levels by using 45 Caucasian and 53 African American families and 
found that the best evidence of genes controlling specific IgE response to Der p was 
obtained in 2 novel regions: chromosomes 2q21-q23 (p=0.0033 for Caucasian subjects) 
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and 8p23-p21 (p=0.0011 for African American subjects). Three regions previously 
proposed as candidate regions for atopy, total IgE, or asthma also showed evidence for 
linkage to Der p-specific IgE responsiveness: 6p21 (p=0.0064) and 13q32-q34 
(p=0.0064) in Caucasian subjects and 5q23-q33 (p=0.0071) in African American subjects 
(Hizawa et al., 1998).  
 
In 1999, Wjst et al. reported a sib pair study of a sample of 97 families, including 415 
persons and 156 sib pairs. Linkage analysis for asthma identified four chromosomal 
regions that could be linked to asthma and IgE: chromosome 2 (at marker D2S2298), 
chromosome 6 (around D6S291), chromosome 9 (proximal to D9S1784), and 
chromosome 12 (D12S351) (Wjst et al., 1999).  
 
In 2000, Ober et al. conducted a second generation genomewide screen for asthma 
susceptibility alleles in USA using 563 markers in 693 Hutteriters, who are members of a 
single 15-generation pedigree. Linkages to loci in 5p, 5q, 8p, 11, 14q, and 16q 
chromosomal regions were identified (Ober et al., 2000). 
 
In 2000, Beyer et al. tested for the association and linkage between atopic dermatitis and 
five chromosomal regions: 5q31-33, 6p21.3, 12q15-24.1, 13q12-31, and 
14q11.2/14q32.1-32.3. Evidence for linkage and allelic association for atopic dermatitis 
was observed for markers on chromosome 13q12-14 and 5q31-33 (Beyer et al., 2000).  
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In 2001, Laitinen et al. carried out a genome-wide scan for susceptibility loci in asthma in 
the Kainuu subpopulation and obtained evidence for linkage in a 20-cM region of 
chromosome 7p14-p15 for three phenotypes: asthma, IgE and the combination of the 
phenotypes (Laitinent et al., 2001).  
 
In 2001, Haagerup et al. conducted experiments to identify candidate regions holding 
genes for allergic rhinitis. They performed a total genome-scan on affected 100 Danish 
sib-pair families. Thirty-three affected sib-pair families qualified for the scan that was 
undertaken using 446 microsatellite markers. Non-parametric linkage results were 
obtained from MAPMAKER/SIBS computer program. The study revealed one major 
candidate region on chromosome 4q24-q27 (LOD=2.83) and eight minor candidate 
regions 2q12-q33, 3q13, 4p15-q12, 5q13-q15, 6p24-p23, 12p13, 22q13, and Xp21 
(LOD=1.04-1.63) likely to contain susceptibility genes for allergic rhinitis (Haagerup et 
al., 2001).  
 
In 2001, Holberg et al. performed factor analysis on 468 Hispanic and non-Hispanic 
white children and their analyses suggested evidence for a locus or loci mapping to 
chromosome 5q31-33 associated with this composite atopic phenotype (Holberg et al., 
2001).  
 
In Singapore, Shek et al. recruited 88 Chinese families with at least two affected 
offspring, totaling 373 subjects, with 125 and 119 sib-pairs for atopy and asthma, 
respectively in 2001. All individuals were genotyped with 19 polymorphic microsatellite 
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markers spanning a distance of 41 cM along chromosome 5q31-33. This study has shown 
linkage of atopy and asthma to chromosome 5q31-33 in a heterogeneous Chinese 
population. There was evidence for linkage of the asthma and atopy phenotypes with 
three markers, D5S2110, D5S2011, and D5S412 (P values of 0.001 to 0.00001) (Shek et 
al., 2001).  
 
In 2002, Koppelman et al. began to study the familial aggregation and co-occurrence of 
atopic phenotypes within family members of patients with asthma and to identify 
chromosomal regions that may contain genes that regulate different atopic phenotypes. 
1174 subjects from 200 Dutch families (n = 1174) were studied. They concluded that 
there was clear familial aggregation of atopy. Specific regions of interest for atopic traits 
were also detected on chromosomes 11q, 17q, and 22q (Koppelman et al, 2002).  
 
In 2002, Yokouchi et al. conducted a genome-wide linkage screening of 48 Japanese 
families (188 members) with orchard grass (OG)-sensitive seasonal allergic rhinitis 
children (67 affected sib-pairs) in Japan. Genotyping data of 400 microsatellite markers 
suggested linkage of seasonal allergic rhinitis to chromosomes 1p36.2, 4q13.3, and 
9q34.3 (P < 0.001), linkage of serum total IgE levels to 3p24.1, 5q33.1, 12p13.1, and 
12q24.2 (P < 0.001), and linkage of OG-RAST IgE levels to 4p16.1, 11q14.3, and 
16p12.3 (P < 0.001). Weak evidence for linkage of seasonal allergic rhinitis to 5q33.1 
was also observed (P = 0.01) (Yokouchi et al., 2002). 
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In 2003, Dizier et al. used the sample of 107 families and investigated linkage to asthma. 
Some evidence for linkage was observed for two markers in the 8p23.3-p23.2 region 
(D8S504 and D8S503) and two markers in the 12q14.2-q21.33 region (D12S83 and 
D12S95) (Dizier et al., 2003).  
 
In 2005, Kurz et al. performed a genome-wide scan in 82 nuclear families with at least 
two affected siblings. They obtained significant results for the region 2p12, 16q21 and 
3q21.3 (Kurz et al., 2005).  
 
In 2006, Blumenthal et al. searched the regions of the genome contributing to skin test 
reactivity to 5 seasonal allergens in 287 families and they found that Chromosomal 
regions that exhibited suggestive linkage (logarithm of the odds >1.18; P < .01) to 
seasonal pollen reactivity were identified on chromosomes 13q34, 20p12, and 21q21 
(Blumenthal et al., 2006).  
 
In 2006, Brasch-Andersen et al. studied twenty eight microsatellite markers in a denser 
map on chromosome 3q in 236 allergic sib-pair families including 125 sib pairs with 
rhinitis, and reported significant evidence for linkage to chromosome 3q13.31 for rhinitis 
(Brasch-Andersen et al., 2006). 
 
As many linkage studies showed that 5q31-33 is a very important region for atopy (Marsh 
et al., 1994; Hizawa et al., 1998 ; Beyer et al., 2000; Holberg et al., 2001), and  especially 
recent report also confirmed the strong linkage of atopy and asthma to chromosome 5q31-
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33 in a heterogeneous Singaporean Chinese population (Shek et al., 2001). Therefore, 
5q31-33 was chosen to be investigated in this study. 
 
1.5.2 Susceptibility genes  
Understanding of the molecular biology of atopy has provided suggestions for candidate 
genes for atopic diseases. These association studies according to pathway of development 
of the atopy are summarized as the following. 
 
(1) From allergen to APC 
Much of the interest in genetic control of the immune response to specific allergens 
has focused on human leukocyte antigen (HLA). For example, in 1994, Young et al. 
reported a weak association between DRB1 allels and IgE responsiveness to specific 
allergens (Young et al., 1994). Gao et al. investigated relationship between HLA-
DQA1, -DQB1 genes polymorphism and susceptibility to bronchial asthma among in 
Chinese and reported that alleles HLA-DQA1 * 0104 and HLA-DQB1 * 0201 are 
correlated with the susceptibility to asthma among Northern of Han nationality (Gao 
et al., 2003). However, the contribution by the HLA genes to the atopy is still not 
clear.  
 
Transporter antigen peptide gene (TAP) products are involved in antigen processing. 
In 2001, Izakovicova et al. examined 184 healthy controls and 243 patients to study 
TAP-1 gene polymorphisms. However, there is no association between 
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polymorphisms in TAP-1 genes alone and atopic diseases in the central Europe 
Caucasian (Czech) population (Izakovicova et al., 2001). 
 
Endotoxin, with its potential to enhance type 1 immunity, is a significant player in the 
hygiene hypothesis. As receptor of Lipopolysaccharide (LPS), CD14 was taken as 
candidate gene. In 1999, a C-to-T polymorphism in the 5’ flanking region of the 
CD14 at position -159 was identified and TT homozygotes were found to be related 
with significantly higher serum soluble CD14 (sCD14) levels and lower levels of total 
IgE (tIgE) (Baldini et al., 1999). More polymorphisms of CD14 were identified at 
position -1619, -1359, -1145, -809 of the CD14 promoter (Vercelli et al., 2001). A 
few other studies also confirmed the association between this polymorphism and 
atopy-related phenotypes (Gao et al., 1999; Koppelman et al., 2001; Woo et al., 2003; 
Buckova et al., 2003). However, some association studies yielded negative results in 
other populations (Lis et al., 2001; Sengler et al., 2003; Heinzmann et al., 2003).  In 
2004, a study showed that the influence of CD14 -159C on atopic phenotypes might 
be age-specific, which is no longer apparent by early adulthood (O’Donnell et al., 
2004). Their results were confirmed by recent studies, e.g., Litonjua et al. reported 
that the polymorphisms of CD14 gene may be associated with eczema in 344 2-year-
old white children from 2 birth cohorts in the northeastern United States (Litonjua et 
al. 2005). In Turkish, Sackesen et al. also reported the effect of polymorphisms of 
CD14 promoter with asthma in children (Sackesen et al., 2005).  
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Toll-like receptor (TLR) families play a fundamental role in pathogen recognition. 
Twelve rare variants of TLR4 have been reported (Smirnova et al., 2001). In 2000, 
Arbour and colleagues first reported that TLR4 mutations were associated with 
endotoxin hyporesponsiveness in human (Arbour et al., 2000). In 2004, 
polymorphisms of TLR4 were reported to be associated with the severity of atopy 
(Yang et al., 2004) and a modified response to endotoxin in asthmatics (Werner et al., 
2003). However, some studies were unable to confirm these two common 
polymorphisms on human TLR4 gene or its associated atopy-related phenotypes 
(Raby et al., 2002; Noguchi et al., 2004). 
  
(2) From APC to T cell 
CD28 and CTLA-4 have been shown to be involved as an important costimulatory 
signal for T-cell activation and thus both genes are good candidate genes for asthma 
and atopy. In 2000, Heinzmann et al. tested the association between common 
polymorphisms in the CTLA-4 and CD28 genes at 2q33 with asthma or atopy. They 
concluded that neither gene was likely to exert a major influence on the development 
of asthma or atopy in their population (Heinzmann et al., 2000). 
 
In 1998, Noguchi et al. examined linkage between the development of asthma in 
childhood and the T-cell receptor beta chain gene in Japanese. Affected sib-pair 
analyses provided evidence for linkage between TCR-beta and nearby markers 
(D7S684) on chromosome 7q35 and both IgE and asthmatic phenotypes, but no 
evidence for linkage of IgE responses nor asthma phenotype to TCR-alpha was 
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detected. The results only suggested the presence of major gene(s) controlling atopy 
and asthma susceptibility in TCR-beta and the nearby region (Noguchi et al., 1998). 
 
(3) From T cell precursor to Th1 and Th2 
This is a very important step for T cell differentiation. Many cytokines affect the 
balance of Th1 and Th2, e.g., IL-4, IL-13, IL-2, IFN-γ, and so on, thus many of them 
were considered as candidate genes for atopy and atopic diseases.  
 
IL-4 is regarded as an essential cytokine to influence Th-cell differentiation and total 
IgE (tIgE) levels. In 1995, Rosenwasser et al. reported IL-4/-590 was associated with 
serum total IgE level (Rosenwasser et al., 1995). In 1998, this polymorphisms was 
reported to be related with development of asthma (Noguchi et al., 1998) and atopy 
dermatitis (Kawashima et al., 1998). In 2002, Zhang et al. studied the association 
between this polymorphism with asthma in Chinese population in China, but no 
association could be found (Zhang et al., 2002). In 2003, Kabesch et al. screened the 
IL-4 gene and reported that a total of 16 polymorphisms were identified in the IL-4 
gene. However, some other studies failed to confirm the association between IL-4 
polymorphism and atopy (Elliott et al., 2001; Rigoli et al., 2004).  
 
It is known that IL-18 influences the balance of Th1/Th2 immune response depending 
on its cytokine milieu. In 2001, five single nucleotide polymorphisms were first 
detected in the promoter (Giedraitis et al., 2001). In 2003,  polymorphisms in exon 1 
+113/ T to G, +127/ C to T and in promoter 1 –137/G to T (GATA3 site) of the IL-18 
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gene were reported to be significantly associated with high IgE levels (P ≤ .005). The 
polymorphism +127/ G to T was also a susceptibility locus for seasonal allergic 
rhinitis (P =0.008) in Germany (Kruse et al., 2003). In 2004, polymorphisms of IL-18 
were confirmed to be related with IgE phenotypes (Nieters et al., 2004). But another 
recent study in Germany in 321 children failed to find association between IL-18 
polymorphisms and asthma (Heinzmann et al, 2004). 
 
IL-13 is an important cytokine secreted from Th2. It is essential for modulating IgE 
synthesis by human B cells. In 2001, Howard et al. identified 10 polymorphisms of 
IL-13 and found a significant associations about asthma (P = 0.005), bronchial 
hyperresponsiveness (P = 0.003), and skin-test responsiveness (P = 0.03) with the -
1111 promoter of IL-13 (Howard et al., 2001).  Leung et al. tested R130Q 
polymorphism of IL-13 in Chinese children and found that the R130Q polymorphism 
of the IL-13 gene is associated with elevated serum total and allergen-specific IgE but 
not asthma in Chinese children (Leung et al., 2001). In 2003, Hummelshoj et al. 
demonstrated a strong association (P = 1.09E-05) between the IL-13/ -1024 marker 
and inhalation allergy (Hummelshoj et al., 2003). In 2003, Wang et al. investigated a 
common IL-13 Arg130Gln single nucleotide polymorphism among Chinese atopy 
patients with allergic rhinitis and reported that there was a significant association of 
the IL-13 Arg130Gln SNP, but not of the IL-13 promoter -1112(C/T) SNP, with 
serum total IgE levels (Wang et al., 2003). It seems that IL-13 is likely a susceptibility 
gene for atopy and needs to be studied further.  
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IFN-γ plays important roles in the differentiation and function of TH2 cells. Its 
polymorphisms were first studied by Barnes in 1999. Nakao et al. reported an 
association of IFN-gamma and IFN regulatory factor 1 polymorphisms with 
childhood atopic asthma (Nakao et al., 2001). In 2004, another experiment confirmed 
the association between the polymorphism with asthma and allergic rhinitis (Gentile 
et al., 2004). 
 
Interleukin-12 (IL-12) is a macrophage-derived cytokine that modulates T 
lymphocyte responses and can suppress allergic inflammation. Noguchi et al. 
screened for mutation in IL12B and found three novel (-4475-4insG, Glu186Asp and 
Ser226Asn) variants and one previously reported (1188A>C) variant in IL12B, but 
they reported that there was no association between IL12B polymorphisms and 
asthma and allergic rhinitis in the Japanese population (Noguchi et al., 2001). In 2004, 
Randolph et al. tested positive associations for replication in a case-control study 
comparing 177 adult moderate-to-severe asthmatics with 177 nonasthmatic controls 
and found a strong association between the IL12B/4237 and IL12B/6402 
polymorphisms and an asthma-severity phenotype in whites (Randolph et al., 2004).  
In 2004, a study in Australia showed IL12B promoter polymorphism was also not 
associated with asthma susceptibility, but the CTCTAA allele may have been 
associated with elevated serum IgE (Khoo et al., 2004). 
 
IL-9 works as mast cell growth factor. Its promoter polymorphism was studied by 
Rosenwasser in 1999, and he suggested that the nature of the polymorphisms may be 
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related to significantly higher outputs of these cytokines in atopy and asthma 
(Rosenwasser, 1999). 
 
Signal transducers and activators of transcription 6' (STAT-6) is a key transcription 
factor involved in both IL-4- and IL-13-mediated biological responses. In 2001, 
Tamura er al. reported that a strong association between the A1 and A3 allele 
(containing 15 repeats of GT) heterozygote and allergic diseases was identified (P = 
0.0002) and concluded that genetic variation in the STAT-6 gene may be associated 
with predisposition to allergic diseases (Tamura et al., 2001). 
 
(4) From Th2 to B cells and IgE –mediated mast-cell activation 
 The β chain of the high affinityreceptor for IgE (FcεRI-β) acts as the allergic trigger 
on mast and other cells. Polymorphisms of FcεRI-β have been reported to associate 
with atopy and asthma (Shirakawa et al., 1996), and bronchial hyper-responsiveness 
(Trabetti et al., 1998). But some other studies fail to confirm the association, e.g. a 
study about FcεRI-β polymorphisms in China was unable to confirm the relationship 
with asthma and atopy (Chen et al., 2000) 
 
IL-5 is the main cytokine controlling eosinophil activity and eosinophils are pivotal in 
the development of airway inflammation. In 1998, Pereira et al. performed an 
experiment on the IL-5 gene and the alpha-chain of its receptor in 30 asthmatic and 
30 non-asthmatic subjects and concluded that mutations of the IL-5 gene were 
unlikely to be common causes for asthma. However, in 2005, Hong et al. conducted 
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an association study between known polymorphisms of IL-5 (T-746C) and asthma 
phenotype and the parameters of atopy and pulmonary function in atopic and non-
atopic Korean children with asthma. The study indicates that IL-5 (T-746C) 
polymorphism alone is associated with spirometric markers of asthma severity. 
 
There are still many other cytokines which could influence allergic procedure, e.g. 
IL-3, IL-9, IL-10, nerve growth factor, stem cell factor and transforming growth 
factor β work as mast cell growth factors; IL-3, GM-CSF and eotaxin affect 
eosinophil growth and activation; Monocyte chemoattractant protein 1 and monocyte 
chemoattractant protein 3 influence histamine-releasing (John et al., 2003). 
 
(5) Others.  
Many receptors have been taken as candidate genes for atopy and atopic diseases. 
Except antigen receptor (T-cell receptor, B-cell receptor) and IgE receptor mentioned 
above, there are still other receptors, including cytokine receptors (IFN-γ receptor β 
chain, macrophage colony-stimulating factor receptor, IL-1 receptor, IL-4 receptor, 
TNF receptors), corticosteroid receptors (Glucocorticoid receptor–heat shock protein 
90) and neurogenic receptors (β2-Adrenergic, cholinergic receptors) (John et al., 
2003). 
 
β2-adrenergic receptor is the target for β2-adrenergic agonists and taken as candidate 
gene. Many association studies about β2AR polymorphisms have been performed in 
recent years. For example: Gly 16 genotypes were reported to be associated with 
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increased airway reactivity and more severe asthma, especially with nocturnal 
worsening of asthma (Tuki et al., 1995; Turner et al.,  2004) as well as reduced lung 
functions in childhood (Turner et al., 2004). In contrast, the Glu 27 genotype was 
reported to be associated with less reactive airways on asthmatic subjects and its 
variant was also reported to be associated with elevated levels of serum total IgE 
(Dewar et al., 1997), bronchial hyperresponsiveness (BHR) (D’amato et al., 1998; 
Ulbrecht et al., 2000) and childhood asthma (Hopes et al., 1998). But, there were still 
many negative results reported for different populations (Deichmann et al., 1998; 
Hakonarson et al., 2001; Fu et al., 2002). 
 
In addition, some adhesion molecules and nuclear transcription factor were 
considered as candidate genes for atopy, e.g. virus-like agent 4, vascularcellular 
adhesion molecule1, intercellular adhesionmolecule 1, leukocyte functionalactivating 
molecule-1, T-cell integrin mucin-like 1/2; activating protein-1, nuclear factor of 
interleukin-2, octamer transcription factor-1, STAT-1/2, T-box expressed in T cells, 
nuclear factor κB, inhibitor of nuclear factor kappa B, nuclear factor of activated T 
cells, STAT-4, STAT-6 and so on (John et al., 2003).  
 
Table 1 lists some samples of the candidate genes, especially those in 5q31-33, for atopic 
diseases found from PubMed (http://www.ncbi.nlm.nih.gov) using searching words: 














Signal transducer of IL-12 which has 
developmental commitment of T helper 1 cells. 





co-stimulatory molecules for T cell-
activation 





A receptor for the CC chemokine which 
plays fundamental roles in the development, 
homeostasis, and function of the immune 
system 
Tsunemi et al., 
2004 
 
5q31 IL-4 Differentiation of Th2 cells 
 
Kabesch et al., 
2003 
5q31 IL-5 Eosinophils activation and indication of IgE  Pereira et al., 
1998 











Modulates T lymphocyte responses and can 




5q31 CD14 Receptor of CD14 which initiates the non-
specific innate immunity response to bacterial 
infection. 






Receptor for Beta-2 adrenergic which is 
useful medicine in clinic. 




HLA Antigen presentation Gao  et al., 
2003 
6p21 TNF-alpha affects immune response and airway 
inflammation 




TAP Transportation of antigenic peptide Izakovicova  et 
al., 2001 
7p15 T cell 
receptor 
γ chain 




Induction of IL-12 production Hasegawa  et 
al., 
2004 




IgE signaling amplifier Van Hage-







In addition, candidate genes can be found in Genetic Association Databas 
(http://www.grc.nia.nih.gov/branches/rrb/dna/comparativegenomics.htm). When we 
searched for “asthma” and “rhinitis”, we found more papers about polymorphisms and 
asthma, but fewer papers were about polymorphisms and rhinitis. In this project, we 
analyzed the association not only between polymorphisms and asthma but also between 
polymorphisms and allergic rhinitis especially in our Singapore population. 
 
Many linkage studies showed that 5q31-33 is a very important region for atopy (Marsh et 











CHRM1 CHRM1 may be involved in airway 
constriction, airway epithelial 
cell proliferation, and airway inflammation. 
 
Maeda et al., 
2006 
11q22 IL-18 Th1 and TH2 balance Kruse et al., 
2003 
12q13 STAT-6 STAT-6 is a key transcription factor 
involved in both IL-4- and IL-13-mediated 
biological responses. 
Tamura et al., 
2001 
12q21 IFN-γ Promote Th1 activity and inhibit Th2 
activity 
Barnes, 1999 




Interleukin 4 mediates Ig isotype switching 
from IgM to IgE. IL-4 operates through the IL-
4 receptor (IL4R). 










factor 5 receptor 
Induction of IL-12 production Barnes et al., 
2004 
Xq13 IL-13 receptor 
α1/ α2 chain 
Signal transducer of IL-13 Ahmed et al., 
2000 
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and many association studies demonstrated that genes in this region related with atopy 
and atopic diseases (Table 1). All these data demonstrated that chromosome 5q31-33 
might be a candidate region related with atopy and atopic diseases. Chromosome 5q31-33 
includes genes CD14, IL-3, IL-4, IL-5, IL-9, IL-13, IL-12B, B2AR and granulocyte-
macrophage colony-stimulating factor (GM-CSF), and these cytokines play important 
roles in IgE isotypes switching, eosinophil survival, and mast-cell proliferation (Holgate 
and Holloway, 2002). Therefore, the candidate genes in this study were mainly selected 
from chromosome 5q31-33. In addition, because TLR-4 on chromosome 9 and IL-18 on 
chromosome 11 are biologically relative with CD14, they were investigated as well in 
this study.    
 
1.6 Environmental factors influencing atopic diseases 
 
1.6.1 Hygiene hypothesis 
 
The hygiene hypothesis was first proposed by Strachan DP (Strachan, 1989), according to 
which, frequent timely exposure to microbes and infections in childhood is postulated to 
prevent the development of atopy and asthma. This hypothesis, postulating that infection 
protects against atopy, is considered immunologically plausible and is consistent with the 
epidemiological features of atopy (Strachan, 1999), and has attracted a lot of interest 
from both immunologists and epidemiologists. In a worldwide study, among 
approximately 500,000 school-aged children from 56 countries, the highest prevalence of 
asthma was found in the United Kingdom, New Zealand, and Australia, and most 
developing countries had comparatively low prevalence rates (Kabesch et al., 2004). 
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Increases in early day care or in numbers of older siblings, or close association with 
animals and higher endotoxin exposures were reported to be associated with decreased 
incidence of asthma and atopy-related phenotypes (Savanes et al., 1999; Ball et al., 2000; 
Gereda et al., 2000; Von Mutius, 2000, Nafstad et al., 2001). Therefore, infection related 
factors become the most promising candidates for the underlying protector of atopic 
diseases.  
 
1.6.2 Plausible mechanism of the hygiene hypothesis  
 
A mechanism was proposed for the protective effect of infections, in which activation of 
Th1 responses could control or reduce Th2 responses (Cookson et al., 1997). A clean 
environment during immune maturation may lead to persistence of a Th2 pathway instead 
of a Th1 pathway, which induces high IgE levels and the predisposition to atopy. Figure 
3 describes the plausible mechanism of hygiene hypothesis (Liu, 2002). On the other 
hand, endotoxin can mediate asthma and increase asthma symptoms (Rizzo et al., 1997). 
The key parameters of timing, dosage, environmental cofactors, and genetics influence 





Figure 3. Plausible mechanism of hygiene hypothesis. Endotoxin induces a Th1-type immune 
response, mitigating Th2-mediated allergy and asthma. Innate immune cells with recognition receptors for 
endotoxin (i.e., TLR4 and CD14) produce chemokines and cytokines that influence the development of 
acquired immunity. Importantly, IL-12 production by innate immune cells induces memory-effector T 
lymphocytes to produce IFN-γ on activation. Both IL-12 and IFN-γ inhibit Th2 cytokine production (e.g., 
IL-4, IL-5, and IL-13) by T lymphocytes. IFN-γ also augments IL-12 production by stimulated innate 
immune cells, generating a positive feedback loop between the acquired and innate immune compartments 
(Liu, 2002). 
 
From Figure 3, we know that many cytokines and chemokines are involved in the process. 
This mechanism not only provides a bridge between innate immunity and acquired 
immunity but also provides a cross between genes and environment. It is well known that 
the induction of atopy is dependent on interactions between genes and the environment. 
Environmental triggers are an important factor for development of atopic diseases (Kay, 
2001). 
 
1.7 Atopic diseases in Singapore  
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Singapore comprises three ethnic groups: Chinese (76.7%), Malays (14%) and Asian 
Indians (7.9%). As in other developed countries, atopic diseases are very common in 
Singapore. Asthma prevalence was reported from 5.5% in 1967 (Chong, 1972), 13.7% in 
1987 (Teo et al., 1988) and 20.0% in 1994 (Chew and Lee, 1994).   
 
In 1994, Ng et al. investigated the prevalence of asthma and risk factors among Chinese, 
Malay, and Indian adults in Singapore (n = 2868). They reported that the cumulative 
prevalence of asthma was significantly higher in Indians (6.6%) and Malays (6.0%) than 
in Chinese (3.0%); but Malays and Indians did not have higher rates of atopy (11.1% and 
15.2%, respectively) than Chinese (15.4%). Their environmental investigation showed 
that ownership of cats or dogs was more frequent in Malays (15.4%) and Indians (11.2%) 
than in Chinese (8.8%). Rugs and carpets were also more frequently used by Malays 
(52.2%) and Indians (40.7%) than by Chinese (8.9%). Current smoking prevalence were 
higher in Malays (27.3%) than in Indians (19.4%) and Chinese (23.0%) (Ng et al., 1994). 
Ng and Tan’s another study showed that higher prevalence was observed in Indians 
compared to Chinese and Malays (Ng and Tan, 1994). In 1996, the prevalence and 
severity of asthma, rhinitis, and eczema in Singapore schoolchildren was investigated. 
The prevalence of doctor diagnosed asthma was 20%, while that for rhinitis and chronic 
rashes was reported as 44% and 12% respectively. Another study showed that more 
severe asthma related symptoms were present among Malays and Asian Indians than in 
Chinese (Goh et al., 1996). 
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From these studies, it seems that the prevalence of atopic diseases in different ethnics is 
different in Singapore. It is still unknown whether the difference is due to genes or 
environment (Shek et al., 2000).  
 
Some experiments have been conducted to search for candidate genes in Singapore, and 
some candidate genes have been chosen to be studied in Singapore population. As early 
as 1996, Tan et al. studied polymorphism of T cell receptor (Tcr) (Tcr beta/Bg1II) in 136 
Chinese, 93 Indian and 88 Malay subjects. They showed Indians had a significantly lower 
frequency of this allele (0.15) than the Chinese (0.29) and Malays (0.26) (Tan et al., 
1996). In 1999, Tay et al. studied the ethnic differences in genetic susceptibility to atopy 
and asthma. They conducted some candidate gene studies for asthma and atopy and 
susceptibility locus mapping for linkage to chromosome 5q and indicated genetic factors 
conferring susceptibility to disease may vary among ethnic groups (Tay et al., 1999). In 
1999, Tan et al. studied IL-4 receptor variant Q576R, and they found that the allele 
frequency for R576 in Chinese population was 2-4 times higher than in Indian and Malay 
subjects, but there was little association between the allele and atopy (Tan et al., 1999). 
Similar results were obtained with another polymorphism on IL-4Rα gene Ile50Val, 
however interethnic difference in allelic frequency was observed across the three ethnic 
groups (Tan et al., 1999). Tan et al. also studied tumor necrosis factor (TNF) variants in 
Chinese and Malay, and no association with asthma could be found. In 2001, Shek et al. 
presented evidences for linkage of the asthma and atopy phenotypes with chromosome 
5q31-33 in Singapore population (Shek et al., 2001). Therefore, susceptibility genes for 
atopy and atopic diseases in Singapore are still not clear and worth further studying.  
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As there is relatively and uniformly high hygiene condition in Singapore, the full blown 
expression of the genetic predisposition is questioned. In this study, CD14 and TLR-4, 
which are related with LPS, were chosen. The reasons for the choices are the following.  
 
  First, although the environment of Singapore is clearer, but it is not bacteria free here. It 
was reported that in different locations, the total bacteria counts ranged between 9-44 
CFU m
-3 
(Cheong and Lau, 2003), and the highest bacteria count of 334 CFU m
-3
 was 
reported at some occupant locations (Cheong and Chong, 1999). Another investigation 
showed that due to extensive use of air-conditioning systems in Singapore, the indoor 
concentrations of bacteria in air were approximately ten times higher than those measured 
outdoors (Goh et al, 2000). In addition, clinic study showed that the incidence of diarrhea 
disease was related with infection of bacteria (Mendis et al., 1995). So there are still 
opportunities for exposure to microbes and the opportunities may be different with 
different environments in Singapore. On the other hand, we also noticed some studies 
about polymorphisms of CD14 and TLR-4 in Japan and some Europe countries, which 
may have similar hygiene conditions with Singapore.  
 
Second, it is expected to study the association for these kinds of candidate genes using 
population which had early exposure to high level of endotoxin and others which did not. 
Regarding the study population in this study, although the hygiene level in Singapore is 
relatively and uniformly high now, it may be not the case 20-50 years ago. So, the current 
study population may still have somewhat difference in their early exposures to microbes. 
As examples, an increase in asthma prevalence was reported as 5.5% in 1967 (Chong, 
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1972), 13.7% in 1987 (Teo et al., 1988) and 20.0% in 1994 (Chew and Lee, 1984). 
However, this increase was reported to have slowed down, suggesting that the 
environmental influence might have reached their maximum effect on a susceptible 
genetic background in Singapore (Wang, et al, 2006).  
 
The reason for the fact that there is high level of atopy but this does not really translate to 
symptomatic atopic diseases in Singapore may lie in the decrease of opportunities for 
contacts with allergen including improvement in prevention effort, decrease of pollutions, 
dietary change and so on.  
 
1.8 Importance of the study 
Although the genetic basis of atopy disorders is the subject of scientific and clinical 
interest, susceptibility genes for atopy remain unclear. Heritability, linkage, association, 
and twin studies have suggested complex multifactorial genetic contributions to these 
diseases. Genetic components of an individual complex disease are often thought to 
involve multiple interacting genetic loci, each of which may contribute small effects in an 
additive manner in the context of epigenetic factors, to overall disease susceptibility. 
environmental factors may include infection, diet, environmental insult, level of exercise, 
stress, and importantly, timing and developmental stage of these epigenetic events. This 
complexity has made the task of identifying disease genes quite difficult. Until now, 
although many candidate genes have been reported about atopic diseases, the available 
data are either inconsistent or inconclusive, and susceptibility genes in different 
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populations may be different (Xu et al., 2001). Hence, it is necessary to study and to 
identify susceptibility genes for atopic diseases particularly in Singapore population.  
1.9 Hypothesis of this study  
According to previous studies, we hypothesized that polymorphisms of CD14 promoter, 
B2AR, IL-4 promoter, TLR-4 and IL-18 promoter might influence the atopy state in 
Singapore population. The hypothesis includes:  
 The allele frequencies in susceptibility genes for atopy could be significantly 
different between atopic and non-atopic subjects. 
 Allelic frequencies of the atopy susceptibility genes and their association with 
rhinitis and asthma could be ethnic-specific between ethnic groups. 
 Polymorphisms polymorphisms of CD14 and IL-18 promoter influence their 
transcriptional activity and may play their respective roles in atopic diseases. 
 
1.10 Objective of this study 
The objective of this study was to determine the relationship between candidate genes 
polymorphisms (CD14, B2AR, IL-4, TLR-4 and IL-18) and atopic phenotypes in 
Singapore population and further investigate the effect of promoter polymorphisms 
(CD14 and IL-18) to transcriptional activity.   
 
The following steps aimed to verify the three corresponding hypothesis. 
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 To determine allele frequencies of  polymorphisms of candidate genes in atopic and 
non-atopic subjects in Singapore population 
 To determine any ethnic differences in allele frequencies of the candidate genes in the 
local Chinese, Malay and Asian Indian population. 
 To investigate the associations of polymorphisms of candidate genes with the serum 
tIgE and the clinical manifestations of allergic diseases (e.g., allergic rhinitis and 
asthma). 
 To determine whether the polymorphisms of CD14 and IL-18 promoter influence their 
transcriptional activity. 
 
1.11 Value of this study 
 
We expected that our study would contribute to an understanding of the pathophysiology 












MATERIALS AND METHODS 
 
 
2.1 Study population 
 
A total of 493 unrelated individuals from Singapore were investigated. Their 
demographic information is shown in Table 2. There were 257 males and 236 females, 
aged from 5 to 74 (32.8 in average). Among them, there were 331 Chinese, 51 Malays, 
101 Asian Indians and the remaining 10 were from other races (Table 2). Most patients, 
with allergic rhinitis and with or without asthma, were recruited from the ear, nose and 
throat (ENT) out-patent clinic. Healthy subjects were recruited as part of a population-
based national survey study for rhinitis. All subjects were informed of the study purpose 
and they all agreed to participate in this study. Approval to conduct this study was 
granted by the National Medical Research Council of Singapore and the institutional 
review board of the Medical Faculty of National University of Singapore.  
 
Table 2.  Characteristics of the study subjects 
 
 Chinese Malay Asian Indian 
Total subjects 331 51 101 









Atopy (%) 51.7 52.1 54.7 
Rhinitis (%) 52.0 60.8 55.4 
Allergic rhinitis (%) 40.5 41.7 42.1 
Asthma (%) 11.2 25.5 26.7 
Allergic asthma (%)   9.6 16.7 22.1 
Both allergy rhinitis and 
allergic asthma (%) 
  9.0 13.1 19.8 
 
 
2.2 DNA extraction 
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2.2.1 Blood collection  
 
The blood samples of study population were collected using two tubes with and without 
anticoagulant (EDTA sodium) respectively. Each blood sample was fractionated into an 
upper serum/plasma layer, a lower red blood cells (RBCs) layer and a thin interface 
containing the white blood cells (WBCs) by centrifuging at 1500-2000g for 20-30 
minutes at room temperature. The serum was carefully collected from the tubes without 
anticoagulant for IgE and sCD14 measurement. The plasma was removed carefully and 
WBCs were collected for genomic DNA extraction. All samples were stored in -20 ºC for 
further use. The outline of this procedure is shown in Figure 4. 
 
 
Figure 4. Procedure for treating blood. 
 








No EDTA EDTA added 
Stored at -20ºC for further use 
sCD14 
tIgE and sIgE 
Genomic DNA extraction 
Spin down 20-30 min at 1500-2000g 
Serum Blood Cells 
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Lysis buffer and washing buffer were prepared before DNA extraction. The former 
contained 0.32 M sucrose, 5 mM MgCl2, 0.01 M Tris and 1% Triton (PH=8), and the 
latter contained 10 mM NaCl and 10 mM EDTA (PH=8). In addition, other reagents were 
also prepared, including 6M guanidine hydrochloride, 7.5M ammonium acetate, 20% 
sodium sarkosyl and proteinase K (10 mg/ml).  
 
Three to five milliliters of peripheral blood samples were thawed at room temperature for 
1 hour or at 4°C overnight. The blood sample was mixed with 15 ml of lysis buffer and 
placed on ice for 15 minutes, then centrifuged at 10.000 rpm for 10 minutes. The 
supernatant was removed and the pellet was resuspended in 15 ml of washing buffer, and 
then vortexed and centrifuged at 10,000 rpm for 10 minutes. The pellet was washed three 
times till it turned white. The pellet was mixed with 210 µl of 20%sodium sarkosyl, 150 
µl of 7.5M ammonium acetate, 2.1 ml of 6M guanidine hydrochloride and 60 µl of 
proteinase K (10 mg/ml). The mixture was then incubated at 60°C for 3-5 minutes until 
the solution was clear and put back on ice and allowed to reach 0°C. 10 ml of cold 
absolute alcohol (-20°C) was used to precipitate DNA, which was spooled with a hooked 
glass rod, transferred to a clean tube, and allowed to dry overnight in air. Finally, the 
DNA pellet was resuspended in an appropriate amount of TE buffer and stored in -20 °C. 
DNA concentration was determined by NanoDrop ND-1000 (NanoDrop Technologies, 
Rockland, DE) in 20 randomly chosen samples. The concentrations were between 300-
700 ng/µl and the ratios of 260/280 were between 1.69-1.89. Because RNA is rather 
unstable, RNase may contaminate from any glass and plastic surface and we did not use 
any reagent to protect the RNA. All these RNase may destroy some RNA in the samples. 
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On the other hand, because we used DNA for PCR only, we did not have too high 
demand for the purity of DNA. Therefore, we did not use RNase to specially deal with 
RNA. 
 
2.3 PCR (Polymerase Chain Reaction)  
2.3.1 Primer design 
All primers used in this study came from published papers or were designed using PCR 
primer design softwares (http://www.bic.nus.edu.sg. GCG, or http://frodo.wi.mit.edu). 
The sequences of all the primers used for genotyping in this study are shown in Table 3. 
 
Table 3.  Primers to assay the polymorphisms on candidate genes 
 
 Polymorphisms 















(Baldini et al., 
1999) 
X74984 GTG CCA ACA 
GAT GAG GTT 
CAC 
CCT CTG TGA 




2 CD14/-550 X74984 GAG AAT TGC 
TTG AAC CCA 
GGA   GGC 
CGG ACA GGC 
TCT GGA AGT 
GCT  TTA  
797bp Sequence 
analysis 
3 CD14/-1145 X74984 GTC  AGG AGT  
GCC TGG  TCA 
AC  
  
GAA TGA GGA 
TTA ATT AGT 
AAC TCA CCA 
GAT T 
321bp RFLP  
HinfI 
 
4 CD14/-1359 X74984 CAC CTG AGG 
TCT GGA GTG 
CCT G    
GCA TTT ACA 
ACA GCC CTC 







M23442 ACT AGG CCT 
CAC CTG ATA 
CG 
CAG GAG GAC 





(Martinez et al., 
1997). 
 GCC TTC TTG 
CTG GCA CCC 
CAT 
CAG ACG CTC 




7 TLR-4  
(Lorenz et al., 
2002) 
NM138556 TCT AGA GGG 
CCT GTG CAA 
TT  
TTG AAA CAA 
ATG AGT GAG 




+113 and +127 
AB015961  
BC007461 
CCA TAT TGA 
GCT TGG GAG 
GA 
ATA GAG GCC 
GAT TTC CTT 





2.3.2 PCR reaction 
 
PCR was carried out using the thermal cycler (ThermoHybaid P×2, Ashford, Middlesex, 
UK). About 0.2-0.5 µg template DNA, 10x amplification buffer, 10 mM solution of four 
dNTPs (pH 8.0), 10 µM forward primer, 10 µM reverse primer, 1-5 units/µl DNA 
polymerases and distilled H2O were added into a sterile 0.2 ml microfuge tube, and 
mixed gently to a final reaction volume of 20 µl or 25 µl. Usually, the mixture of PCR 
contains 1.5 mM Mg
2+
, 50 mM KCl, 200 µM dNTPs, 0.2-1 µM Primers and 1-5 units 
DNA polymerase. The template was amplified using the denaturation, annealing, and 
extension for PCR cycles. The steps are listed below. Time and temperatures were 
optimized to suit the particular reaction conditions. After PCR reaction, gel 
electrophoresis was used to confirm DNA amplification.  
                                                         Time                                        temperature 
Initial denaturation                           3 min                                       95ºC                            
Denaturizing                                    30-60 sec                                  95ºC                                                                             
Annealing                                        30-60 sec                                  50-65ºC    
Extension                                         30-60 sec                                  72ºC    
Number of cycles                             30-40 
Final extension                                 5-10 min                                   72ºC               
Store                                                                                                   4ºC 
 
2.4 Gel electrophoresis 
 
1x TAE buffer was used for agarose gel electrophoresis. For 1% agarose gel, 0.5g of 
agarose (BioRad, Hercules, CA, USA) was dissolved in 50 ml of 1x TAE buffer and the 
mixture was heated on a heater (BIBBY, HB502) for 2 minutes. 2 µl of ethidium bromide 
(10mg/ml, BioRad, Hercules, CA, USA) was added to the mixture to stain the gel. The 
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mixture was poured into a mini gel-casting chamber with a comb. The gel solidified at 
room temperature after 30 minutes and was placed into an electrophoresis tank. TAE 
buffer was added into the tank to cover the gel. 3-5 µl DNA samples were mixed with 
loading buffer (Promega, Madison, WI, USA; or prepared using 5X TBE, 0.5 mol/L 
EDTA, 10%(v/v) glycerol and 0.05% (w/v) Bromophenol Blue) and loaded into the wells. 
DNA ladder (Promega, Madison, WI, USA) of the appropriate size (100 bp or 1 kb) was 
also loaded into a well subsequently. Electrophoresis was performed at 100 volts for 30 
minutes. The gel was viewed with UV transilluminator and photographed. DNA with the 
correct size was chosen to do Restriction Fragment Length Polymorphism (RFLP). 
 
2.5 RFLP --- Restriction Fragment Length Polymorphism   
 
A suitable restriction enzyme from New England Biolab (Beverly, MA, USA) was 
applied to the PCR products. The digestion was performed at 37°C for 6-8 hours or over 
night. The digested mixture was run on 1-4% agarose gel and photographed. The 
polymorphism at a special position of the candidate gene was detected according to the 
size of the restriction fragments of PCR products.  
 
2.6 DNA sequence analysis  
 
Before DNA sequencing reaction, the PCR product was purified using QIAquick PCR 
purification Kit (Qiagen, Hilden, Germany). Sequencing reactions were performed using 
the BIG Dye Terminator Cycle sequencing ready Reaction Kit (ABI, Foster, CA, USA). 
The working protocol was based on the manufacturer’s instruction. Briefly, the 
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sequencing PCR was performed in a final volume of 20 µl, containing 2 µl  (90ng) PCR 
products, 3 µl 5×buffer, 2µl Big Dye, 1 µl 3.2mM Primer and 12 µl ddH2O. The 
temperature cycling was set as 96 °C for 3 seconds, 50 °C for 15 seconds and 60 °C for 4 
minutes for 25 cycles. To remove excess dye terminators, the entire content of reaction 
was transferred into a 1.5 ml microfuge tube containing 2 µl of 3 M sodium acetate (PH 
4.6) and 50 µl of 95% ethanol (Merck, Damstadt, Germany). The mixture was vortexted 
and placed on ice for 15 minutes to precipitate the extension products. After ethanol 
precipitation, the mixture was then centrifuged for 30 minutes at maximum speed. 
Supernatant was carefully removed. The pellet was rinsed with 250 µl of 70% ethanol  
and centrifuged at full speed for 5 minutes. The supernatant was carefully removed again 
and the pellet was dried at room temperature. Finally, the dried DNA pellet was dissolved 
in 12 µl of loading buffer (Deionized formamide, ABI, Foster city, CA, USA). Sequences 
were analyzed using the ABI PRISM 3100 genetic Analyzer System (PE Applied 
Biosystems, Foster City, CA, USA). The nucleotide sequences obtained were compared 
with known sequences in Genbank (http://www.ncbi.nlm.nih.gov). Figure 5 shows the 
two methods for detection of genotypes. 
                                   





                                                      
DNA 
PCR 
Gel electrophoresis to confirm 
RFLP DNA purification 
Sequencing 
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2.7 Cell culture  
2.7.1 Cell culture materials 
Hepatoma-derived HepG2 (HB 8065), epithelial-like Hela, Human promonocytic THP-1 
(TIP-202) and myelomonoblastic U937 (CRL-1593.2) were obtained from the American 
Type Culture Collection (ATCC Manassas, VA, USA). Culture medium RPMI-1640, 
Dulbecco’s modified Eagle’s medium (DMEM) and all other culture reagents including 
sodium pyuvate, non essential Amino acid, glutamine, penicillin-streptomycin and 
trypsin were purchased from Sigma (Sigma, St. Louis, MO, USA). Febserum (FBS) were 
obtained from Hyclone (Hyclone, Perbio, Erembodegem, Belgium). Because the serum 
contains several types of complement proteins which serve as part of the animal’s 
immune system, these proteins can interfere with certain procedures in experiments 
especially in immunological assays. Heat inactivating was done before use. 
 
2.7.2 Environment for cell culture 
All mammalian cells were incubated at 37ºC with a humidified 5% CO2 in a CO2 
incubator (SANYO, NCO-17AIC, Japan). The caps of culture vessels were left loose for 
gas exchange. 
 
2.7.3 Culture of adherent cell lines 
HepG2 and HeLa cells were maintained in the DMEM medium with 10% fetal bovine 
serum, 1 mM sodium pyruvate, 2mM glutamine, 0.1 mM non-essential amino acid 
(NEAA), 100u/ml penicillin and 100µg/ml streptomycin. When HepG2 or HeLa cells 
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became 80-90% confluent, they were subcultured, and the culture medium was then 
removed. The cells were briefly rinsed with 1×PBS solution to remove all traces of the 
serum that contained trypsin inhibitor. 1 ml of 1×Trypsin-EDTA was added to 25 cm
2
 
flask or 2 ml to 75 cm
2
 flask until the cell layer was dispersed. After 5 to 15 minutes, 6.0 
to 8.0 ml of complete growth medium was added and aspirated by gently pipetting. 
Appropriate aliquots of the cell suspension were transferred to new culture vessels and 
the cells were incubated at 37ºC. The subcultivation ratio of HepG2 was 1:4 to 1:6 and 
the subcultivation ratio of HeLa was 1:2 to 1:6 as recommended by ATCC. 
 
2.7.4 Culture of suspension cell lines 
THP-1 and U937 cells were cultured in RPMI-1640 medium with 10% fetal bovine 
serum, 1 mM sodium pyruvate, 2mM glutamine, 0.075% sodium bicarbonate, 100u/ml 
penicillin and 100µg/ml streptomycin. The cells were maintained by addition of fresh 
medium or replacement of medium. Alternatively, cultures could be established by 
centrifugation with subsequent resuspension at 1×10
5





 viable cells/ml. When cell density was more than 
1×10
6
 cells/ml, the cells were subcultured.  
 
2.7.5 Refreshing cells  
The cells taken out from liquid nitrogen were thawed at 37ºC and then immediately 
diluted with 10 ml DMEM or RPMI-1640 in a 15 ml tube and centrifuged at 1000 rpm 
for 5 minutes. The medium was discarded, and the cell pellet was resuspended into 10 ml 
complete medium in a 25 cm
2
 flask. Then, a cell count was carried out to determine the 
cell viability. 
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2.7.6 Freezing cells  
At first, freezing medium was prepared by mixing FBS (90%) and DMSO (10%) (Sigma, 
St. Louis, MO, USA) or mixing DMEM/1640 complete medium (90%) and DMSO 
(10%). The cells were harvested in a good growing condition (log phase) using the    
standard procedure and then applied to cell count. The cell pellets were resuspended in 
the freezing medium at approximately 5×10
6
 cells/ml density. The cells were aliquoted 
into sterile vials, which were placed in a small styrofoam box, covered with tissue and 
placed in -20 ºC freezer for 3-4 hours, and then transferred to a -80ºC freezer for 24 hours.  
Finally, the frozen cells were stored in liquid nitrogen.  
2.7.7 Cell counts 
50 µl of the cell suspension containing appropriate amount of cells was mixed with the 
same volume of trypan blue solution (Sigma, St. Louis, MO, USA) into a 1.5ml tube 
(creating a dilution factor of 2) to make the optimal concentration of cells ranging at 
5~10×10
5
 cells/ml. The mixture was mixed thoroughly and allowed to stand for 5 to 15 
minutes. With a cover-slip in place, 20 µl of the trypan blue-cell suspension was 
transferred to a chamber on the hemocytometer. The hemacytometer was placed on the 
stage of an inverted microscope. Cells in the 4 outer squares of chamber were counted 
(see Figure 6). For those cells on the boundary lines of squares, only the cells resting on 2 
adjacent boundary lines were counted and the cells on the other 2 boundary lines were 
excluded. The cell concentration was calculated by the following formulation: 













Figure 6: Hemocytometer. Cells in the “W” squares of chamber and on the 2 adjacent boundary 




DNA sequences of CD14 and IL-18 in the study were obtained directly from public 
databases (http://www.ncbi.nlm.nih.gov). Polymorphisms of CD14 promoter DNA 
fragments (CD14/-159, -550, -1145 and -1359) and of IL-18 5’-UTR DNA fragments (IL-
18/-137, +113 and +127) and luciferase reporter gene pGL3-basic vector (Promega, 
Madison, WI, USA) were digested by suitable restriction enzymes, and then DNA 
fragments were inserted into pGL3-Basic individually. DH5α was used for 
transformation in order to acquire successfully-constructed luciferase fusion plasmids.  
 
 
2.8.1 Primer design 
The CD14 promoter and IL-18 promoter with different polymorphisms were cloned in the 
pGL3-basic vector. All primers used for cloning in this study are shown in Table 4. All 
primers were designed with recognition sequence of restriction enzymes in order to be 




Table 4. Primers for PCR to amplify inserted DNA 
 
















GGT CTC GAG 
GTG CCA ACA 
GAT GA 
(XhoI) 
CAC AAG CTT 




2 CD14/-550 X74984 
X06882 
AGT CTC GAG 
AAA AGG AAG 
GGG GAA 
(XhoI) 
CTC AAG CTT 
GGA AGG ATT 






AGT CTC GAG 
AAA AGG AAG 
GGG GAA 
(XhoI) 
CAC AAG CTT 










CAG CTC GAG 
AAT TGC TGG 
AAC CTG  
(XhoI) 
CAC AAG CTT 





+113 and +127 
(Giedraitis et 
al.,  2001) 
AB015961  
BC007461 
AGT CTC GAG 
CTC TTT GCT 
ATC ATT CCA 
GGA A (SacI)  
 
GTA CTG CTA 
GCT TTC CTC 
TTC CCG AAG 




2.8.2 PCR amplification and purification 
All PCR was performed using Promega Pfu PCR system (Madison, WI, USA). 41.55 µl 
of ddH2O, 5 µl of 10x PCR buffer, 1 µl of 10 mM dNTPs mixture, 1 µl of template DNA 
(0.5 µg) and 0.6 µl of both primers (0.2 µg/ml) were mixed together in a 200 µl PCR tube. 
0.5 µl of Pfu polymerase (5 units) was added to the mixture finally to make up a 50 µl 
reaction volume. PCR was carried out using the thermal cycler (ThermoHybaid P×2, 
Ashford, Middlesex, UK) with appropriate conditions for different primers. After 
subjected to gel electrophoresis to ensure the correct size, PCR products were 
precipitated using 50 µl 100% ethanol and 2 µl  3 M sodium acetate (NaOAc) on ice for 
30 minutes, and spun down at 14,000 rpm for 20-30 minutes. The supernatant was 
removed carefully and the DNA pellet was washed with 250 µl of 70% ethanol and spun 
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down at 14,000 rpm for 5-10 minutes.  The pellet was dried at room temperature, and 
then DNA was dissolved in 50 µl of TE buffer (pH 8.0). 
 
2.8.3 Vectors 
The firefly luciferase gene is widely used as a reporter gene for studying the regulation of 
gene expressions. The pGL3 luciferase reporter vectors constructed with the firefly 
luciferase gene provide a basis for quantitative analysis of the factors that potentially 
regulate mammalian gene expressions. In this study, the effect of the polymorphisms of 
CD14 promoter and IL-18 5’-UTR was investigated by luciferase expressions. Figure 7 
shows the map of pGL3-basic vector (http://www.promega.com).  
  
 
    
 
Figure 7. pGL3 vector Map. Additional description: luc+, cDNA encoding the modified firefly luciferase; 
Ampr, gene conferring ampicillin resistance in E. coli; f1 ori, origin of replication derived from filamentous 
phage; ori, origin of replication in E. coli. Arrows within luc+ and the Ampr gene indicate the direction of 
transcription; the arrow in the f1 ori indicates the direction of ssDNA strand synthesis 
(http://www.promega.com). 
 
The co-reporter vector (also known as control reporter vector) is widely used to 
normalize experimental variations including transfection efficiency in transient 
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transfection experiments. To correct for variables that may confound data interpretation, 
a second control reporter under a constitutive promoter is often co-transfected into cells 
acting as an internal control to normalize experimental variations. Renilla luciferase, like 
firefly luciferase, may function as a genetic reporter immediately following translation. In 
this study, pRL-CMV was chosen as the control reporter vector (figure 8, 
http://www.promega.com). 
 
           
          
 
Figure 8. pRL-CMV vector Map. Additional description: Rluc, synthetic cDNA sequence encoding the 
Renillaluciferase enzyme; Ampr, gene conferring ampicillin resistance in E. coli; ori, origin of plasmid 




2.8.4 Digestion  
Restriction enzyme digestion was performed using Promega digestion system (Promega, 
Madison, WI, USA). The PCR products and the PGL3 vector were digested with matched 
enzymes, e.g. XhoI and HindIII for CD14 promoter, and SacI and NheI for IL-18 5’-UTR 
PCR fragments. 60 µl of digestion reaction mixture consisting of 2 µl (5-10 units) of 
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restriction enzyme, 6 µl of 10 x buffer, 0.6 µl of BSA (1 mg/ml), 45 ul of DNA sample 
(1-2 µg) and nuclease-free water was incubated at 37°C for 3-6 hours. Agarose gel 
electrophoresis was then carried out to purify the digested products. 
 
2.8.5 DNA purification 
DNA purification kit from GFX (Amersham, Little Clalfont Buckinghamshire, UK) was 
used for purification of digested products. The digestion mixture and PGL3 vector were 
loaded on 1% agarose gel and the gel containing the correct DNA fragments was cut out 
and weighted. Capture buffer was added at the ratio of 1 µl buffer for 1 mg gel slice to 
dissolve the gel slice. The maximum weight of gel slice that can be processed with the kit 
is 300 mg. The mixture was then incubated at 65°C for 5-15 minutes until the gel slice 
was completely dissolved in the capture buffer. After incubation, a GFX column was 
placed in a collection tube and the respective samples were loaded into each GFX column. 
The tubes were incubated for 1 minute at room temperature and the samples were spun at 
14,000 rpm for 30 seconds. The flowing-through was discarded and 500 µl of wash 
buffer was added. The tubes were then centrifuged at 14,000 rpm for 30 seconds and the 
collection tubes were replaced with 1.5 ml tubes. 50 µl of TE buffer (pH 8.0) was added 
directly to the top of the fiber matrix in the GFX column. After incubation for 1 minute at 





The pGL3-basic vector was ligated with the inserted DNA fragments respectively using 
T4 DNA ligase based on the ratio of 3:1 (insert:vector). Ligation was performed in a final 
volume of 10 µl when cloning a fragment of the inserted DNA into the vector. The 
following formula is used for calculating the amount of the inserted DNA. 
 
(ng of vector × kb size of insert/kb size of vector)  × Molar ratio of insert/vertor  
 
A 10µl reaction of ligation contained 1µl of 10 × buffer, 100 ng of vector DNA, 
appropriated amount of inserted DNA, 1 µl of T4 DNA ligase (Promega, Madison, WI, 
USA), and ddH2O. The mixture was centrifuged for a few seconds in a microcentrifuge 
and ligation was performed overnight at room temperature. After ligation, the mixture of 
ligation was precipitated on ice using 50 µl of 100% ethanol and 2 ul of 3 M sodium 
acetate (NaOAc) for 30 minutes. It was then spun down at 14,000 rpm for 20-30 minutes. 
The supernatant was carefully discarded, and the DNA pellet was washed with 250 µl of 
70% ethanol and spun down at 14,000 rpm for 5-10 minutes. The pellet was dried at 
room temperature, and then DNA was dissolved in 5 µl of TE buffer (pH 8.0) for 
transformation. Sometimes the mixture of ligation was used for transformation directly. 
 
2.8.7 Preparation of competent cells  
0.1 M Cacl2 solution was sterilized by filtering through a 0.22 µm filter (Millex
TM
, 
Molsheim, France) and kept at 4°C. A single colony of DH5α cells from a fresh plate was 
picked and incubated in 10 ml of LB medium. The culture was incubated overnight at 37 
°C with vigorous shaking at 200 rpm. 1 ml of the bacterial culture was transferred into 
another 20 ml of LB on the second day and incubated at 37°C for an hour or until 
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OD600nm reached 0.5 – 0.7. 1 ml of the cultured LB was aliquoted to 1.5 ml tube and cells 
were harvested by centrifugation at 4000 rpm for 5 minutes at 4°C and the bacterial pellet 
was resuspended in 0.5 ml of ice-cold 0.1 M Cacl2 per tube. After incubation on ice for 
30 minutes, the cells were centrifuged again at 4000 rpm for 5 minutes at 4°C. The pellet 
was resuspended in 0.2 ml of ice-cold 0.1 M CaCl2 and was centrifuged again at 4000 
rpm for 5 minutes at 4°C. The cell pellet was resuspend in 100µl ice-cold 0.1 M CaCl2 
containing 7% DMSO, and then the tube was dipped into the liquid Nitrogen, later stored 
at -80 ˚C for further use. 
 
2.8.8 Transformation  
100 µl of DH5α Competent cells were thawed on ice, and 2-5 µl ligated DNA was added 
into 100 µl competent cells. Then, the mixture was allowed to stand on ice for 30 minutes, 
incubated at 42 °C for 1 minute and promptly transferred back to ice. After at least 2 
minutes, 900 µl of LB was added and the mixture was incubated at 37 °C with vigorous 
shaking for 1 hour. Then, 1000 µl of LB with transformed cells was plated on LB plate 
with 0.1mM ampicillin solid media, and the plates were incubated at 37 °C overnight for 
colony formation. 
 
2.8.9 Minipreparation of plasmid DNA  
 
A single colony of transformed bacteria was picked up incubated into 2 ml of rich LB 
medium with 0.1 mM ampicillin. The culture was incubated overnight at 37°C with 
vigorous shaking. 1.5 ml of the culture was then transferred into a microfuge tube and 
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centrifuged at maximum speed for 30 seconds at 4°C. The culture medium was removed 
by aspiration and the bacterial pellet was resuspended completely in 100 µl of ice-cold 
alkaline lysis solution I (50 mM Glucose, 25 mM Tris.Cl, and 10 mM EDTA) by 
vigorous vortexing. 200 µl of freshly prepared Alkaline lysis solution II (2 N NaOH 5 ml, 
10% SDS 5 ml) was added to each bacterial suspension. The tube was closed tightly, and 
the contents were mixed by inverting the tube rapidly five times. 150 µl of ice-cold 
Alkaline lysis solution III (5 M potassium acetate 60 ml, Glacial acetic acid 11.5 ml, H2O 
28.5 ml) was added and mixed by inverting the tube several times. The bacterial lysate 
was centrifuged at maximum speed for 15 minutes at 4 °C in a microfuge. The 
supernatant was transferred to a fresh tube. 0.6 volumes of 100% isopropenol and 0.1 
volumes 3 M sodium acetate were added to precipitate plasmid DNA. The solution was 
mixed by vortexing and then cooled at -80°C for 10 minutes. The precipitated nucleic 
acids were collected by centrifugation at maximum speed for 15 minutes at 4°C in a 
microfuge.  The supernatant was removed by gentle aspiration. 1 ml of 70 % ethanol was 
added to wash the pellet, and then centrifuged at maximum speed for 5 minutes at 4°C. 
The supernatant was removed and the pellet was dried at room temperature for 10-15 
minutes. The nucleic acids dissolved in 50 µl of TE (pH 8.0) containing 20 µg/ml DNase-
free RNase A (pancreatic RNase). The solution was gently vortexed for a few seconds 
and stored at -20°C for further use.  
2.8.10 Plasmid selection  
The plasmid DNA by small-scale preparation was digested for 2-4 hours at 37°C with 
matched restriction enzymes to check whether the right-size DNA fragment was inserted 
into the constructed plasmid. Gel electrophoresis was applied and the correctly 
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constructed plasmids were identified by digestion when two fragments (one with the size 
of inserted DNA and the other with the size of vector DNA) were present. The correctly 
constructed plasmid DNA was chosen for DNA sequencing. DNA sequencing used 
BigDye
TM
 Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystem from 
Perkin-Elmer Corp., Foster, CA, USA) as was mentioned in 2.6.  
 
2.8.11 Large-scale preparation of endotoxin free plasmid DNA 
Large scale extraction of plasmid DNA was carried out using the QIAGEN midi-
preparation kit (QIAGEN, Hilden, Germany) following the protocol of the manufacturer. 
A single colony was picked up from a LB ampicillin selective plate, incubated in a starter 
culture of 5-10 ml LB medium containing ampicillin and grown for about 8 hours at 37 
°C with vigorous shaking (about 300 rpm). 1ml starter was diluted into 500 ml ampicillin 
selective LB medium and grown at 37 ºC for 12-16 hours with vigorous shaking (about 
300 rpm). The bacterial cells were harvested by centrifugation at 6000 g for 15 minutes at 
4 ºC. The medium was discarded, and the bacterial pellet was resuspend in 50 ml of 
Buffer P1 with RNaseA. 50 ml of buffer P2 was added and mixed gently by inverting 4-6 
times, and the mixture was incubated at room temperature for 5 minutes. 50 ml of chilled 
Buffer P3 was added and mixed immediately and thoroughly by inverting 4-6 times. The 
QIAfilter Mega Cartridge was screwed onto a 45 mm neck glass and connected to a 
vacuum source. The lysate was poured into the QIAfilter Mega Cartridge and incubated 
at room temperature for 10 minutes, and then the vacuum source was switched on. After 
all liquid had filtered through, the vacuum source was switched off. 50 ml Buffer FWB 
was then added to the QIAfilter Cartridge and the precipitation was gently stirred using a 
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sterile spatula. The vacuum source was switched on until the liquid had been filtered 
through completely. 12.5 ml of buffer ER was added to the filtered lysate, mixed by 
inverting the bottle approximately 10 times, and incubated on ice for 30 minutes. A 
QIAGEN-tip 2500 was equilibrated in advance by applying 35 ml of Buffer QBT through 
the column by gravity flow. The filtered lysate was put onto the QIAGEN-tip and 
allowed to enter the resin by gravity flow. The QIAGEN-tip was washed with a total of 
200 ml of Buffer QC. 35 ml of Buffer QN was then used to elute DNA. The DNA was 
precipitated by adding 24.5 ml of room-temperature isopropanol (0.7 volumes). The 
mixture was centrifuged immediately at above 15000g for 30 minutes at 4ºC, the 
supernatant was carefully decanted. DNA pellet was washed with 7 ml of endotoxin-free 
room-temperature 70 % ethanol and centrifuged at above 15000g for 10 min. The 
supernatant was carefully decanted and the pellet was air-dried for approximately 10-20 
minutes. The pellet was dissolved in suitable volume of endotoxin –free Buffer TE. The 
plasmid was stored at -20°C for transfection. Figure 9 summarizes the basic steps in the 





Figure 9. Basic steps of subcloning. 
 
2.9 Transfection  
 
2.9.1 Transfection by the Lipofectamine reagent 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used to transfect the plasmid 
DNA into adherent cell lines including HepG2 and HeLa in this study. Adherent cells  
were transfected with each of the 8 constructed plasmids of the CD14 promoter (-159/C, -
159/T, -550/C, -550/T, -159/C&-550/T, -159/T&-550/C, -159/C&-550/T&-1145/A&-
1359/T, -159/C&-550/T&-1145/G &-1359/G) and the 2 constructed plasmids of IL-18 
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pGL3-Basic (0.8-1 µg) and a control Renilla luciferase reporter plasmid (pRL-CMV, 25 
ng; Promega) using lipofectamine 2000.  
 
Transfection of adherent mammalian cells was carried out in a 24-well plate. One day 
before transfection, 0.5-2 x 10
5
 cells were plated in 500 µl of growth medium without 
antibiotics per well so that they would be 90-95% confluent at time of transfection. 0.8-
1µg constructed plasmid DNA or pGL-3 DNA and 25 ng pRL-CMV were mixed and the 
mixture DNA was diluted in 50 µl of Opti-MEM® I Reduced Serum Medium without 
serum. The appropriate amount Lipofectamine 2000 was mixed gently before use, diluted 
in 50 µl of Opti-MEM® I Medium, and incubated for 5 minutes at room temperature. 
After that, the diluted DNA was combined with the diluted Lipofectamine 2000 and 
mixed gently. The mixture was incubated for 20 minutes at room temperature to allow 
the DNA-Lipofectamine 2000 complexes to form. 100 µl of DNA-Lipofectamine 2000 
complexes were added to each well containing cells and medium and mixed gently by 
rocking the plate back and forth. The cells were incubated at 37°C in a CO2 incubator 
until they were ready for luciferase assay. It was optional that the complete medium be 
changed when the cells were incubated at 37°C in a CO2 incubator (usually 6-8 hours 
after transferction).  
 
2.9.2 Transfection by electroporation  
 
All suspension cell lines including THP-1 and U937 were transfected by electroporation. 
Suspension cells were co-transfected with one of the 8 constructed plasmids of CD14 
promoter and 2 constructed plasmids of IL-18 5’-UTR respectively or pGL3-Basic (25 µg) 
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and a control Renilla luciferase reporter plasmid (pRL-CMV, 2.5 µg) using 
electroporation. Suspension cells were prepared 1 day before electroporation such that the 
cell density is < 2 x10
6
 cells/ml. Cells were harvested by spinning down 1000g for 5 
minutes and washed with serum-free 1640 medium once. Cells were resuspended in 0.4 
ml of serum-free 1640 (1-2 x 10
 7
/ml). DNA mixture was prepared containing 27.5 µg 
DNA (25 µg pGL3 or constructed plasmid DNA respectively + 2.5 µg PRI-CMV), 5 µl 
100 µg/ml Yeast tRNA (Roche, Mannheim, Germany) and 6.8 µl NaCl, then topped up 
with dH2O to total volume of 50 µl. Before electroporation, 5 ml well RPMI complete 
medium was added to a 6-well plate and warmed in a 37ºC incubator. Electroporation 
was carried out using Gene Pulser (Bio-Rad, Gene Pulser, Hercules, CA). The prepared 
DNA was mixed with 0.4 ml of serum-free RPMI in cuvettes (Bio-Rad, Gene pulser, 
Hercules, CA) and incubated on ice for 10 minutes before electroporation. 
Electroporation was carried out at 312 V and 950 µF. After electroporation, the cells were 
put at room temperature for 10 minutes, transferred to a 6-well plate (with warmed RPMI 
complete medium) and then incubated at 37 °C in a CO2 incubator for 6-8 hours or until 
they were ready for luciferase assay. 
 
2.10 Luciferase activity assay 
A dual-luciferase Reporter Assay system (Promega, Madison, WI, USA) was used to 
measure luciferase activity on a TD 20/20 Luminometer (DLReady
TM
, Sunnyvale, CA, 
USA). The growth medium from the cultured cells was removed, and a sufficient volume 
of PBS (phosphate buffered saline) was gently applied to wash the surface of the culture 
vessel. Each culture well was dispensed with 100 µl of 1 ×PLB (passive lysis buffer) to 
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completely cover the cell monolayer. The culture plates were rocked at room temperature 
for 15-30 minutes. 100 µl of LAR II (Luciferase assay reagent II) was predispensed into 
luminometer tubes. 20 µl of cell lysate was carefully transferred into the luminometer 
tube containing LAR II, and mixed by pipetting 2 or 3 times. The tube was transferred in 
the TD 20/20 luminometer, and the reading was initiated, and then the firefly luciferase 
activity measurement was recorded. The sample tube was removed from the luminometer, 
and 100 µl of Stop & Glo® Reagent was added and vortexd briefly to mix rapidly. The 
sample was replaced in the luminometer, and the reading was initiated, and then the 
renilla luciferase activity measurement was recorded. The reaction tube was discarded, 
and the RLA (related luciferase activity) was then calculated. 
 
2.11 Immunofluorecence staining of HepG2 cells 
HepG2 cells were cultured in completed DMEM in a humidified atmosphere of 5 % CO2 
at 37 ºC. Glass coverslips were put in a 12-well plate and HepG2 cells were subcultured 
in the plate 1-2 days before experiments. Some cells were stimulated with LPS from 
Salmonella Minnesota (100 ng/ml; Sigma-Aldrich) one day before experiment. When 
cells were at 60-80 % confluence on glass coverslips, medium was aspirated and cells on 
glass coverslips were fixed in 500 µl of 4% para-formaldehyde. The cells were then kept 
at room temperature for 20-30 minutes and washed with 1×PBS for three times, and then 
blocked with 5% milk for 1 hour at room temperature. After the milk was removed, 1:100 
diluted CD14-FITC (BD, Franklin Lakes, NJ USA) was added for 1 hour at room 
temperature. Excess antibodies were washed away with TBS-T (Tris-buffered saline 
PH=6.2 containing 0.2 % Tween 20) once and washed with PBS three times. One drop of 
fluorsave reagent was put on glass slides and coverslips were mounted on the slides. 
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When glass coverslips were dry, they were ready to be observed under confocol 
microscopy. 
 
2.12 Flow cytometry 
THP-1 cells and U937 cells were prepared in two flasks respectively with about 2×10
6 
cells per flasks. For one of them, we used LPS 100 ng/ml stimulation and then incubated 
it at 37 ºC for 12 hours. The cells were transferred to a tube and spun down at 1000g for 5 
minutes. The medium was removed and cells with or without LPS stimulation were 
separated into three tubes and washed with PBS twice. 1000 µl of PBS was added to the 
frist tube as negative control, 1000 µl of PBS and 10 µl of isotype Ab (mouse IgG2α 
FITC) (BD, Franklin Lakes, NJ USA) were added to the second tube as background and 
1000 µl of PBS and 10 µl of isotype CD14 FITC (BD, Franklin Lakes, NJ USA) were 
added to the third tube. All tubes were put at 4 ºC for 15 minutes and washed with PBS, 
and 500 µl of 1% para-formalin was added for fixation and washed with PBS. Then the 
cells were ready for flow cytometry analysis. All results of flow cytometry were analyzed 
by WinMDI v2.8 software. 
 
2.13 sCD14 ELISA 
Serum sCD14 levels were measured using enzyme-linked immunosorbent assay 
(ELISA). The commercially available kits were supplied by Biosource (Biosource, 
Camarillo, CA). The sera were diluted 1/101 times with diluent buffer. The coated plate 
was washed three times with 0.4 ml of wash solution per well. 50 µl of respective 
standard, control or diluted samples were pipetted into the appropriate wells. 50µl of 
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diluted antibody-biotin was added into all wells. The plate was incubated for 2 hours at 
room temperature on a horizontal shaker set at 700rpm. The liquid from each well was 
aspirated, and the wells were washed by 0.4 ml of washing solution.  150 µl of diluted 
enzyme conjugate was pipetted into all wells and the plate was incubated for 1 hour at 
room temperature on a horizontal shaker set at 700rpm. The liquid from each well was 
aspirated, and the wells were washed by 0.4 ml of washing solution. 200µl of freshly 
prepared Chromogenic solution was pipetted into all wells within 15 minutes and the 
plate was incubated for 30 minutes at room temperature on a horizontal shaker set at 
700rpm avoiding sunlight. 50µl of stop solution was pipetted into each well. Absorbance 
was read at 450nm within 30 minutes. The minimal detectable concentration of the 
sCD14 was 4 ng/ml. The concentration range of the standard curve was 4-64 ng/ml. 
 
2.14 Total serum IgE  
Serum total IgE (tIgE) and specific IgE (sIgE) to five common antigens, namely Bermuda 
grass (G2), Aspergillus fumigatus (M3), Blatella germanica (Cockroach) (I16), 
Dermatophagoides pteronyssinus (house dust mite) (D1) and Dermatophagoides farinea 
(house dust mite)  (D2). were measured by UniCAP system, using commercially 
available kits from Pharmacia Diagnostics (Fluoro-enzyme immunoassay, Pharmacia & 
Upjohn AB, Uppsala, Sweden). The detectable range was 0.35-100 ku/l of serum tIgE 
and sIgE. 
 
2.15 Statistical analysis 
 
2.15.1 Determination of sample size for a case-control design  
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In order to estimate the sample size required for case-control study, the following 
parameters were considered: 
 
Type I error (α)     =  5% or 1% 
Power  (1-β      = 80% 
Test value of odds ratio (OR)   =  1 
‘Risk’ allele/haplotype frequency in cases = pi1 
‘Risk’ allele/haplotype frequency in controls = pi2 
Anticipated OR    = AOR 
Sample size (allele/haplotype copies)  =  n 
Sample size (subjects)   =  n/2 
 
 
The estimated number of subjects (n/2) required for each study group is tabulated below 
for a given range of allele/haplotype frequency and the anticipated odds ratio (AOR) for 
disease due to the effect of the risk allele/haplotype using open Epi software 
(http://www.openepi.com) (Table 5). The sample size is calculated based on the methods 
of Fleiss with CC (Continuity correction).   
 







Freq 1.25 2 4 
0.1 3304 307 68 
0.2 1902 187 45 
0.3 1482 153 41 
0.4 1327 144 41 
5% 
0.5 1303 148 45 
0.1 4827 446 96 
0.2 2805 271 65 
0.3 2186 222 58 
0.4 1957 209 59 
1% 




Assuming a risk allele/haplotype frequency of 0.1 and a moderate effect of odds ratio of 2, 
the estimated sample size of the subjects required to detect a significant effect with 80% 
power and type I error of 5% was 307 for both case and control. In this study, samples for 
normal control were limited, especially for Malay and Indian groups, so the conclusion 
for the association study was drawn only with a moderate effect on atopy. 
 
2.15.2 Hardy-Weinberg equilibrium  
The Hardy-weinberg equilibrium is a means of caculating expected genotype frequencies 
from allele frequencies determined in the same population and vice versa. Allele 
frequency and genotype frequency are two main measures of the genetics of a population: 
• Allele frequency: the proportion of a specific allele out of all the alleles in all the 
individuals in a population. Allele frequencies must always add up to one, so 
p+q=1 
• Genotype frequency: the proportion of a specific genotype out of all the 
genotypes in all the individuals in a population. Genotype frequencies must 









 = Sum [ (observed-expected)
 2
/ expected] 
If a population is found not be in   Hardy-weinberg equilibrium, there are several possible 
cause: (1) Selection. The effect of selection depends on the relative fitnesses of the 
genotypes. (2) Migration. It can lead substantial changes in allele frequencies over shot 
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periods of time. (3) Assortative mating. (4) Subpopulation. For example:  The effect of 
inbreeding in a population is to increase the frequency of homozygotes. (5) Mutation. 
Mutation pressure alone is a very weak evolutionary force. (6) Random genetic drift. The 
“drift” properly applies to chance changes in allele frequency between generations 
(Winter et al., 2002; Rimoin et al., 2002) 
2.15.3 Statistical methods 
Levels of serum tIgE were logarithmically transformed to normalize the distribution. The 
difference of allele frequency between different ethnic groups was analyzed by z-test. 
The association between polymorphisms and tIgE or sCD14 was determined by ANOVA 
and pairwise comparisons between groups were determined by Bonferoni of post-hoc 
test. General linear model was used to correct for known confounding variables, e.g., age 
and sex. The association of genotype frequency with atopy and atopic diseases was 
determined by Pearson Chi-square analysis. If any cell number in the 2 x 2 contingency 
table was < 5 subjects, Fisher’s exact method was used. The extent of pair-wise linkage 
disequilibrium among the polymorphisms was determined by D’ and r
2 
caculated using 
Jlin software (http://www.genepi.com.au/project/jlin). Pair-wise linkage disequilibrium 
among the four polymorphisms was then calculated using χ2 statistics. Luciferase 
expression was compared using paired t test and/or Wilcoxon Signed Ranks Test of non-
parametric test. Results were considered to be significant if p<0.05. All statistic analysis 
was carried out using SPSS Version 12.0 (Chicago, IL, USA).  
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Haplotypes were inferred by the statistical software package PHASE (Stephens et al., 
2001) using the default settings. Phase-Standard analysis version 2.0.2 was available on 
the website of Oxford university in UK (http://archimedes.well.ox.ac.uk/pise/). 
 
In addition, the tool Match
TM
 provided an initial promoter analysis. The MatchTM program 
uses a library of mononucleotide weight matrices from TRANSFAC Professional to 
search in sequences provided by the user for potential transcription factor binding sites. 
Conclusions can be drawn about where and when the investigated promoter is likely to be 
active. Match
TM
 is designed for searching potential binding sites for transcription factors 

















ASSOCIATION BETWEEN CD14 POLYMORPHISMS AND ATOPY 
 
3.1 Introduction  
It is widely acknowledged that environmental factors are important in the development of 
atopy. According to the hygiene hypotheses, infections in early childhood prevent the 
development of atopic diseases (Strachan, 1989). As receptor of Lipopolysaccharide 
(LPS), CD14 has been considered as a bridge between genes and environment 
(Koppelman et al., 2003). It is reasonable to take CD14 as a candidate gene for atopy and 
atopic diseases. 
 
3.1.1 Role of CD14 
CD14 is a glycoprotein of 55 kD. It is mainly expressed on the cell surface of monocytes, 
macrophages and neutrophils. There are two forms of CD14: mCD14 and sCD14. mCD14 
is a membrane receptor that allows myeloid cell activation, and sCD14 is a soluble form 
presented in the extracellular compartment and its level is a marker of 
monocyte/macrophage activation.  
 
CD14 plays an important role in the link between nonadaptive and adaptive immune 
responses to the environment. It is believed to be the primary receptor for LPS, which is the 
main component of the outer layer of gram-negative bacteria and formed by a 
phosphoglycolipid called lipid A. The ligation of LPS to CD14 depends on the presence of 
a transporter protein --- the LPS binding protein (LBP) (Lapa e Silva et al., 2000; Baldini et 
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al., 2002). The interaction between CD14 and LPS increases the likelihood of developing a 
Th1-type response by up-regulating the expression of IL-12, which in turn decreases the 
IgE-mediated immunity (Cleveland et al., 1997).  
 
CD14 may have a dual effect, i.e., inhibition of IgE production before and aggravation of 
allergic inflammation after the onset of asthma. In early life, CD14-mediated reactions to 
pathogens would elicit strong IL-12/IL-18 expression by innate immune pathway. Th1 
differentiation, rather than Th2 differentiation, would be favoured, decreasing the 
likelihood of vigorous IgE-dependent responses following allergen exposure (Vercelli, 
2002). On the other hand, CD14-mediated stimulation of monocyte/macrophages results in 
the secretion of cytokines such as IL-6 which potently amplify IgE synthesis induced by 
IL-4/IL-13 and CD40 engagement (Jabara and Vercelli, 1994). Therefore, activation of the 
CD14 pathway may inhibit or enhance IgE expression depending on the biological context 
and timing of stimulation (Vercelli, 2003; Leung et al., 2005). Since CD14 is related with 
the level of IgE, it was considered as one candidate gene for atopy. 
 
3.1.2 Current studies on CD14 polymorphisms 
CD14 is located on chromosome 5q31-33, an area which was suggested as a genetic 
linkage to atopy (Baldini et al., 2002). In 1999, a C-to-T polymorphism in the 5’ flanking 
region of the CD14 at position -159 was identified and TT homozygotes were found to be 
related with significantly higher serum soluble CD14 (sCD14) levels and lower levels of 
total IgE (tIgE). On the contrary, CD14-159C may induce downregulation of CD14, with 
reduced IL-12 and IL-18 expression which may be a critical factor in the predominance 
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of Th2 polarization and eventually result in increase of the IgE levels (Baldini et al., 1999; 
Vercelli D, 2003). The putative mechanism may be that the C-T polymorphism at 
position –159 has different binding affinity for Sp proteins, which results in differences in 
the expression of CD14 levels. In addition, there is an inverse correlation between the 
levels of sCD14 and IgE (Baldini et al., 1999). 
 
Recently, more polymorphisms of CD14 were identified at position -1619, -1359, -1145, 
-809 of the CD14 promoter. Carriers of the -1359TT/-1145AA/-159CC genotype were 
shown to have significantly higher levels of IgE than other genotypes (Vercelli et al., 
2001). A few other studies also confirmed the association between this polymorphism 
and atopy-related phenotypes (Gao et al., 1999; Koppelman et al., 2001; Woo et al., 2003; 
Buckova et al., 2003). However, some association studies yielded negative results in 
other populations (Lis et al., 2001; Sengler et al., 2003; Heinzmann et al., 2003).  
 
Table 6 lists current association studies about CD14 polymorphisms and atopic-
phenotypes. Table 6 shows that the association results of this polymorphism are not 
consistent in different populations. Thus, the role of CD14 polymorphisms in regulating 








Table 6. Summary of association studies on CD14 polymorphisms 
* not atopic diseases. 
3.1.3 Objective  
The objective of this study was to search for novel polymorphisms of CD14 in Singapore 
population, and investigate the association of polymorphisms of CD14 with the 
phenotypes of atopy. In addition, the transcriptional activity of CD14 promoter 




3.2.1 CD14 sequences 



















513 48.6% Yes  sCD14 and tIgE 
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levels  
Koppelman  et 
al., (2001) 
Netherlands Asthmas: 159 
Controls:158 
NA Yes Severe allergic 
phenotype. 











asthma and food 
allergy 






47%         22.8% 
44.2%      24.3%  
Yes Modifiers of IgE-
mediated allergic 
diseases. 




97 15.6% Yes Modulation of 
lung function 
Lis  et al., 
(2001) 









872 46% No Atopy 




250 P:47.5%   22.6% 
C: 46%     23.8% 
No Asthma 









The sequence of CD14 was searched from http://www.ncbi.nlm.nih.gov, and it consisted 
of two parts (Genbank accession number X74984 and X06882). Known polymorphisms 
and position number are showed in bold. All primers were designed according to the 





































































The following is the genomic structure and relative positions of the four polymorphisms 





3.2.2 tIgE measurement 
All serum specific IgE (sIgE) results were obtained from the Clinic Lab of National 
university hospital (Figure 10). Serum total IgE (tIgE) was measured by UniCAP system 













Pharmacia Diagnostics (Fluoro-enzyme immunoassay, Pharmacia & Upjohn AB, 
Uppsala, Sweden) (Figure 11). The detectable range of serum tIgE was 0.35-100 ku/l. 
 
 
Figure 10. sIgE results from clinical Lab 
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Figure 11. tIgE results using UniCAP. 
 
3.2.3 sCD14 measurement 
Serum sCD14 levels were measured using a commercially available ELISA kit supplied 
by Biosource (BioSource Europe S.A, Nivelles, Belgium). All samples were diluted 
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1/101 by diluent buffer following the manufacturer’s instructions. The minimal 
detectable concentration of the sCD14 was 4 ng/ml. The concentration range of the 
standard curve was 4-64 ng/ml. Table 7 shows the sCD14 concentration for standard 
curve, and Figure 12 shows the standard curve. Since all samples were diluted 100 times, 
all the values of sCD14 were multiplied 100 times in order to obtain the actual value of 
sCD14 for each study subject (Table7, B). 
 
Table 7. Concentration for standard curve and raw data for sCD14. (A): OD and 
concentration for making standard curve; (B) raw data for sCD14. As the serum were 
diluted 100 times, the the actual concenteation were timed 100.  
 
 
(A)   









(B)   
 






C1 0.437 33.97983 3397.983 
C2 0.571 42.61374 4261.374 
C3 0.578 43.04492 4304.492 
C4 0.421 32.90066 3290.066 







Figure 12. sCD14 standard curve 
 
 
3.2.4 CD14/-159 polymorphism 
 
3.2.4.1 RFLP results  
 
Identification of the polymorphism of CD14/-159 was done by RFLP assay using 
restriction endonuclease AvaII. Commercially available endonuclease AvaII (New 
England) is specific for the following sequence:  
5´ ... G^G W C C... 3´ 
3´ ... C C W G^G... 5´ 
 
GGTCC is present only in the subjects carrying the CD14/-159T allele. Therefore, PCR 
products only in those subjects having the CD14/-159T allele could be digested. Thus, the 
assay yielded one band of 497 bp for the CC homozygotes, three bands of 144 bp, 353 bp 
and 497 bp for CT heterozygotes and two bands of 144 bp and 353 bp for TT 
homozygotes. Figure 13 shows the results of RFLP assay for CD14/-159. 
 














     
 
Figure 13.  CD14/-159 RFLP results. CC homozygotes are shown in lane 6 and 8 (497bp); TT 
homozygotes are in lane 1, 2, 4, 5, 12, 14, 16 and 18 (353bp and 144bp), and CT heterozygotes are in lanes 
3, 7, 9, 10, 11, 13, 15 and 17 (497bp, 353bp and 144bp). 
 
 
3.2.4.2 Sequence analysis  
The RFLP of CD14/-159 was performed in 331 Chinese subjects, among whom the 
sequences for 237 subjects were confirmed by sequence analysis. There was only one 










                          
 
Figure 14.  CD14/-159 sequencing results. A: C homozygote; B: CT heterozygote and C: TT 
homozygote. All sequences are 5’-3’. 
 
 
3.2.4.3 Genotype frequency  
The genotype frequencies of CD14/-159 were in agreement with the Hardy-Weinberg 
equilibrium in each group. Allele frequency for T was more than 50 %, which 
demonstrated that this mutation was common in Singapore population. No significant 
difference of the genotype frequency between non-atopic and atopic group was found in 
any subject group using Chi-square analysis (Table 8). 
   













Table 9 shows that C allele frequency in atopic group is 56%, while in non-atopic group 
is 35% in Malays, however, there was no significant difference in the C allele frequency 
between non-atopic and atopic group in statistics (p=0.098). There was also no significant 
difference in the frequency of the C allele among Chinese, Malay and Indian population 
(Table 9). 
 
Table 9. Comparison of CD14/-159 allele frequency among three different ethnic 
groups 
 




   C     T Atopy z-test  
    (p-value) 
Non-atopy z-test 
      (p-value) 
Non-atopy 46% 54% Chinese 
 Atopy 44% 56% 
Non-atopy 35% 65% Malays 
Atopy 56% 44% 
Non-atopy 52% 48% Asian 
Indians Atopy 42% 58% 
Chinese & Malays 
Z=0.838, NS 
Chinese & Indians 
Z=0.230, NS 
Malays & Indians 
Z=0.849, NS 
Chinese & Malays 
Z=0.687, NS 
Chinese & Indians 
Z=0.284, NS 
Malays & Indians 
Z=0.840, NS 
NS: No significance 
 
3.2.4.4 Association between CD14/-159 polymorphisms and sCD14 
We assessed sCD14 levels in 130 randomly selected Chinese subjects. Among them, 32 
were non-atopic and 88 were atopic. Between atopic and non-atopic groups, there was no 
significant difference for sCD14 among CC, CT and TT genotypes (Table 10). 
 
 
Chinese Malays Asian Indians CD14/-159 
genotypes Non-atopy Atopy Non-atopy Atopy Non-atopy Atopy 
CC 24% (36) 18% (31) 17% (4) 36% (9) 23% (10) 17% (9) 
CT 44% (68) 53% (90) 44% (10) 40% (10) 58% (25) 50% (26) 















P-value 0.293 0.295 0.289 
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Table 10. Serum sCD14 levels by CD14/-159 genotypes in Chinese group (n=130). 
Results are expressed as mean and 95% confidence interval for mean (ug/ml).  
 
CD14 SNPs  Non- atopic group 
          n=32 
      Atopic group 















3.2.4.5 Association between CD14/-159 polymorphisms and tIgE levels 
We separated the study population into non-atopic and atopic groups according to sIgE to 
at least one common house dust mite. In Baldini’s study, cases were stratified by positive 
and negative allergen skin-test reactivity. Although the criteria for subject stratification 
were different, both methods were dependent on sIgE levels to specific antigens. Baldini 
M reported that the association between serum total IgE and CD14/-159 genotypes was 
statistically significant only among those subjects positive for allergen skin tests (Baldini 
M, 1999). However, we could not confirm their results, and no association could be 
found between serum tIgE and CD14/-159 genotypes in Chinese, Malay and Asian Indian 
populations (Table 11). 
Table 11. Geometric mean (95% CI of the mean) serum tIgE(kU/l) by CD14/-159 
genotypes  three different ethnic groups 
 
Chinese Serum tIgE  Malays Serum tIgE  Asian Indians Serum tIgE  CD14/-
159 
 























































p-value 0.174 0.756 0.394 0.464 0.560 0.295 
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3.2.4.6 Association between CD14/-159 polymorphisms and atopic phenotypes 
The relationship between CD14/-159 and atopic phenotypes including atopy, allergic 
rhinitis, asthma and allergic asthma was analyzed. Stratified analysis of CD14 
polymorphisms and atopic diseases was conducted. Table 12 shows that there is no 
significant difference of CD14/-159 genotypes between any case and control groups in 
Chinese and Asian Indian populations. But in Malay population, there is a significant 
difference of the allele frequency between allergic asthma and non-allergic asthma 
groups (p=0.024 and p=0.003). T allele frequency is 58.5% in non-allergic asthma group 
and 18.8% in allergic asthma group. Thus, CD14/-159 may be associated with allergic 
asthma in Malay population. This result was consistent with the report that T was 
associated with higher levels of sCD14 expression and lower IgE levels. Thus, T allele 
frequency should be higher in non-atopic group than that in atopic group. But the sample 
size in Malay population is relatively small, and the results need to be confirmed by 
larger sample size in future and further function study.   
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Asthma vs non-asthma 
Allergic asthma vs non-allergic asthma 











Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 
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Allergic asthma vs non-allergic asthma 










3.2.5 CD14/-550 polymorphism 
3.2.5.1 Sequence analysis   
The polymorphism of CD14/-550 was identified by sequence analysis in 238 Chinese 
subjects. A C-to-T polymorphism was identified at -550 in Chinese population. Figure 15 
shows the results of sequence analysis. 
 
 
Figure 15. CD14/-550 sequencing results. A: C homozygote; B: CT heterozygote and C: TT 
homozygote. All sequences are 5’-3’. 
 
 
3.2.5.2 Genotype frequency  
 
The genotype frequencies of CD14/-550 were in agreement with the Hardy-Weinberg 
equilibrium in non-atopic and atopic groups. In Chinese population, the frequencies of 











the frequencies of CC, CT and TT genotypes in atopic group were 47%, 47% and 6% 
respectively. No significant difference in the genotype frequencies of the polymorphisms 
between the non-atopic and atopic groups was found in Chinese population (Table 13). 
 
Table 13. Genotypes distribution of CD14/-550 in non-atopic and atopic subjects 









CC 45% (69) 47% (80) 
CT 41% (62) 47% (80) 







P value 0.056 
 
3.2.5.3 Association between CD14/-550 polymorphism and sCD14 
The result suggested that there was no association of CD14/-550 with serum sCD14 
concentrations among atopic patients and non-atopic controls (Table14). 
 
Table 14. Serum soluble CD14 levels by CD14/-550 genotypes in Chinese group 
(n=130). Results are expressed as mean and 95% confidence interval for mean (ug/ml) 
 
CD14 SNPs  Non- atopy group 
          n=32 
      Atopy group 















3.2.5.4 Association between CD14/-550 genotypes and tIgE levels 
No significant difference of serum tIgE levels between CD14/-159 genotypes was found 
in either atopic patients or non-atopic controls (Table 15). 
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Table 15. Geometric mean (95% CI of the mean) serum tIgE (kU/l) by CD14/-550 




                          tIgE among 
 n                    non-atopic subjects 
                    tIgE among 



















P-value 0.775 0.095 
 
3.2.5.5 Association between CD14/ -550 polymorphisms and atopic phenotypes 
 
The genotype and allele occurred with similar frequency in atopic patients and non-atopic 
controls, and no significant association between CD14/-550 and atopic diseases were 
found (Table 16).  
 








(p value)  
Allele  
frequency 




Atopy & non-atopy  
Asthma & non-asthma 
Atopic asthma & non-atopic asthma 











3.2.6 CD14/-1145 polymorphism 
 
3.2.6.1 RFLP results  
The polymorphism of CD14/-1145 was identified by RFLP assay. Commercially 
available HinfI endonuclease (New England) is specific for the sequence:  
5´ ... G^A N T C... 3´ 
3´ ... C T N A^G... 5´ 
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It is present only in those subjects carrying the CD14/-1145G allele. Therefore, PCR 
products only in those subjects with the CD14/-1145G allele could be digested to yield 
two bands of 390bp and 31bp. In addition, there was another GANTC in this DNA 
sequence, and DNA of both genotypes could be digested into two fragments. Thus, the 
assay yields three bands of 290 bp, 100 bp and 31 bp for GG homozygotes, four bands of 
321 bp, 290 bp, 100 bp and 31 bp for GA heterozygotes and two bands of 321 bp and 100 
bp for AA homozygotes. The band of 31 bp was too small to be observed, and we 
identified the genotypes of subjects according to the difference between fragments of 290 
bp and 321 bp on agarose gel. Figure 16 shows results of RFLP assay for CD14/-1145’. 
RFLP results of CD14/-1145 were confirmed by DNA sequencing with 10 random 
samples. All were found to be concordant with genotypes obtained from RFLP analysis. 
 






Figure 16. CD14/-1145 polymorphisms results. (1) RFLP results of CD14/-1145 
polymorphisms. GG homozygotes are shown in lane 4, 9, 11, 13 and 14 (290bp, 100bp and 31bp), AA 
homozygotes are in Lane 1, 8, 15 and 17 (321bp and 100bp), and GA heterozygotes are in lanes 2, 3, 5, 6, 7, 





10, 12, 16 and 18 (321bp, 290bp, 100bp and 31bp). (2) Confirmation of polymorphism at CD14/-1359 by 
sequence analysis. A: GG homozygote; B: GT heterozygote and C: TT homozygote. All sequences are 5’-
3’. 
 
3.2.6.2 Genotype frequency 
The genotype frequencies of CD14/-1145 were in agreement with the Hardy-Weinberg 
equilibrium in every group. No significant difference between atopic group and non-
atopic control group was found in the genotypes of CD14/-1145 (Table17).  
Table 17. Genotypes distribution of CD14/-1145 in non-atopic and atopic subjects 
and Hardy-Weinberg Equilibrium 
 
The G allele occurred in 57% atopic patients vs. 61% controls in Chinese, 42% atopic 
patients vs. 64% controls in Malays, and 56% atopic patients vs. 50% controls in Asian 
Indians. No significant difference of allele frequency was found between atopic and non-
atopic groups. There was neither significant difference in the frequency of the G allele 
among Chinese, Malay and Asian Indian populations (Table 18). 
Table 18. Comparison of CD14/-1145 allele frequency among three different ethnic 
groups 
 




   G     A Atopy z-test  
    (p-value) 
Non-atopy z-test 
      (p-value) 
Non-atopy  61% 39% Chinese 
 Atopy 57% 43% 
Non-atopy 64% 36% Malays 
Atopy 42% 58% 
Non-atopy 50% 50% Asian 
Indians Atopy 56% 44% 
Chinese & Malays 
 z=-1.44, NS 
Chinese & Indians 
 z=0.29, NS 
Malays & Indians 
 z=1.54, NS 
Chinese & Malays 
 z=1.74, NS 
Chinese & Indians 
 z=0.18, NS 
Malay & Indians 
 z=-1.63,  NS 













GG 30% (48) 31% (53) 41% (9) 20% (5) 26% (11) 30% (15) 
GA 45% (72) 51% (85) 45% (10) 44% (11) 48% (20) 52% (26) 















P-value 0.233 0.134 0.635 
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3.2.6.3 Association between CD14/-1145 polymorphism and sCD14 
 
There was no significant difference of sCD14 levels among GG, GA and AA genotypes 
in either non-atopic or atopic groups (Table19). 
Table 19. sCD14 levels by CD14/-1145 genotypes in Chinese group (n=130). Results are 
expressed as mean and 95% confidence interval for mean (ug/ml)  
 
CD14 SNPs  Non- atopy group 
          n=32 
      Atopy group 

















                 
3.2.6.4 Association between CD14/-1145 polymorphism and tIgE levels 
No statistical difference between serum total IgE and CD14/-1145 genotypes could be 
found in Chinese and Asian Indian populations (Table 20). In Malay non-atopy group, 
AA seemed to be associated with higher IgE than GG and GA did (p=0.013), but the 
frequency of AA in this subgroup is very low (3). 
 
Table 20. Geometric mean (95% CI of the mean) serum tIgE(kU/l) by CD14/-1145 
genotypes in three ethnic groups 
 
Chinese 
Serum tIgE  
Malays 
Serum tIgE  
Asian Indians 




 Non-atopy Atopy Non-atopy Atopy Non-atopy Atopy 






















































p value 0.100 0.390 0.013 0.50 0.82 0.92 
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3.2.6.5 Association between CD14/-1145 genotypes and atopic phenotypes  
The association between the polymorphism of CD14/-1145 and atopic diseases was 
analyzed (Table 21). There was no significant difference between non-atopic and atopic 
disease groups in Chinese and Asian Indians. In Malay group, there was a significant 
difference of the allele frequency between atopic and non-atopic subgroups (p=0.036), 
and also a significant difference between allergic asthma and non-allergic asthma 
subgroups (p=0.017). G allele frequency was 57.7% in non-allergic asthma subgourp and 
25% in allergic asthma subgroup. The result suggested that there could be an association 
between the atopic state and the CD14/-1145 polymorphism in Malay population. 
 











 (p value) 
Chinese 
 
Atopy vs non-atopy 
Asthma vs non-asthma 
Allergic asthma vs non-allergic asthma 
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Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 












Atopy & non-atopy 
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 











3.2.7 CD14/-1359 polymorphism 
 
3.2.7.1 RFLP results  
 
Identification of the polymorphism of CD14/-1359 was done by RFLP assay using 
restriction endonuclease BpmI. Commercially available BpmI endonuclease (New 
England) is specific for the following sequence:  
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5´ ... C T G G A G (N)16^... 3´ 
3´ ... G A C C T C (N)14^... 5´ 
 
It is present only in the subjects carrying the CD14/-1359G allele. PCR products only in 
those subjects with the CD14/-1359G allele could be digested to yield two bands of 164 
bp and 134 bp. Thus, the assay yielded two bands of 164bp and 134 bp for GG 
homozygotes, three bands of 298 bp, 164 bp, and 134 bp for GT heterozygotes and two 
bands of 298 bp for TT homozygotes.  
 
Figure 17 shows results of RFLP assay for CD14/-1359. RFLP results of CD14/-1359 
were confirmed by DNA sequencing with 10 random samples. All were found to be 
concordant with genotypes obtained from RFLP analysis. 
                            (1)              1      2       3     4      5      6      7 
 
    (2) 
     
   
Figure 17. CD14/-1359 polymorphism results. (1) RFLP results of CD14/-1359 polymorphism. 
GG homozygotes are shown in lane 1, 3 and 6 (164bp and 134bp), TT homozygotes are in Lane 5 (298bp), 
and GT heterozygotes are in lanes 2, 4 and 7 (298bp, 164bp and 134bp). (2) Confirmation of polymorphism 
at CD14/-1359 by sequence analysis. A: GG homozygote; B: GT heterozygote and C: TT homozygote. All 
sequences are 5’-3’. 
 
 







3.2.7.2 Genotype frequency  
 
The genotype frequencies of CD14/-1359 were in agreement with the Hardy-Weinberg 
equilibrium in every group. There was no significant difference in the frequency of the C 
allele between non-atopic and atopic groups in all three ethnic groups (Table 22). 
 
Table 22. Genotypes distribution of CD14/-1359 in non-atopic and atopic subjects 
and Hardy-Weinberg Equilibrium 
 













GG 43% (69) 47% (80) 57% (13) 36% (9) 57% (24) 52% (27) 
GT 42% (67) 46% (79) 35% (8) 48% (12) 31% (13) 46% (24) 















P-value 0.060 0.347 0.078 
 
There was also no significant difference in the frequency of the C allele among Chinese, 
Malay and Indian populations (Table 23). 
 
Table 23. Comparison of CD14/-1359 allele frequency among three different ethnic 
groups 
 




   G     T Atopy z-test  
    (p-value) 
Non-atopy z-test 
      (p-value) 
Non-atopy 66% 34% Chinese 
 Atopy 70% 30% 
Non-atopy 74% 26% Malay 
Atopy 60% 40% 
Non-atopy 73% 27% India 
Atopy 75% 25% 
Chinese & Malay 
 z= -1.05, NS 
Chinese & India 
 z= -1.12, NS 
Malay & India 
 z= 0.12, NS 
Chinese & Malay 
 z= 1.36, NS 
Chinese & India 
 z= -1.02, NS 
Malay & India 
 z= -1.85, NS 
 
 
3.2.7.3 Association between CD14/-1359 polymorphism and sCD14 
 
In atopic and non-atopic groups, no significant difference for sCD14 could be observed 
among GG, GT and TT genotypes (Table 24). 
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Table 24. sCD14 levels by CD14/-1359 genotypes in Chinese group (n=130). Results are 









3.2.7.4 Association between CD14/-1359 polymorphism and tIgE levels 
 
No statistical difference between serum total IgE and CD14/-1359 genotypes could be 
found in Chinese, Malay and Asian Indian populations (Table 25). 
 
Table 25. Geometric mean (95% CI of the mean) serum tIgE(kU/l) by CD14/-1359 
genotypes in three ethnic groups 
 
Chinese 
Serum tIgE  
Malays 
Serum tIgE  
Asian Indians 































































3.2.7.5 Association between CD14/-1359 polymorphism and atopic phenotypes 
The association between this polymorphism of CD14/-1359 and the atopic disease was 
analyzed. There was no significant difference between non-atopic and atopic disease 
groups in Chinese and Asian Indians (Table 26). In Malay group, there was a significant 
difference of genotype frequency between allergic asthma and non-allergic asthma 
CD14 
SNPs 
 Non- atopy group 
          n=32 
      Atopy group 














subgroups (p=0.015). G allele frequency was about 63.7% in non-allergic asthma 
subgourp and 42% in asthma subgroup. The result showed that there could be an 
association between the atopic state and the CD14/-1359 polymorphism in Malay 
population. 










3.2.8 CD14/-1619 polymorphism 
The polymorphism of CD14/-1619 was identified by allele specific PCR. PCR was 
carried out in a volume of 20 µl containing 30 ng genomic DNA, 10×buffer, 0.2mM 
dNTP, 1 unit Taq polymerase (Promega), 0.1µM control primers and 0.4 µM allele 
special primers. A couple of control primers were: 5’- CTG GAG TCA GAA TGA GGC 
AC -3’ (forward) and 5’- CTC AGC TGA TAA AGG AGC TC -3’ (reverse). The other 
allele specific primers were: 5’- GAA CAA AAC TCC GTC TCA AAT AAA TAA ATA 
AAT A -3’ (forward of wile type) OR 5’- GAA CAA AAC TCC GTC TCA AAT AAA 
TAA ATA AAT G -3’ (forward of mutant type), and 5’- CTA GAC CTC TGG GGA 
AAG AAC TAT ATG AAA-3’ (common reverse). PCR for each sample was conducted 
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different allele specific forward primers, one for wild type and the other for mutant type. 
The wide type DNA could only be amplified by the wild type primer while the mutation 
DNA amplified by the mutation primer. The DNA was denatured at 95ºC for 3 minutes, 
and the temperature cycling was set at 95ºC for 30 seconds, 59ºC for 40 seconds and 
72ºC for 40 seconds totally for 35 cycles, followed by a final extension at 72ºC for 10 
minutes. The size of the generated PCR products was 960 bp for control and 376 bp for 
identifying the polymorphism at CD14/-1619 (Figure 18).  
 
Only 40 samples were chosen for identification of the polymorphism. However, the 
genotype frequencies of CD14/-1619 were not in agreement with the Hardy-Weinberg 
equilibrium. Therefore, we did not check more samples and did not conduct association 
study on this polymorphism. However, we at least confirmed that this polymorphism also 
existed in our population.  
             1       1      2      2     3     3      4      4 







   
   
Figure 18. Allele specific PCR results of CD14/-1619. AA homozygotes are shown in 










3.2.9 Linkage disequilibrium among polymorphisms on the CD14 promoter  
A significant linkage disequilibrium was found among these four loci of CD14 promoter 
(r
2
>0.3) (Table 27).  
Table 27. Pair-wise linkage disequilibrium of CD14 gene 
 
all pairs of 
loci of CD14 
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3.2.10 Association between haplotypes and atopic phenotypes 
Haplotypes of CD14/-159, –550, -1145, -1359 were analyzed by Phase-Standard analysis 
(version 2.0.2). Our study found a total of fourteen haplotypes in Chinese population, 
among which three haplotypes are common, i.e., CD14/-159T/-550C/-1145G/-1359G 
(49.1%), CD14/-159C/-550T/-1145A/-1359T (28.1%), CD14/-159C/-550C/-1145A/-
1359G (11.8%). We also found that there is no significant association between frequency 
of the haplotypes, serum sCD14, tIgE, and phenotypes of allergic diseases (allergic 
rhinitis and asthma) in our subjects (Table 28). In addition, we analyzed the association 
between haplotypes and sCD14, tIgE and atopic in Malay and Asian Indian, and no 
association of these 3 common haplotypes with concentrations of sCD14, tIgE and atopic 








Atopic Asthmatic Rhinitic Haplotype at 









(95% CI) No Yes No  Yes  No  Yes 




149 176 287 36 187 136 




93 93 171 15 114 72 




35 43 68 10 44 34 
p-value  0.148 0.088  0.610  0.412  0.681 
 
3.2.11 Association between sCD14 and tIgE levels 
According to the hypothesis of CD14, an inverse association should exist between sCD14 
and IgE levels. Therefore, we analyzed the association between sCD14 and total serum 
IgE levels. The result showed that r value was -0.032, and p value was 0.715. We could 
not find the inverse association between sCD14 and IgE levels (Figure19). In addition, 
the scatterplot figure showed that there were lower total IgE levels in non-atopic group 
while higher total IgE levels in atopic group, but there was no regular distribution of 
sCD14 in atopic and non-atopic groups. 















       2
       1
  
r=0.032, p= 0.715 
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Figure 19. No correlation between sCD14 and serum tIgE level. Every spot stands for 
concentration of sCD14 and tIgE levels for every subject.  Red color spot refers to the subjects in non-
atopic group; green color spot refers to the subjects in atopic group. 
      
 
3.2.12 Functional study  
 
3.2.12.1 Transcription factor binding sites on CD14 promoter 
Before functional study for the promoter, we need learn whether the promoter 
polymorphisms affected the binding of transcription factor, and we used Match
TM
 to 
analyze the binding sites of the CD14 promoter. 
The result demonstrated that the CD14/-1145 polymorphism was exactly located on the 
transcription factor C/EBP and Oct-1 binding site in the cells (Table 29). Thus the 
polymorphism might affect the binding of transcriptional factors and furthermore affect 
the CD14 expression. In addition, software MatInspector was also used, but no binding 
sites could be found on or near CD14 promoter polymorphisms. 
Table 29. Match results for the CD14 promoter. Tissue specificity of the transcription 
factors in TRANSFAC position; potential binding sites for transcription factors and the name of 
transcription factors. CD14/-1145 polymorphism was exactly located on TTTGC in all cells. 
 
           
Muscle 
V$CEBP_C        336 (-)  0.949  0.908  tgtttTTTGCaaaactgg     C/EBP              
V$OCT1_Q6       337 (-)  1.000  0.836  gtttTTTGCaaaact        Oct-1 
 
Immune cells 
V$CEBP_C        336 (-)  0.949  0.908  tgtttTTTGCaaaactgg     C/EBP            
V$OCT1_Q6       337 (-)  1.000  0.836  gtttTTTGCaaaact        Oct-1 
 
Cell cycle 
V$CEBP_C        336 (-)  0.949  0.908  tgtttTTTGCaaaactgg     C/EBP                
V$OCT1_Q6       337 (-)  1.000  0.836  gtttTTTGCaaaact        Oct-1 
 
Liver 
V$CEBP_C        336 (-)  0.949  0.908  tgtttTTTGCaaaactgg     C/EBP            
V$OCT1_Q6       337 (-)  1.000  0.836  gtttTTTGCaaaact        Oct-1 
 
Best 
V$OCT1_Q6       337 (-)  1.000  0.836  gtttTTTGCaaaact        Oct-1 
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3.2.12.2 Selection of suitable cell lines 
In order to check whether the CD14 promoter polymorphisms affected the CD14 
expression, the first and most important thing was to select a suitable cell line for 
transfection. Since CD14 is specifically and highly expressed in monocytic cells as well as 
in the human liver (Li et al., 2002), we chose THP-1, U937 and HepG2 as the cell lines for 
studying the CD14 promoter activity. The expression in cell lines was determined by 
confocal microscope and flow cytometry.  
 
3.2.12.2.1 CD14 expression in HepG2 
The expression of CD14 for adherent cell lines was determined by confocal microscope. To 
do that, HepG2 cells were treated with or without LPS respectively, and stained with 
immunofluorecent CD14-FITC (protocol in chapter 2.11). Figure 20 shows the confocol 
pictures of immunofluorecent staining of HepG2 Cells with or without LPS stimulation. 
 
3.2.12.2.2 CD14 expression in THP-1 and U937 
The expression of CD14 in suspension cell lines was determined by flow cytometry 
(protocol in chapter 2.12). To do that, THP-1 and U937 cell lines were cultured by routine 
methods and stained using CD14-FITC to confirm CD14 expression in these two cell lines. 
IgG2α-FITC was used as a negative control. Figure 21 shows that 5.1% THP-1 cells were 
stained by CD14-FITC, while Figure 22 shows that only 0.1% U937 cells were stained by 
CD14-FITC, which demonstrated that the expression of CD14 in U937 was relatively low. 
In order to test whether U937 had CD14 expression, U937 cells were cultured with LPS 
(100ng/ml) for 36 hours and stained again, and the results showed that 1.6% U937 cells 
were stained by CD14-FITC (Figure 23). The data of flow cytometry demonstrated that 
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THP-1 and U937 had CD14 expression and could be selected as the suitable cell lines for 
activating the CD14 promoter. Figure 21, 22 and 23 shows the results of flow cytometry 




Figure 20. CD14 immunofluorecent staining of HepG2 Cells (20×). A and B: HepG2 
negative control; C and D: immunofluorecent staining of HepG2 Cells; E and F: immunofluorecent staining 













Figure 21. Results of CD14-FITC binding to THP-1 cells. (A) Histogram: IgG2α-FITC 
staining THP-1 as background control. (B) Histogram: CD14-FITC staining THP-1. (C) Histogram: 
Overlay of A and B. (D) DotPlot: IgG2α-FITC staining THP-1 as background control. (E) DotPlot: CD14-
FITC staining THP-1. (F) DotPlot: Percentage of CD14-FITC staining THP-1 except background. 5.1% 
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Figure 22. Results of CD14-FITC binding to U937 cells. (A) Histogram: IgG2α-FITC staining 
U937 as background control. (B) Histogram: CD14-FITC staining U937. (C) Histogram: Overlay of A and 
B. (D) DotPlot: IgG2α-FITC staining U937 as background control. (E) DotPlot: CD14-FITC staining U937. 
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Figure 23. Results of CD14-FITC binding to U937 cells stimulated by LPS for 36 
hours. (A) Histogram: IgG2α-FITC staining U937 as background control. (B) Histogram: CD14-FITC 
staining U937 stimulated by LPS for 36 hours. (C) Histogram: Overlay of A and B. (D) DorPlot: IgG2α-
FITC staining U937 as background control. (E) DorPlot: CD14-FITC staining U937 stimulated by LPS for 
36 hours. (F) DotPlot: Percentage of CD14-FITC staining U937 stimulated by LPS for 36 hours. 1.6% 
U937 cells were stained by CD14-FITC. 
 
 
3.2.12.3 Results of transformation using DH-5α 
The functional significance of SNPs in the 5’-flanking region of the CD14 gene was 
investigated using reporter gene assay. A total of 8 plasmid constructs were prepared by 
inserting DNA fragments, which contained a single polymorphism of -159/C and T 
(position -513/+179), -550/C and T (position -578/-167), two common haplotypes with 
two polymorphisms <-159/C -550/T> and <-159/T -550/C> (position -578/+179), and 
two haplotypes with all four together: <-159/C -550/T -1145/A -1359/T> and <-159/T -




550/C -1145/G -1359/G> (position -1719/+179) (Figure 24). According to previous study, 
CD14/-159 was considered as wild type, in order to simply mark the plasmids, all 
plasmids with CD14/-159C were named as wild type plasmids and plasmids with CD14/-




Figure 24: Structure of 8 constructed plasmids.  
 
The inserted DNA fragments were created by PCR amplification of genomic DNA from 
two individual homozygotes representing the two most common haplotypes (Table 28), 
and were amplified using an appropriate set of primers which were incorporated by the 
specific cleaving sequence for restriction endonucleases Xho-I or Hind-III (Table 4). The 
generated PCR products were digested with Xho-I or Hind-III and the cleaved products 
were cloned into the pGL3-Basic plasmid. All constructed plasmids were transformed 
into E.Coli (DH-5α) by heat-shock. Because pGL3-Basic vector had Amp
r
 gene, only the 
E. Coli transformed successfully by pGL3-constructed plasmids could form clones in LB 
5’-1359/TT -1145/AA  -550/TT -159/CC 3’ (1891bp) 
 5’-1359/GG -1145/GG  -550/CC -159/TT 3  (1891bp) 
5’ -550/TT   -159/CC 3’  (757bp) 
 5’ -550/CC   -159/TT 3’  (757bp) 
5’  -159/CC  3’ (692bp) 
  5’  -159/TT   3’ (692bp) 
5’-550/TT 3’  (411bp) 
 5’-550/CC 3’ (411bp) 
 114 
plate containing penicillin. Figure 25 shows that one of the constructed plasmids was 





Figure 25. A constructed plasmid transformed into E.Coil in the LB plate. A: a LB 
plate containing penicillin with clones. B: Clones in the LB plate containing penicillin. 
 
 
3.2.12.4 Gel electrophoresis to confirm the constructed plasmids 
The amplified fragments with different polymorphisms of CD14 were inserted into the 
pGL3-Basic vector and cloned into competent cells. In order to confirm whether the 
constructed plasmids contained the polymorphisms of CD14, the DNA of the constructed 
plasmids was digested with matched restriction enzymes. Agarose gel electrophoresis 
was used to screen the correct plasmids with the inserted DNA containing different 
polymorphisms and pGL3-Basic vectors (Figure 26, Figure 27). 
 
 
 B A 
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Figure 26.  Gel electrophoresis to confirm inserted DNA (A). The DNA sizes for 
constructed plasmids with CD14/-159C (-159CC) and CD14/-159T (-159TT) are 4818bp and 692bp; for 
those with CD14/-550C (-550CC) and CD14/-550T (-550TT) are 4818bp and 411bp; for those containing 
CD14/-159C, -550T (C) and CD14/-159T, -550C (C) are 4818bp and 757bp. 
 
 
                               
 
Figure 27. Gel electrophoresis to confirm inserted DNA (B). The DNA sizes for constructed 
plasmids with four polymorphisms CD14/-159C, -550T, -1145A, -1359T (C2/FP) and CD14/-159T, -550C, -
1145G, -1359G (C15/FP-1 and C15/FP2) are 4818bp and 1894bp.  
 
 
Figure 27 shows that both C15/FP-1 and C15/FP-2 plasmids have inserted DNA but with 
different sizes. We used PCR and restriction enzyme digestion to choose the correctly 
constructed plasmids. Three plasmid DNA and primers for CD14/-159 were used for PCR. 
The DNA fragment of 497bp was amplified to confirm that the plasmid had inserted DNA. 
The DNA fragments were digested using AvaII to confirm that C2/FP had CD14/-159C 
pGL3-Basic vector DNA 
Inserted DNA 
pGL3-Basic vector DNA 
Inserted DNA 
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and C15/FP2 had CD14/-159T (Figure 28). Here, PCR conditions were not optimized since 
we only need to screen for the constructed plasmids.  
                                 
 
Figure 28. Gel electrophoresis to confirm inserted DNA (C). Three lanes to the left of the 
marker are PCR products, and three lanes to the right are digestion results.  
 
3.2.12.5 Sequence analysis to confirm the constructed plasmids 
Sequence analysis was used to confirm whether the 8 constructed plasmids contained the 
correctly inserted DNA with different polymorphisms of CD14. Sequencing reactions were 
done using standard protocol. After that, Blast was then used to test these plasmids with 
both sequencing of pGl-3 and inserted DNA (http://www.ncbi.nlm.nih.gov/blast/bl2seq). 
The results of Blast confirmed that the 8 constructed plasmids contained PGL-3 vectors and 
fragments of the CD14 promoter with different polymorphisms. CD14/-159, -550, -1145 
and -1359 were confirmed in the constructed full length promoter plasmids by sequence 
analysis. Table 29 and Table 30 show that the 8 constructed plasmids contain the wild type 
and mutation fragments of CD14 gene.  
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B: Constructed Plasmid (5’-1359/GG, -1145/GG, -550/CC, -159/TT 3’) 






Figure 30. Sequence results for 2 constructed. A: Constructed Plasmid (5’-1359/TT, -1145/AA, 
-550/TT, -159/CC 3’); B: Constructed Plasmid (5’-1359/GG, -1145/GG, -550/CC, -159/TT 3’) 
 
3.2.12.7 RLA results 
Transcriptional activity of these polymorphisms was investigated using reporter gene assay. 
Three cell lines HepG2, THP-1 and U937 were used. They were transiently transfected 
with the 8 different plasmid constructs as described. Results were expressed as fold 
increase in relative luciferase activity (RLA) of the constructed plasmids compared to that 
of pGL-3-Basic. The data was analyzed by both Paired Samples T Test and Wilcoxon 
Signed Ranks Test. The p value of Paired Samples T Test is shown in Tables 30-33. In 
addition, the times for transfection in different cell lines are also shown in the tables.   
 
3.2.12.7.1 RLA results of HepG2 
HepG2 cells were transiently transfected with each of the 8 constructed plasmids or 
PGL3-Basic and a control Renilla luciferase reporter plasmid (pRL-CMV, promega) 
using lipofectamine 2000. The RLA result for HepG2 cell line is shown in Table 30. 
There was no statistically significant difference in transcriptional activity between the 
constructed plasmids with a single construct at CD14/-159 (-159C vs -159T) or at CD14/-
550 (-550C vs -550T), and the combination of these two polymorphisms showed no 
statistically significant difference either. The fold increase of RLA was significantly 
higher when cells were transfected with the plasmids containing two polymorphisms of 
CD14/-159 and CD14/-550 (p<0.05). This may be due to a larger fragment inserted. 
When plasmids with the four polymorphisms were transfected, there was a significant 
difference in promoter activity between the wild type plasmid  (5’-1359/TT, -1145/AA, -
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550/TT, -159/CC 3’) and the mutation plasmid (5’-1359/GG, -1145/GG, -550/CC, -
159/TT 3’) in the HepG2 cell line, but the increase in the fold of RLA was low. 
 






















15 15 19 19 19 19 19 19 




0.60 0.92 0.98 0.85 0.83 0.99 1.13 1.02 
P value 0.030 0.673 0.875 0.494 
 
* stands for difference between wild-c and wild-159/ wild-550 (p<0.05) 
# stands for difference between mutation-c and mutation-159/mutation-550 (p<0.05) 
 
 
HepG2 cells were stimulated with LPS (100ng/ml, Sigma-Aldrich) for 6 hours before 
measuring luciferase activity. However, we could not find any significant difference in 
promoter activity between wild type plasmids and mutation plasmids in HepG2 cell lines 
using LPS stimulation (Table 31).  
 
Table 31. Increase of RLA for CD14 promoter with different polymorphisms in 

















4 4 4 4 4 4 
Mean 3.14 2.89 2.06 2.14 2.31 2.29 
Std. 
Deviation 1.95 2.12 1.22 0.83 1.50 1.42 
p value 0.216 0.831 0.944 
 
 
3.2.12.7.2 RLA results of THP-1 
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THP-1 cells were transiently transfected with each of the 8 constructed plasmids or PGL3-
Basic and a control Renilla luciferase reporter plasmid respectively by electroporation. 
There was no significant difference in promoter activity between all pairs of wild type and 
mutation promoters. All p values were more than 0.05 (Table 32).   
 






















6 6 12 12 12 12 12 12 
Mean 1.25 2.83 2.06 1.71 1.32 1.40 2.45 2.31 
Std. 
Deviation 
0.145 1.69 0.68 0.64 0.77 0.81 1.33 1.34 
P value 0.079 0.064 0.814 0.269 
 
 
3.2.12.7.3 RLA results of U937 
U937 cells were transiently transfected with each of the 8 constructed plasmids or PGL3-
Basic and a control Renilla luciferase reporter plasmid respectively by electroporation. 
There was no significant difference in promoter activity between all pairs of wild type and 
mutation promoters. All p values were more than 0.05 (Table33).   
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1.16 1.74 1.42 0.80 0.46 0.60 0.21 0.36 
P value 0.072 0.128 0.779 0.293 
 











































Figure 31. Relative luciferase activity (RLA) of transfected cells. HepG2, THP-1 and U937 
were transiently transfected with different plasmid constructs as described. The numbers in bracket show the 
time of transcription. Luciferase activity was normalized for transfection efficiency using a control plasmid 
pRL-CMV. Results are expressed as fold increase in RLA of the CD14 promoter construct vector as 
compared to pGL3-Basic. #There is a significant (p=0.03) difference between constructions of (5’-1359/G, -
1145/G, -550/C, -159/T 3’) and (5’-1359/T, -1145/A, -550/T, -159/C 3’) in HepG2 cell lines only.  
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5’ -1359/TT,-1145/AA,-550/TT,-159/CC 3’ 
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3.2.13 Sequence analysis of the CD14 exon 
In order to investigate whether other polymorphisms exist in the CD14 exon, we screened 
the complete CD14 exon.  
 
3.2.13.1 PCR   
The polymorphism of CD14 exon was investigated by sequence analysis. The primers 
were: 5’-CCC TCC CTG AAA CAT CCT TC -3’ (forward) and 5’- CCA GCA CAT 
AGC AGA CAT CC-3’ (reverse). The size of the generated PCR products was 1649 bp 
(Figure 32).  
 
 
Figure 32.  CD14 exon PCR results. The size of PCR product was 1649 bp. 
 
 
3.2.13.2 Sequence analysis  
  
25 subjects (12 non-atopic controls and 13 atopic patients) were selected at random for 
sequence analysis. Two original primers for PCR and another primer (5’- CGG CAG 
TAT GCT GAC ACG -3’) in the middle of the sequence were used for sequence analysis 
to generate the three overlapping DNA sequencing results. Two novel polymorphisms in 
exon region of CD14 gene were identified at position +264 (T to C) and +891 (G to A) 
(Figure 33). CD14/+891 heterozygote was found in 4 subjects (3 atopic and 1 non-atopic) 
and CD14/+264 heterozygote in 1 non-atopic subject. The A allele frequency of 
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CD14/+891 was 8% and the T allele frequency of CD14/+264 was 2%. These two novel 




Figure 33. Sequencing results of two novel polymorphisms on CD14 exon.  T to C 
polymorphism was identified on CD14/+264, G to T polymorphism was identified on CD14/+891.  
 
3.3 Discussion 
A family history of atopic disease has been recognized as a strong genetic risk factor for 
development of allergic symptoms, irrespective of various environmental risk factors in 
different societies. However, the mode of inheritance of atopy and atopic diseases 
remains an intense area of research. In addition to various reported candidate genes, the 
Homozygote of  
CD14/+264TT 
Heterozygote of  
CD14/+264TC 
 
Homozygote of  
CD14/+891GT 
Homozygote of  
CD14/+891GG 
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association between CD14 polymorphisms and atopy has received great attention 
worldwide. CD14 interacts with different components of Gram-negative bacteria, as well 
as fungi, acting as a central pattern recognition molecule in innate immunity (Haziot et 
al., 1988). It may modulate immune responses by repositioning the endotoxin switch 
along the bacterial load axis. It was explained that carriers of CD14/-159 T with higher 
CD14 expression would require less environmental endotoxin to switch to Th1 responses 
and would therefore be more protected from allergic inflammation than the CD14/-159C 
individuals (Vercelli, 2003). However, conflicting data has been reported during the past 
few years (Lis et al., 2001; Sengler et al., 2003; Heinzmann et al., 2003). 
 
Our study was carried out in two steps, i.e., to illustrate the localization of CD14 
promoter polymorphisms and their relationship with atopic phenotypes in Singaporean, 
and the subsequent biological characterization of these polymorphisms. In the first step, 
our data confirmed all three previously reported SNPs (CD14/-159, CD14/-1359, CD14/-
1145) in Singapore population. In addition, we also identified a novel SNP at position 
CD14/-550 which was common among the Singapore Chinese population. These four 
polymorphisms had a strong linkage disequilibrium, but did not have any significant 
association with atopic phenotypes in single or combined analysis in Chinese and Asian 
Indian groups. The association could only be found between CD14 polymorphisms and 
atopic phenotypes in Malay group. However, the sample size for Malay group is not 
enough, the statistic power for Malay population is only 31%, therefore, we could not 
draw conclusion. More samples should be added in order to confirm the results.  
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We compared the allele frequencies with previous studies. Taking the Chinese group as 
an example, the result suggested that the C/G allele frequency was 46% (at CD14/-159) 
and 64% (at CD14/-1359) in non-atopic group. The C allele frequency of CD14/-159 was 
found to differ from that of other ethnic groups, such as USA (51.4%) and Germany 
(54.0%), but comparable to that from UK (48.0%) and Japan (40.0%) (Gao et al., 1999; 
Baldini et al., 1999; Sengler et al., 2003). The G allele frequency of CD14/-1359 was 
reported as 76.2% in a German study (Heinzmann et al., 2003), which was slightly higher 
than that in our population (64%). Although we do not know whether there is significant 
difference in statistics, these data confirmed that different ethnic background might alter 
allele frequencies of phenotype-associated genes in humans. However, we could not find 
any significant difference of the allele frequency in different races in Singapore 
population including Chinese, Malays and Asian Indians. 
 
Our study found a total of eleven haplotypes, among which three haplotypes are 
common, i.e., CD14/-159T/-550C/-1145G/-1359G (49.6%), CD14/-159C/-550T/-1145A/-
1359T (27.7%), and CD14/-159C/-550C/-1145A/-1359G (13.2%). There is no significant 
association found between the haplotypes and serum sCD14, tIgE or phenotypes of 
allergic diseases (allergic rhinitis and asthma) in Chinese and Asian Indian groups.  
 
In our association study, no significant associations could be found in Chinese and Asian 
Indian groups. Only in Malay population, we found CD/-159, -1145 and -1359 
polymorphisms had significantly different allele frequencies between non-allergic asthma 
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and asthma subgroups (p=0.003, 0.017 and 0.015 respectively). Furthermore, CD14/-
1145 may have relationship with IgE level with (p=0.013).  
 
In the second step, the transcriptional activity of these polymorphisms was investigated 
using reporter gene assay system (LeVan et al., 2001). CD14 is mainly secreted by 
monocytes and hepatocytes (Hetherington et al., 1999; Li et al., 2002).
 
Hence, the three 
cell lines HepG2, THP-1 and U937 were used. The CD14 promoter segments with 
different lengths, including individual polymorphisms of CD14/-159 and –550, were first 
constructed into PGL3-Basic vector. For CD14/-159, we inserted a longer DNA fragment 
(692bp at the position of -513/+179) in the reporter vector than that was used in LeVan et 
al’s study (304bp at the position of -232/+72) (LeVan et al., 2001).
 
The three cell lines 
were transfected with the 6 constructed plasmids. Subsequently, the fold increase of RLA 
was used to quantify the effects of the CD14 promoter polymorphisms. 
 
Our data showed no significant difference between any couple of the polymorphisms in 
all the three cell lines. However, we found that except in THP-1, RLA was significantly 
higher in the plasmids constructed by the two polymorphisms of –159 and –550 than in 
those plasmids having just one polymorphism. One possible explanation may be that the 
combination of the two polymorphisms results in the increase of transcriptional activity. 
Another more possible explanation may be that those longer promoters result in the 
increase of RLA. Therefore, the studies of polymorphisms of promoters might suffer 
from the bias of an incomplete promoter. Although it is impossible to complete avoid the 
bias, in order to decrease bias due to incomplete promoters, it was necessary to study the 
 128 
longer CD14 promoter with different polymorphisms. Therefore, two fragments of DNA 
about 2000bp containing all four polymorphisms (CD14/-159, -550, -1145 and -1359) 
were constructed into pGL3-BASIC vectors. A significant difference could be found 
between different polymorphisms only when four polymorphisms were inserted together 
in HepG2 (p=0.03). The reporter assay showed that mutation in the promoter could 
increase the gene expression in HepG2. Similar significant difference could not be found 
in THP-1 and U937. However, the fold increase of RLA is lower in both cases. Hence, 
we conclude that these polymorphisms may not have decisive effects on the 
transcriptional efficiency of CD14 gene.  
 
Although the polymorphism of CD14 promoter seemed to play a little role, the function 
result was consistent with our association result in Malay population, since the mutation 
allele frequency was higher in non-allergic asthma group. However, we could not 
confirm the relationship between the four polymorphisms of CD14 and atopy in our 
Chinese and Asian Indian groups. In Malay group, there was an association between 
CD14 polymorphisms and allergic asthma, however the sample size of Malay group in 
this study was relatively small, and a larger group of Malay population would be 
necessary to confirm the role of CD14 polymorphisms. 
 
The reason for pursuing a functional study was due to the conflicting results in 
association studies between CD14 promoter polymorphisms and atopic manifestations 
from reports of other studies and our data. It has been shown that the T allele results in 
decreased affinity of DNA/protein interactions at a GC box that contains a binding site 
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for transcription factors Sp1, Sp2 and Sp3 (Baldini et al., 1999). In the same study, the 
authors were able to demonstrate a 32% increase in transcriptional activity from C to T 
for SNP at CD14/-159 in a constitutive gene expression. To confirm this finding, DNA 
sequence from position CD14/-2390 to CD14/+1, covering the entire four polymorphic 
sites, was inspected for any potential transcription factor binding sites using Matinspector 
on-line tool (http://www.gene-regulation.com/index.html). Although all polymorphisms 
of CD14 promoter were near some known transcriptional factor binding sites, no exact hit 
was obtained. Therefore, we thought it was worthwhile to perform the reporter assays and 
to confirm their functional activity by including the other three polymorphisms of CD14 
promoter. At the time of completing this study, we noticed an updated version of MatchTM 
program (http://www.gene-regulation.com/pub/programs.html#match) and repeated the 
inspection using the same DNA sequence. In this occasion, we could only find that the 
CD14/-1145 polymorphism is located on the transcription factor C/EBP and Oct-1 
binding site. We could assume that the transcriptional activity of CD14/-1145 is 
miniscule. Otherwise, one would be able to see a major change in the combination of all 
four polymorphisms in our experiments. In addition, the polymorphisms at different cells 
might affect the transcription, since different cell types appeared to possess different 
transcription activity. 
 
It is known that atopy may be regulated by the interaction of multiple genes and multiple 
environmental factors, and the difference of ethnicity, environment and age may affect 
the results. According to the hypothesis of endotoxin switch, a dose-dependent 
relationship is between environmental exposure to bacterial products and the outcome of 
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the immune response (Vercelli, 2003). The quantity of environmental endotoxin may also 
affect the balance of the Th1/Th2 cytokine level. CD14 may have a dual effect on IgE 
level, inhibitory or enhancing, depending on the biological context and timing of 
stimulation (Lapa e Silva et al., 2000; Vercelli, 2003). Even if CD14 plays an important 
role in mediating the response to LPS in allergic procedures, other genes, such as TLR-4, 
IL-12 and IL-18, may also be involved in this complex pathophysiology stage. Therefore, 
one or two genetic variations might not be sufficient to cause diseases in individuals.  
 
In addition, different population based on different recruiting criteria may also affect the 
result. Unlike the population used by Baldini et al. (Baldini et al., 1999), all subjects in 
our study were adults. A recent study showed that the influence of CD14/ -159C on 
atopic phenotypes might be age-specific, exerting an effect during midchildhood, which 
is no longer apparent by early adulthood (O’Donnell et al., 2004). A protective effect of 
the T allele of SNP CD14/-159T against atopic disorders was found in 344 2-year old 
children (Litonjua et al., 2005). We can not exclude the possibility that CD14 
polymorphisms might play a more important role for the atopic state in children than in 
adults. 
 
In this study, two novel polymorphisms in the exon region of CD14 gene were identified 
at position +264 (T to C) and +891 (G to A). The allele frequency of CD14/+891A was 
8% and the allele frequency of CD14/+264T was 2%. But the results were only acquired 
from 25 samples. It is worth investigating whether they are related with atopic 
phenotypes as well as their functions in further studies. 
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In summary, our study confirmed three reported and one novel SNPs of CD14 promoter 
in Singaporean population and all these polymorphisms were in linkage disequilibrium. 
However the association study indicated that these polymorphisms might have no direct 
association with the phenotypes of atopy and had no decisive effects in the expression 
efficiency of CD14 promoters especially in Chinese and Asian Indian population. CD14 
polymorphisms might be related with allergic asthma in Malay population. Susceptibility 
genes for atopy were different in different ethnic groups. Future studies would be needed 
to identify the key genes for atopic phenotypes and investigate the interactions between 
genetic and environmental factors that influence the complex traits of allergic diseases. In 
this aspect, the proposed initiative of haplotype map (HapMap) is expected to be a 
powerful resource to study the genetic factors contributing to variation in response to 
environmental factors, susceptibility to infections and host immune responses to various 












ASSOCIATION BETWEEN IL-4 POLYMORPHISM AND ATOPY 
 
4.1 Introduction  
Atopy is often used to describe IgE-mediated allergic diseases.  IL-4 is regarded as an 
essential cytokine to influence Th-cell differentiation and total IgE (tIgE) levels and has 
been studied extensively these years (Ricci, 1994; Kidd, 2003). It may be expected that 
the polymorphisms of IL-4 lead to atopic diseases. Therefore, polymorphism of IL-4 
promoter was chosen for study in our population. 
 
4.1.1 Role of IL-4  
IL-4 has many biological activities that support its important role in the pathophysiology 
of asthma and allergy, including the ability to induce the IgE isotype switch, promoting 
eosinophil transmigration across endothelium, stimulating mucous secretion and inducing 
Th2 lymphocyte differentiation which leads to release of IL-5, IL-9, and IL-13.  One of 
the most important biological activities of IL-4 is to activate naïve T helper lymphocytes 
(Th0) into Th2 lymphocytes. Th1 and Th2 cells are formed from a common Th0, and Th0 
differentiates into polarized populations based on signals from the local 
microenvironment. In the presence of IL-12, IL-18 or IFN-γ, they differentiate into Th1 
cells. This evolution is mediated by a mechanism that is dependent on signal transducer 
and activator of transcription-1 (STAT-1) and the T-bet transcription factor. In the 
presence of IL-4 (which comes from IgE-activated mast cells or DCs) or IL-13, Th2 cells 
are formed. This is a complex process that involves STAT-6–mediated signal 
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transduction and the activation of a variety of transcription factors, including GATA-3, 
nuclear factor of activated T cells-c (NFATc) and c-maf. On the other hand, TH-2 cells 
secreted IL-4 cytokine that stimulates the production of IgE and induces eosinophil-
mediated attacks against allergens. In addition, IL-4 has also shown to inhibit production 
of IFN-γ which inhibits IgE synthesis. Thus, IL-4 plays an important role in balancing 
Th1 and Th2 (Figure 34). The Th2 pathway is regarded as the basis of IgE-mediated 
diseases (Ricci, 1994; Kidd, 2003) and IL-4 is thought to be a direct participant in the 
generation of high serum IgE levels (Sandford et al., 2000). 
                              
Figure 34. Biological effects of IL-4. IL-4 plays an important role in IgE synthesis by development 
of Th2 cells and inhibiting production of  IFN- γ. 
 
4.1.2 Current studies on IL-4 polymorphisms 
A cluster of cytokine genes including IL-4 is located on chromosome 5q31 which is 
strongly implicated in linkage with atopic disease (Marsh et al., 1994). A number of 
association studies have shown an association between the IL-4 promoter polymorphisms 
and a number of the phenotype characteristics of atopy including asthma, atopy, IgE life-
threatening asthma and so on (Noguchi et al., 1998; Burchard et al., 1999; Sandford et al., 
2000; Kabesch et al., 2003).   
 Antigen 
APC 





Among the polymorphisms, IL-4/-590 was reported to be associated with serum total IgE 
level (Rosenwasser et al., 1995), development of asthma (Noguchi et al., 1998) and atopy 
dermatitis (Kawashima et al., 1998). In 2003, Kabesch M et al. screened the IL-4 gene 
and reported that a total of 16 polymorphisms were identified in the IL-4 gene and the 
linkage disequilibrium was very strong among the 10 polymorphisms using IL-4/-590 C-
T as a reference point. In a functional study, reporter gene assay experiments in Jurkat 
cells showed threefold higher promoter activity of the T allele and electrophoretic 
mobility shift assays (EMSA) analysis showed a strong transcription factor-binding 
activity at the T allele (Rosenwasser, 1995). However, some other studies failed to 
confirm the association between this polymorphism and atopy (Elliott et al., 2001; Rigoli 
et al., 2004). 
 
 In addition, the allele frequency of the IL-4 promoter polymorphism in different races is 
quite different. For example, the T allele is common (70-73%) in Japanese (Noguchi et 
al., 1998), but rare (12.5%) in German population (Kabesch et al., 2003). This difference 
may lead to discrepant results among association studies between the IL-4/-590 
polymorphism and atopic phenotypes. In 2002, Zhang et al. studied the association 
between this polymorphism with asthma in Chinese population in China, but no 
association could be found. However, little is known about the prevalence of the gene 
variants in Singapore population. 
 
Overall, IL-4 is a very important cytokine in development of atopic disease. However, the 
association between the polymorphisms of IL-4 and atopic phenotypes still needs further 
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studies especially in different races. Table 34 summarizes the association studies of IL-4/-
590 polymorphism. 
Table 34. Summary of association studies on IL-4/-590 polymorphism 
 






























asthma and atopy, 
but not IgE 
Beghe et al., 
(2003) 
United Kingdom 1495 16 Y Severity of 
atopy and asthma 



















Y Atopy, asthma 
and rhinitis 
Kabesch  et 
al., (2003) 
Germany  1120 12.5 Y Asthma and 
serum tIgE  
Kawashima  
et al., (1998) 
Japan  88 
family 
NA Y Eczema 
Noguchi  et 
al., (1998) 
Japan 521 70-73 Y Asthma 
Soderhall  et 
al.,  (2002) 
Sweden 1194 NA Y Severity of 
atopic dermatitis 
Sandford  et 
al., (2000) 











Liu  et al., 
 (2003) 
Germany 823 17.6 N  Serum tIgE 
Elliott  et 
al., (2001) 
Australia  101 41 N Atopic eczema 
Hakonarson  
et al., (2001) 
Iceland 1548 11.7-
15.4 
N Atopic asthma 
Hijazi  and 
Haider (2000) 
Kuwaiti Arabs 184 75-79 N Asthma 
Noguchi  et 
al.,  (2001) 
Japan   476 NA N  Asthma 
Tanaka  et 
al., (2001) 
Japan 424 68 N Atopic eczema 
Cui  et al.,  
(2003) 
China  NA NA N Asthma 
Takabayashi  
et al., (2000) 
Japan 200 NA N Asthma 
Rigoli  et 
al., (2004) 
Italy 203 3% N Atopy 
Zhang  et 
al., (2002) 
China 221 NA N Asthma 
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4.1.3 Objectives  
This study aimed to investigate the association of IL-4/-590 polymorphism with atopy 
and atopic diseases (i.e., allergic rhinitis and asthma) in ethnic groups of Chinese, Malays 




4.2.1. IL-4 sequence 
The sequence of IL-4 was found from the website (http://www.ncbi.nlm.nih.gov) and the 
Genbank accession number was M23442. The primers and polymorphisms are shown in 










In addition, the Match
TM 
program was used to search for potential transcription factor 
binding sites of IL-4 promoter. However, we could not find the polymorphism of IL-4/-
590 on or near the potential binding sites for transcription factors. Therefore, reporter 
assay was not conducted for the polymorphism of IL-4 promoter. 
 




4.2.2 RFLP results of the IL-4 polymorphism 
A total of 357 unrelated subjects in Singapore were investigated, which included 233 
atopic subjects and 124 controls with mean age of 32.6 ± 13.2 years (ranging 7-74).  
Among them, there were 219 Chinese, 45 Malays and 93 Indians. Identification of the 
polymorphism of IL-4/-590 was conducted by RFLP assay (restriction endonuclease 
using BsmFI from New England Biolabs). The size of the generated PCR products was 
253bp (Figure 35). 
 
Figure 35. IL-4 PCR results. 
 
Commercially available BsmFI endonuclease (New England Biolabs) is specific for the 
follow sequence: 
 5´ ... G G G A C (N)10^... 3´ 
 3´ ... C C C T G (N)14^... 5´ 
  




-590            
Exon1 Exon 4 
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GGGAC is present only in the subjects with the IL-4/-590C allele. Therefore, PCR 
products only in those subjects with the IL-4/-590C allele could be digested, yielding two 
bands whose sizes were 209bp and 44bp. Therefore, RFLP yielded one 253bp band for 
TT homozygotes, three bands of 253bp, 209bp and 44bp for CT heterozygotes, and two 
bands of 209bp and 44bp for CC homozygotes. (Figure 36.)  
 
Figure 36. IL4/-590 RFLP results. C-to-T mutations at IL-4/-590 were differentiated 
using BsmFI endonuclease. The results are shown as two bands 205- and 44-bp for CC 
homozygotes (lane 1); three bands of 253-, 205- and 44-bp for CT heterozygotes (lane 5); 
and 253-bp for TT homozygotes (lane2, 3, 4).  
 
4.2.3 Sequence analysis of the IL-4 polymorphism 
The results of RFLP were confirmed by direct sequencing of the IL-4/-590 in 16 
randomly selected subjects (Figure 37).  
 
 
Figure 37. IL-4/-590 sequencing results. A: TT genotype; B: CT genotype 
 
B A 
1         2        3         4         5  1       2     3        4          
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4.2.4 IL-4/-590 polymorphism 
The distribution of genotypes was in agreement with Hardy-Weinberg equilibrium 
(p>0.05) in each ethnic group using Chi-square test. Table 35 shows the genotype 
frequency and allele frequency in both atopic and non-atopic groups of each population. 
There was no difference in the frequency of the genotypes between non-atopic and atopic 
groups. However, there existed heterogeneity in T allele frequency among the three 
ethnic groups. The frequency of CC at IL-4/-590 was extremely low in Chinese and 
Malays. Unlike in the Caucasian population, TT appeared to be the common genotype in 
these two ethnic groups. For Indians, the frequency of CC was much higher (38.1% for 
non-atopic and 32.7% for atopic) than the other two ethnic groups. There was a 
significant difference in allele frequency between Chinese and Asian Indians (p<0.001) 
or between Malays and Asian Indians (p<0.01), which again confirmed that the 
polymorphism may have obvious ethnic difference. 
Table 35. Frequency of IL-4/-590 genotypes in non-atopic and atopic groups and 


























Chinese        
Non-atopy (61) 0 (0) 12 (19.7) 49 (80.3) 9.8 90.2 0.584 P<0.001† 
Atopy (158) 2 (1.3) 36 (22.8) 120 (75.9) 12.7 87.3  P<0.001† 
Malays        
Non-atopy (21) 0 (0) 7 (33.3) 14 (66.7) 16.7 83.3 0.590 P<0.01 ‡ 
Atopy (24) 1 (4.2) 9 (37.5) 14 (58.3) 22.9 77.1  P<0.05 ‡ 
Asian Indians        
Non-atopy (42) 16 (38.1) 20 (47.6) 6 (14.3) 61.9 38.1 0.655  
Atopy (52) 17 (32.7) 23 (44.2) 11 (21.1) 55.9 44.1   
 140 
† Chinese vs Asian Indians (z test) 
 ‡ Malays vs Asian Indians (z test) 
   
4.2.5 Association between IL-4/-590 polymorphism and tIgE levels 
A significant difference between IL-4/-590 genotypes and tIgE levels was observed in the 
atopic group of Chinese (p=0.032) (Table 36), in which the TT genotype was associated 
with a lower tIgE level and CC associated with a higher tIgE level. Pairwise comparisons 
between the sub-groups were determined by Bonferoni of post-hoc test in this Chinese 
group, and the difference was derived from CC homozygote and TT homozygote. 
However since the CC genotype was very rare in the Chinese group (only 2 CC 
homozygote in 153 subjects), a significant conclusion could not be drawn from this data 
(Table 37). Furthermore, no statistical difference between serum total IgE and IL-4/-590 
genotypes could be found in Chinese, Malay and Asian Indian population (Table 36). 
Table 36.  Geometric mean of tIgE levels (IU/ml) (mean ±95%CI) and IL-4/-590 
genotypes in three ethnic groups 
 
Chinese 
Serum tIgE (Mean ±SD) 
Malays 
Serum tIgE (Mean±SD) 
Asian Indians 







Atopy Non-atopy Atopy 












TT 30.9±3.5 275.4±2.9 40.7±3.5 389.0±3.5 
 
56.2±1.5 354.8±3.4 





Table 37. Multiple comparisons between IL-4/-590 genotypes and tIgE in Chinese 




IL-4 genotype group 
Mean 
Difference  Std. Error     Sig. 
CC CT .76217 .32662 .063 
  TT .82765 .32055 .032 
CT CC -.76217 .32662 .063 
  TT .06548 .08544 1.000 
TT CC -.82765 .32055 .032 
  CT -.06548 .08544 1.000 
 
4.2.6 Association between IL-4/-590 polymorphism and atopic phenotypes 
The association between the polymorphism of IL-4/-590 and the atopic disease, including 
atopy, asthma and allergic rhinitis, is shown in Table 38. Stratified analysis was 
conducted under a codominant model. No significant correlation between IL-4/-590 
genotypes and atopic phenotypes was found in each ethnic group.  
 
Table 38. Association between IL-4/-590 polymorphism and atopic phenotypes in 














Atopy vs non-atopy  
Asthma vs non-asthma 
Allergic asthma vs non-allergic asthma 











Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 












Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 










4.3 Discussion  
IL-4 is a primary atopic susciptibility gene and plays a central role in Th2 immune 
responses and allergic diseases. Since the first report by Rosenwasser LJ (Rosenwasser et 
al., 1995), several studies had confirmed that the IL-4/-590 C-T polymorphism was 
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significantly associated with the risk of atopic diseases and/or modulating the severity of 
atopy and IgE levels. However, not all studies were able to confirm such a finding as 
several studies had reported no association at all between this polymorphism and atopic 
phenotypes (Table 34). Hence, the potential role of the IL-4/-590 polymorphism in 
phenotype determination of atopic diseases remains controversial.  
 
By reviewing the published data, we can see that there exists a large difference in 
distribution of T allele frequencies at IL-4/-590. The ethnic background of the subjects 
from the population is a critical factor influencing the outcome of genetic 
epidemiological studies. For example, it seems that T allele is less frequent in Caucasians 
than in Asian populations, with a difference of up to 6 folds (Table 34). A study 
performed in Canada showed the T allele frequency was higher in Canadian of Asian 
ancestry (79.5%) than Canadian of white ancestry (16.9%) (Zhu et al., 2000).  
 
Although most negative results were reported in Asian studies, it seemed impossible to 
make a reasonable explanation only based on T allele distribution. Interestingly, there 
were a few discrepant results of association studies, which were reported in the same 
population (e.g., Australians, Germans and Japanese) with a similar T allele distribution 
but by different investigators (Noguchi et al., 1998; Kabesch et al., 2003; Kawashima et 
al., 1998; Elliott et al., 2001; Liu et al., 2003; Noguchi et al., 2001; Tanaka et al., 2001; 
Takabayashi et al., 2000). Even with the same investigators, some confusion in 
association between IL-4/-590 and asthma could be found in different individual studies 
(Noguchi et al., 1998; Noguchi et al., 2001). It is still unclear whether the difference was 
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due to methodological, environmental or ethnic variations among different study 
populations. 
 
A C to T polymorphism was observed at IL-4/-590 in Singapore population, and the 
ethnic expression of the IL-4 promoter polymorphism was different. Our study 
demonstrated a significant difference of T allele frequency at IL-4/-590 among Chinese 
(non-atopic 90.2% and atopic 87.3%), Malays (non-atopic 83.3% and atopic 77.1%) and 
Asian Indians (non-atopic 38.1% and atopic 44.1%). These three ethnic groups form 
majority of the Singapore’s population. Although there is a significant difference in T 
allele frequency among these ethnic groups, there is no association between IL-4/-590 C-
T polymorphism and atopic phenotypes (allergic rhinitis and asthma) in each group. 
However, there is a significant (p=0.032) association between this polymorphism and 
lower level of serum tIgE in atopic Chinese patients, but the CC genotype is very rare in 
Chinese (only 2 CC homozygote in 153 subjects), which affects the significance of the 
association. 
 
Not like previous studies, we could not find association between atopy and IL-4/-590 
polymorphism. The possible explanations are: First, because of variation of the 
phenotypes of atopic diseases, even the definition of the atopy or atopic diseases may be 
different in different studies, which may induce false positive or false negative. Therefore 
correct and careful definition is very important to reduce inconsistent results. Second, 
atopy is a polygenic disease, and it may be difficult to determine susceptibility genes with 
only one polymorphism or one gene taken into consideration at a time. Third, gene-
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environment interaction is necessary to develop atopic diseases. Without exposure to 
environmental factors, the subjects could not develop atopic diseases in clinic, even with 
a genetic background. Different populations are exposured to different environment, 
which may contribute to different results.  
 
On the other hand, is it possible that other polymorphisms in IL-4 are more functionally 
important than this one? According to Michael Kabesch et al.’s results in 2003, 16 
polymorphisms in the IL-4 gene were identified, and the linkage disequilibrium was 
determined among all the polymorphisms in the IL-4 gene by using IL-4 /-590 as a 
reference point (Kabesch et al., 2003). If there was really an association between these 
polymorphisms in IL-4 and atopy, the association of IL-4/-590 with phenotypes of atopy 
would gain some kind of support. Another polymorphism at -34C/T was reported in the 
5’-untranslated region of IL-4 (Takabayashi et al., 1999). Elliott K et al. demonstrated 
that this polymorphism had strong linkage disequilibrium with IL-4/-590, however, 
neither polymorphisms seemed to be predisposed to early-onset atopic eczema (Elliott et 
al., 2001). Since negative results were obtained from the study on IL-4/-590 
polymorphism, we did not study other polymorphisms of this gene. 
 
In addition, the etiology of rhinitis is closely linked to atopy and is known to have a 
genetic component. Our previous epidemiologic study in Singapore has shown an overall 
prevalence of 13.1% rhinitis in the general population (12.8% in males and 13.5% in 
females), and there was no significant difference of prevalence between Asian Indians 
(15.1%), Malays (12.3%) and Chinese (12.1%) (Wang et al., 2002). If allele frequency of 
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IL-4/-590 is associated with atopic condition, one could expect a different prevalence of 
rhinitis among these three ethnic groups in Singapore.  
 
In conclusion, our study demonstrates a large difference in the allele frequency of IL-4/-
590 between various ethnic groups in Singapore. This finding is in accordance with 
previous literature. However, it seems that this allele is unlikely to be an important 
determinant for atopy and atopic phenotypes in the context of the three Asian populations 
that we have studied. IL-4/-590 polymorphism seems not responsible for the reported 



























ASSOCIATION BETWEEN β2-ADRENERGIC RECEPTOR 
POLYMOR-PHISMS AND ATOPY  
 
5.1 Introduction  
The β2-adrenergic receptor (B2AR) is located on the long arm of chromosome 5 (5q31-33) 
which is strongly implicated in linkage with atopic disease (Kobilka et al., 1987). On the 
other hand, β2-adrenergic receptor agonists remain the main bronchodilator agents used in 
treatment of asthma, and the β2-adrenergic receptor is the target for β2-adrenergic 
agonists (Barnes, 1995). In this chapter, we study the polymorphisms of B2AR in our 
population, and the relationship between the polymorphisms and atopic diseases. 
 
5.1.1 Role of β2-adrenergic receptor 
The β2-adrenergic receptor belongs to G protein coupled receptor superfamily, with an 
extracellular amino terminus localized, seven transmembrane spanning domains and an 
intra-cellular carboxyl-terminus. It is a cell surface receptor responsible for the binding of 
endogenous catecholamine and their exogenously administered agonists. Activation of the 
receptor by its ligand results, via coupling with Gs, in stimulation of adenylyl cyclase, 
increases concentrations of cAMP and stimulation of cAMP-dependent protein kinase. 
cAMP acts as a classic intracellular second messenger, activating protein kinases and 
eliciting an extensive array of the physiological effects of  B2AR (Figure 38) (Liggett, 
1995; Siegal et al., 1999).  
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Figure 38. Effects of β2-adrenergic receptor (Siegal et al., 1999). Activation of the receptor by its 
ligand results, in stimulation of adenylyl cyclase, and then increases concentrations of cAMP and stimulates of 
cAMP-dependent protein kinase. cAMP acts as  classic intracellular second messenger, to activate protein 
kinases. 
 
The β2-adrenergic receptor is expressed on a number of cell types in the lung (Barnes, 
1995), including bronchial smooth muscle cells, mast cells, various other immune cells, 
epithelial cells and never terminals. Bronchial smooth muscle has abundant expression of 
the β2-adrenergic receptor, so circulating catecholamine and exogenously administered β2 
–agonists exert their primary effect on it, resulting in relaxation and bronchial dilatation. 
The proposed effect of the β2-adrenergic receptor on these cells includes enhanced 
mucociliary function, changes in vascular permeability, modulation of alveolar sodium 
and water content, and alterations in neurotransmitter release. Clearly, the β2-agonists in 
the treatment of asthma are predominantly via their action at these smooth muscle 
receptors, but other effects such as decreasing inflammation by affecting immune cell 
functions, increasing mucocilliary clearance and decreasing acetylcholine release may 
also play a role in the ultimate effects of β2-agonists (Spina et al., 1989; Liggett, 1995).  
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5.1.2 Current studies on B2AR polymorphisms 
B2AR codes for an intronless gene product of about 1200 base pairs (Kobilka et al., 1987). 
It is composed of 413 amino acid residues of 46500 daltons (Da) (Johnson, 1998). Initial 
studies have shown nine point mutations at nucleic acid position 46, 79, 100, 252, 491, 
523, 1053, 1098 and 1239 respectively (Figure 39). 
 
         
Figure 39. Primary amino acid sequence and proposed membrane topography of the 
human B2AR. The darkened circles indicate codons where degenerate polymorphisms of the B2AR gene 
were found (Liggett , 1995). 
 
It has been shown that some polymorphisms are degenerate and they do not result in a 
change in the encoded amino acid. However, those polymorphisms at nucleotide 46, 79, 100 
and 491 result in changes in the indicated amino acids at position 16, 27, 34 and 164 (Liggett, 
1995). Among the four polymorphisms, the polymorphisms at loci 16 and 27 occur 
frequently, while the other two are too infrequent (Liggett, 1995). Therefore, in our study, we 
only concentrated on the polymorphisms at position 16 and 27.  
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There is an A to G change at nucleotide 46, resulting in an argnine to glycine substitution at 
amino acid 16 (Arg16/Gly16), and a G to C change at nucleotide 79, resulting in a glutamine 
to glutamate acid alteration at amino acid 27 (Gln27/Glu27) (Hall, 1996; Ramsay et al., 
1999). Many association studies about these polymorphisms have been performed in recent 
years. For example: Gly 16 genotypes were reported to be associated with increased airway 
reactivity and more severe asthma, especially with nocturnal worsening of asthma (Tuki et al., 
1995, Turner et al.,  2004) as well as reduced lung functions in childhood (Turner et al., 
2004). In contrast, the Glu 27 genotype was reported to be associated with less reactive 
airways on asthmatic subjects and its variant was also reported to be associated with elevated 
levels of serum total IgE (Dewar et al., 1997), bronchial hyperresponsiveness (BHR) 
(D’amato et al., 1998; Ulbrecht et al., 2000) and childhood asthma (Hopes et al., 1998). In 
addition, the two polymorphisms showed marked linkage disequilibrium (Martinez et al., 
1997). 
 
Although many association studies demonstrated that there was a relationship between the 
polymorphisms of B2AR and atopic phenotypes, airway activity, modification of asthma and 
so on, there were still many negative results reported for different populations. The exact 
contribution of polymorphisms of B2AR to the clinical picture of allergic diseases still 









Table 39. Summary of association studies on B2AR polymorphisms and atopy 


















Diseases for comparison 
Hall, 
(1995) 
USA 65 patients NA 55 Y Disease-modifying effect in 
asthmatic airway 
Turki  et al., 
(1995) 





















Y Gly16 enhanced agonist down 
regulation; the Glu27 resistant 
to down regulation. (In vitro 
study) 
D’amato  et 
al., (1998) 
Italy NA NA NA Y BHR 




425 NA 49.2 Y Gln27Glu and asthmain 
children 










Y Haplotype and BHR 
 
Gao  et al., 
(2000) 
China 58 asthma 





Y Arg16Gly and asthma severity 
Wang  et al., 
(2001) 






Y Arg16 and ever cigarette 
smoking with asthma 
 





180 59 44.4 Y Arg16Gly with AR in infancy 
and asthma severity 




324 66.8 47.7 Y&
N 
Gln27Glu and IgE, but no 
asthma 




269 61.7 36.2 Y&
N 
Arg16Gly and response to 
albuterol, but no association 
between Gln27Glu and 
response to albuterol. 
Linkage disequilibrium. 
Ramsay  et 
al., (1999) 
Australia 332 54.4 40.5 Y&
N 
Arg16Gly and wheeze, 
Gln27Glu and airway 





Japan NA 49 9 Y&
N 
Severe asthma, but no change 
in the bronchoprotective 
effect. Race difference. 



















Arg16Gly and asthma 
severity, but no association 
with asthma. 








Arg16 and asthma 






5.1.3 Objectives  
The objective of this study was to investigate the association of polymorphisms of B2AR 
with asthma, allergic rhinitis and tIgE in Singapore population. In addition, we also 
evaluated the allele frequency of B2AR polymorphisms in Singapore population, 
including Chinese, Malays and Asian Indians.  


























USA 361 55.1 35.6 Y&N Arg16Gly and lung growth or 
the rate of decline of lung 
function with age, But not 
with asthma. 
Israel  et al.,   
(2001) 
USA 190 asthma NA NA Y&N Arg16Gly and regular use of 
albuterol in asthma, but not 
Gln27Glu. 




440 46.7 10.4 Y&N Nocturnal cough, but not 
associated with atopy and 
bronchial hyperresponsiveness 
Weir  et al., 
(1998) 
UK 86 fatal 








N  Fatal or near-fatal asthma. 
Ethnic difference. 





630 61.3 48.2 N Allergic diseases and asthma. 
Linkage disequilibrium. 
Deichmann  




NA NA N IgE level. 






64.2 50.8 N Response to regular inhaled 
beta2-agonist treatment. 
Hakonarson  
et al., (2001) 
Iceland 269 patients 





N Asthmatic phenotype or atopic 
asthma 






NA NA N  IgE level, skin test and FEV1. 
Race difference 













NA Marked ethnic difference. 
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5.2 Results 
5.2.1 B2AR sequence  
The sequence of B2AR was searched from http://www.ncbi.nlm.nih.gov. Genbank accession 
number of B2AR was J02960. The primers and polymorphisms are showed in bold in the 










The following is the genomic structure and relative positions of the polymorphism at 
B2AR gene.  
 
 
5.2.2 RFLP results of the B2AR polymorphisms 
The polymorphisms of B2AR were identified by RFLP assay. The size of the generated PCR 










                                
Figure 40.  B2AR PCR results. The brightest band of the marker is 500 bp. The size of B2AR is 168bp.  
 
An A-to-G mutation was identified by restriction enzyme digestion of PCR products at 
amino acid 16 of B2AR using the NcoI (New England Biolab) endonuclease, which is 
specific for the follow sequence:  
5´ ... C^CATGG... 3´ 
3´ ... GGTAC^C... 5´ 
 
CCATGG is present only in the subjects with G at amino acid 16 of B2AR. NcoI cut 22 bp 
from the 3’ end and cut 18 bp from the 5’ end if G was present. The RFLP yielded three 
bands of 128 bp, 22 bp and 18 bp for GG homozygotes, four bands of 150 bp, 128 bp, 22 bp 
and 18 bp for AG heterozygotes and two bands of 150 bp and 22 bp for AA homozygotes. 
Among them, 22bp and 18bp were too small to be observed on agarose gels (Figure 40). 
 
A C-to-G mutation was identified by restriction enzyme digestion of PCR at amino acid 27 
of B2AR using the BbvII endonuclease, which is specific for the following sequence:  
5´ ... G C A G C (N)8^... 3´ 
3´ ... C G T C G (N)12^... 5´ 
 
GCAGC is present only in the subjects with C at amino acid 27 of B2AR. Therefore, the 
RFLP yielded two bands of 105 bp and 63 bp for CC homozygotes, three bands of 168 bp, 
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105 bp and 63 bp for GC heterozygotes and one band of 168 bp for GG homozygotes. 




Figure 41. B2AR RFLP results. A: A-to-G mutation at amino acid 16 was differentiated using NcoI 
endonuclease. One 150bp band for AA genotype, two bands of 150bp and 128bp for AG heterozygotes and 
one band of 128bp for GG homozygotes. B: C-to-G mutation at amino acid 27 was differentiated using 
BbvII endonuclease. One 168bp band for GG genotype, three bands of 168bp, 105bp and 63bp for CG 
heterozygotes and two bands of 105bp and 63bp for CC homozygotes. 
 
5.2.3 B2AR polymorphisms 
A total of 370 samples from the study population were amplified by PCR and genotyped by 
PRFL. The mean age of the cohort was 32.8±13. There were 194 male (52.4%) and 176 
female (47.6%). Among them, there were 223 Chinese, 47 Malays, 94 Asian Indians and 6 
others. Of these 370 individuals, 133 (35.9%) were non-atopic and 237 (64.1%) were atopic, 
74 individuals (20%) had physician-diagnosed current asthma and 189 individuals (51.1%) 
had physician diagnosed allergic rhinitis.  
 
Sample  1     2     3     4     5     6 
CC  CC  CC  CG  GG  CC   
Sample  1     2     3     4     5     6 
AG  AG  AG  GG  AA  GG    
  A   B 
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The genotype distribution of the two polymorphisms did not deviate from Hardy-Weinberg 
equilibrium (p>0.05) in all the subgroups except two atopic groups for Chinese and Malay at 
polymorphism at amino acid 16. 
 
5.2.3.1 Genotype frequency of B2AR polymorphism at amino acid 16 
Table 40 shows the distribution of the B2AR polymorphism at amino acid 16 in non-
atopic and atopic subject groups. No significant difference in the frequency of the B2AR 
polymorphism at amino acid 16 was found between non-atopic and atopic groups (Table 
40).  
Table 40. Genotypes distribution of B2AR polymorphism at amino acid 16 in non-
atopic and atopic subjects and Hardy-Weinberg Equilibrium 
 





















AA 23 (35.9) 53 (33.3) 4 (17.4) 6 (25) 8 (18.6) 14 (27.5) 
AG 39 (60.9) 89 (56.0) 12 (52.2) 17 (70.8) 24 (55.8) 27 (52.9) 















P-value P=0.187 P=0.057 P=0.552 
 
5.2.3.2 Genotype frequency of B2AR polymorphism at amino acid 27 
Table 41 shows the distribution of the B2AR polymorphism at amino acid 27 in non-
atopic and atopic subject groups. From the table, GG homozygote was rare in Singapore 
population and only 5 GG homozygotes were identified among the 370 subjects. 
Furthermore, the frequencies of CC, GC and GG genotypes did not present a significant 
difference between any atopic and non-atopic groups (Table 41). 
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Table 41. Genotypes distribution of B2AR polymorphism at amino acid 27 in non-
atopic and atopic subjects and Hardy-Weinberg Equilibrium 
 






















CC 53 (82.8) 127 (79.9) 17 (73.9) 22 (91.7) 26 (60.5) 32 (62.7) 
GC 9 (14) 32 (20.1) 6 (26.1) 2 (8.3) 16 (37.2) 17 (33.3) 
GG 2 (3.1) 0 (0) 0 (0) 0 (0) 1 (2.3) 2 (3.9) 














P-value P=0.052 P=0.105 P=0.858 
 
 
5.2.4 B2AR polymorphisms in three populations 
 
Table 42 shows the comparison between the allele frequency of the polymorphisms across 
the ethnic races in atopic and non-atopic groups. In non-atopic group, the allele frequencies 
in the three races had no significant difference in statistics. In atopic group, no significant 
difference of the allele frequency at position 16 was found. However, at amino acid 27, the C 
allele frequency of Indians was higher than that of Chinese and Malays in atopic groups. A 
significant difference of C allele frequency was found between Malays and Asian Indians 
(p<0.01). In addition, in disagreement with previous reports for Caucasians, the G allele 
frequency at position 27 of B2AR was infrequent in our population.  
 
Table 42. Comparison of B2AR allele frequency among three ethnic groups 
Allele frequency Comparison of allele  frequency Group Race 





























Chinese vs Malays 
Z=1.21 
Chinese  vs Indians 
Z=1.39 
Malays vs Indians 
Z=0.14 
 
Chinese  vs Malays 
Z=0.43 
Chinese vs Indians 
Z=1.68 































Chinese vs Malays 
Z=0.06 
Chinese  vs Indians 
Z=0.70 
Malays vs Indians 
Z=0.38 
 
Chinese  vs Malays 
Z=1.65 
Chinese vs Indians 
Z=1.95 





5.2.5 Association between B2AR polymorphisms and tIgE levels 
According to sIgE levels, subjects were stratified into atopic and non-atopic groups. 
Table 43 demonstrated that we were unable to detect any association between these two 
polymorphisms and serum tIgE among the three ethnic groups (Table 43). 
Table 43. Geometric mean tIgE levels (IU/ml) (95% CI) by B2AR polymorphisms at 
position 16 and 27 in three ethnic groups 
 
Chinese 
Serum tIgE (95% CI) 
Malays 
Serum tIgE (95% CI) 
Asian Indians 
Serum tIgE (95% CI) 
Polymorphim 
positions 




























































































p-value 0.771 0.668 0.285 0.417 0.280 0.436 
 
5.2.6 Association between B2AR polymorphisms and atopic phenotypes  
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Table 44 shows that no significant association was found between the genotypes at either 
position 16 or 27 and atopic diseases, e.g., atopy, asthma, allergic asthma, and allergic 
rhinitis in each ethnic group (Table 44).  
Table 44. Association between B2AR polymorphisms at position 16 and 27 and 
atopic diseases in three ethnic groups 
 
Position16 
 (p value)  
Position27 






genotype allele genotype allele 
Chinese 
 
Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 



















Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 




















Atopy & non-atopy  
Asthma & non-asthma 
Allergic asthma vs non-allergic asthma 


















5.2.7 Linkage disequilibrium between B2AR polymorphisms  
Cross-tabulation of Arg16Gly and Gln27Glu of B2AR is shown in Table 45. The r
2
 value of 
lingkage disequilibrium between these two polymorphisms was not so high in Singapore 
population (D’=0.73; r
2
=0.11) (Table 45).  
 












101 151 28 
Gln27/Glu27 
  
7  59 19 
Glu27/Glu27  
 






5.2.8 Association between haplotypes of B2AR polymorphisms and atopic phenotypes 
Because the function of β2-adrenergic receptor molecular depends on relative contribution of 
different amino acid substitutions in this polypeptide, we investigated the association of 
B2AR haplotypes with atopic phenotypes. The haplotype was determined using Phase-
Standard analysis (version 2.0.2, http://archimedes.well.ox.ac.uk/pise/). The following is a 
list of the haplotypes found in the best reconstruction. 
         1          GC  Gly16/Gln27 255 31.2% 
         2          GG    Gly16/Glu27 87 10.7% 
         3          AC  Arg16/Gln27 455 56.1% 
         4          AG    Arg16/Glu27 9 2% 
 
A total of 4 haplotypes were found in this study. Arg16/Gln27 was the most frequent, 
constituting up to 56.1% of the total study population, while Arg16/Glu27 was identified 
only in 9 subjects. Table 46 shows that there was no association found between B2AR 
haplotypes and atopic phenotypes in Chinese, Malays and Asian Indians (Table 46).  
Table 46. Association between B2AR haplotypes and atopic phenotypes 
 
   Atopy P1 Race Haplotype 
16       27 
No Yes No Yes 
P2 P3 P4 P5 
G         C 34 94 
G         G 9 29 
A         C 81 193 
Chinese 
 
A         G 4 2 
0.622 0.413 0.168 0.448 0.370 0.079 
G         C 21 17 
G         G 5 2 
A         C 19 29 
Malays 
 
A         G 1 --- 
0.634 0.598 0.185 0.237 0.698 0.615 
G         C 29 27 
G         G 17 19 




A         G 1 1 
0.321 0.950 0.600 0.449 0.465 0.529 
 
P1: haplotypes and tIgE levels in atopic and non-atopic groups 
P2: haplotypes between atopy and non-atopy 
P3: haplotypes between asthma and non-asthma 
P4: haplotypes between allergic asthma and non- allergic asthma 
P5: haplotypes between allergic rhinitis and non-rhinitis 
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5.3 Discussion  
It has long been speculated that B2AR polymorphisms may contribute to various severity 
of atopic-related phenotypes such as asthma. A number of studies have been carried out 
to understand the association between the polymorphisms at amino acid position 16 and 
27 of B2AR and asthma phenotypes, however with confusing and conflicting results. The 
Gly 16 of B2AR was reported to be associated with nocturnal asthma (Turki et al., 1995) 
and asthma severity (Holloway et al., 2000). On the other hand, the polymorphism of 
Glu27 was found to be significantly associated with the risk of asthma in children (Hopes 
et al., 1998), IgE levels (Dewar et al., 1997) and airway responsiveness (Ramsay et al., 
1999). In fact, the potential role of these polymorphisms in determining the phenotypes 
of atopic diseases remains controversial. 
 
The results of our association study suggested that these two polymorphisms of B2AR at 
position 16 and 27 were not risking factors for atopy and atopic phenotypes (allergic 
rhinitis and asthma) in the study groups. Linkage disequilibrium has been reported before 
(Martinez et al., 1997; Dewar et al., 1998). In our study, we found that there was not so 
strong linkage disequilibrium between these two polymorphisms. We further investigated 
the association of haplotypes with atopic phenotypes. A total of 4 haplotypes were found 
in this study. However, no association between the haplotypes of B2AR and atopic 
diseases was found. 
 
The ethnic background of study subjects may be a critical factor influencing the outcome 
of genetic epidemiological studies. By reviewing the published data, there exists a huge 
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difference in G allele frequencies at Gln27Glu of B2AR. G allele is more common in 
Caucasians than in Asian populations, with up to 6-7 fold difference, and studies in USA 
and UK showed that G allele frequency was almost 50% in their population, but it was 
only 8-9% in Japanese and Chinese population (Hall, 1996; Hopes et al., 1998; Sato, 
2000; Wang et al., 2001). According to our results, the G allele frequency was rather low, 
which was consistent with previous reports for Asian populations. For atopic patients, the 
G allele frequency at position 27 of B2AR was significantly higher in Asian Indians 
(20.6%) than in Malays (4.2%) (p<0.01), and the frequency in Chinese is somewhat 
between (10.1%).  
 
The lack of association between B2AR polymorphisms and atopic phenotypes had some 
possible explanations. Firstly, it was possible that the B2AR had no influence on IgE 
levels and development of asthma and allergic rhinitis. From previous studies, it was 
demonstrated that the polymorphisms of B2AR related with asthma severity (Turner et al., 
2004), nocturnal asthma (Turki et al., 1995; Kim et al., 2002), adjustment for the effect of 
agonist (Liggett, 1997) and airway responsiveness (Hall, 1996; Ramsay et al., 1999). It 
seems that the polymorphisms of B2AR are more likely to play a modifying rather than a 
decisive role in development of asthma. Secondly, some significant results of association 
between B2AR polymorphisms and atopic phenotypes were reported in childhood 
population (Hopes et al., 1998; Turner et al., 2004). While, the mean age of the 
population was higher in this study and the heritability of IgE decreases with increasing 
age, thus decreasing the power to detect an association (Dewar et al., 1996). Thirdly, the 
potential role of other B2AR polymorphisms could not be excluded.  
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In conclusion, our study demonstrates that there is no association between the B2AR 
polymorphisms and the prevalence of allergic diseases in our adult population. Marked 
linkage disequilibria exists between the B2AR polymorphisms at amino acid 16 and 27.  
However, these two B2AR polymorphisms seem unlikely to be important determinants 






















ASSOCIATION BETWEEN TLR4 POLYMORPHISMS AND ATOPY 
 
 
6.1 Introduction  
Recently, there is evidence that endotoxin exposure during early life is protective against 
development of atopy and asthma (Stracahn, 2000; Liu, 2002). CD14 binds 
Lipopolysaccharide (LPS), but has no transmembrane domain and requires toll-like 
receptor 4 (TLR4) for signal transduction (Yang et al., 2004). TLR4 is the principal 
receptor for bacterial endotoxin recognition (Raby et al., 2002). Therefore, it is possible 
that genetic variation in the TLR4 locus contributes to atopy susceptibility.  
 
6.1.1 Role of TLR4  
Toll-like receptor (TLR) families play a fundamental role in pathogen recognition and 
activation of innate immunity. 10 such receptors have been identified, and functional data 
are available only for two TLRs, i.e., TLR2 and TLR4 (Kopp and Medzhitov, 1999). 
TLR4 is suspected in cellular responses to LPS which is the major constituent of the 
Gram-negative bacteria outer membrane (Qureshi et al., 1999; Hoshino et al., 1999). 
Through interaction with both CD14 and LPS, endotoxin binds to membrane-bound 
TLR4 and initiates a complex intracellular signaling pathway, resulting in the activation 
of several nuclear transcription factors, e.g. NF-κB (Anderson, 2000). The details are 






Figure 42.  Signaling Pathway of Toll-like Receptors (Medzhitov and Janeway, 
2000). The recognition of LPS is mediated by three different gene products: CD14, TLR4, and MD-2. The 
binding of LPS to CD14 presumably leads to the association of CD14 with the TLR4–MD-2 complex and 
is thought to induce the dimerization of TLR4. When TLR4 is activated, it recruits the adapter protein 
MyD88, which is associated with the serine–threonine protein kinase interleukin-1 receptor– associated 
kinase (IRAK). IRAK is then phosphorylated and associated with the tumor necrosis factor–associated 
factor 6 (TRAF-6) adapter protein. Oligomerization of TRAF-6 is thought to activate a member of the 
mitogen-activated protein kinase (MAP3K) family, which directly or indirectly leads to the activation of 
IkB kinase 1 (IKK1) and IkB kinase2 (IKK2). These kinases phosphorylate IkB on serine residues, thus 
targeting IkB for degradation and releasing NFkB, which moves into the nucleus and induces the 
transcriptional activation of a wide variety of inflammatory- and immune-response genes.  
 
TLRs are pattern-recognition receptors that bind bacterial ligands and act via signaling 
pathway to mediate innate immune responses, with bridging to adaptive immunity (Yang 
et al., 2004). TLR4 regulates Th Cell development on APCs. Through the recognition of 
pathogens or their products, TLR4 induces production of cytokines e.g., IL-12 and IL-18 
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in APCs. These cytokines drive naïve T cells to differentiate into Th1 cells. Pathogens are 
also captured and presented to T cell as MHC. This procedure requires costimulatory 
molecules. The up-regulation of costimulatory molecules are triggered by TLR signaling. 
TLR-stimulated APCs mainly induce Th1 development (Akira et al., 2001). This may 
reduce the incidence of atopy because the immune system is progressively replaced by 




Figure 43. TLR4 in pathway of immune response. Endotoxin binds to CD14, LBP and TLR4 
to initiate a complex intracellular signaling pathway. TLR4 induces the production of cytokines e.g., IL-12 
and IL-18, which can drive naïve T cells to differentiate into Th1 cells.  
 
6.1.2 Current studies on TLR4 polymorphisms 
Human TLR4 gene is located at chromosome 9q32-33 and comprises of four exons 
spanning about 10kb (http://www.ncbi.nlm.nih.gov, AF177765). Twelve rare amino acid 





















have identified an additional 29 polymorphisms of this gene (Raby et al., 2002). However, 
most association studies have concentrated on two positions: an A to G polymorphism at 
nucleotide 896 from the start codon of the TLR4 gene resulting in an aspartic acid to 
glycine substitution at position 299 of the amino acid sequence (Asp299Gly), and a C to 
T polymorphism at nucleotide position 1196 resulting in a threonine to isoleucine 
substitution at position 399 of the amino acid sequence (Thr399Ile). Many studies have 
reported an association between the polymorphisms at TLR4 Asp299Gly and Thr399Ile 
with clinical diseases (Lorenz et al., 2002; Michel et al., 2003; Werner et al., 2003; Yang 
et al., 2004). In 2000, Arbour and colleagues first reported that TLR4 mutations were 
associated with endotoxin hyporesponsiveness in human (Arbour NC, 2000). Using an in 
vitro cultured cell approach, the same group reported that Asp299Gly mutation 
interrupted TLR4-mediated lipopolysaccaride (LPS) signaling (Schwartz, 2001b). The 
study provides a genetic evidence to support that human TLR4 Asp299Gly mutation 
could be associated with difference in LPS responsiveness and, consequently, could alter 
the ability of the host to respond to environmental stimulus (Schwartz, 2001b). 
 
Recently, polymorphisms of TLR4 were reported to be associated with the severity of 
atopy (Yang et al., 2004) and a modified response to endotoxin in asthmatics (Werner et 
al., 2003). However, some studies were unable to confirm these two common 
polymorphisms on human TLR4 gene or its associated atopy-related phenotypes (Raby et 
al., 2002; Noguchi et al., 2004).  
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In addition, some other studies demonstrated that TLR4 polymorphisms were associated 
with Gram-negative septic shock (Lorenz et al., 2002) and systemic responsiveness to 
LPS (Michel et al., 2003). Table 47 shows current association studies about the 
polymorphisms of TLR4 Asp299Gly and Thr399Ile. 
 
Table 47. Summary of association studies on TLR-4 polymorphisms 
 
 

























Diseases for comparison 
Agnese et al., 
(2002) 
US Patients: 77 
Controls: 39 
NA NA Yes Gram negative infections 
Lorenz et al., 
(2002) 
France Patients: 91 
Controls: 73 
6-8 6.6-11 Yes Gram-negative septic 
shock 
Werner et al., 
(2003) 
Germany 334 8.3 8.6 Yes Modify endotoxin effects 
on asthma 
Michel et al., 
(2003) 




Reindl et al., 
(2003) 
Australia 190 6.05 5.8 Yes Multiple sclerosis 
 




Family: 336 5.9-8.1 NA Yes & No Atopy severity, but not 
asthma. 





90 NA NA No Asthma or atopy-related 
phenotypes 
Noguchi et  
al., (2004) 
Japanese 32 NA NA No asthma 
Folwaczny et 







No Chronic periodontitis 
Smirnova  et 
 al., (2001) 
US 
Caucasians 
348 7 7 NA NA 
Okayama  et 
 al., (2002) 




NA NA NA 
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6.1.3 Objectives 
This study was designed to screen the existence of the two common TLR4 
polymorphisms (Asp299 Gly and Thr399Ile) and confirm the association with atopy-
related phenotypes in the Singaporean Chinese group. 
 
6.2 Results 
6.2.1 TLR4 sequence  
In order to investigate the polymorphisms of TLR-4, the sequence of TLR-4 was acquired 
from: http://www.ncbi.nlm.nih.gov, and the Genbank accession number was AF 177765. 















The following is the genomic structure and relative positions of the polymorphisms at 
TLR-4 gene. 
  









6.2.2 PCR results 
A total of 117 unrelated Singapore Chinese residents, aged from 9 to 72 years, with a 
mean age of 31.7±11.7 years, were investigated.  Among them, 66 subjects were atopic, 




Figure 44. TLR4 PCR results. The size of PCR product is 496bp. 
 
 
6.2.3 Sequence analysis of the TLR4 polymorphisms 
 
Sequencing reactions were carried out using standard protocol. In all subjects, we could 
not find any polymorphisms at TLR Asp299Gly and Thr399Gly in Chinese population. 
Since these two polymorphisms could not be detected in 117 samples in the Chinese 
group, we did not do more samples about these polymorphisms (Figure 45).  
 
              
 
Figure 45. TLR4 sequencing results. A: AA homozygote at amino acid position 299. B: CC 






In all the 117 subjects, we were unable to identify polymorphisms at either TLR 
Asp299Gly or Thr399Ile. It appeared that the allele frequencies of the mutation at these 
two positions were rare (lower than 1%) in the Singaporean Chinese population. This 
study indicated that all sequenced samples had Asp at amino acid 299 and Thr at amino 
acid 399 (Figure 56). In addition, we were unable to detect any polymorphism within the 
DNA fragments that were amplified and sequenced in this study.  
 
Allele frequencies of TLR4 Asp299Gly and Thr399Ile were also found to be low in other 
published studies. Asp299Gly was present with frequencies between 3.3% and 9.4%, 
while Thr399Ile was between 3.7% and 11% in several Caucasian studies (Table 48). A 
study performed in 32 asthmatic Japanese showed that Gly299 variant was undetectable 
in all patients (Noguchi et al., 2004). In another Japanese study, the Asp299Gly allele of 
the TLR4 gene was undetectable in any of the specimens from 107 healthy volunteers 
and 168 patients with various diseases (Okayama et al., 2002). From available data, it 
seemed that the polymorphisms of TLR4 at amino acid position of 299 and 399 were rare 
in Asian population. 
 
Exposure to bacterial endotoxin has received considerable attention as a potential risk 
factor for development of asthma and atopic diseases (Schwartz , 2001). As a receptor for 
LPS, TLR4 is one of the most commonly investigated candidate genes for studying 
interaction between genetic variation and environmental factors for development of 
atopic or atopy-related diseases. Although associations between polymorphisms of 
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Asp299Gly and Thr399Ile at TLR4 gene and atopic diseases have been reported by some 
studies, they may not be the key players in development of atopic phenotypes. Otherwise, 
we could expect to confirm these polymorphisms in different population since allergic 
disease is a common disease worldwide.  
 
TLR4 is a candidate gene for atopic diseases because of its important biologic 
characteristics. It is possible that polymorphisms at other positions of TLR4 might play an 
important role in atopy-related phenotypes and this is in combination with the 
environmental exposure of bacterial endotoxin. Alternatively, it is also possible that 
genetic susceptibility to asthma and atopic-related phenotypes might be different in 
various populations. This notion was supported by the recent genome-wide studies for 
identifying the asthma susceptibility loci in ethnically diverse populations (Xu et al., 
2001; Hakonarson and Halapi, 2002). In view of the conflicting evidences, future studies 
are needed to identify the key genes for atopic phenotypes and to investigate the 
interaction between the genetic and environmental factors influencing the complex trait 
of allergic diseases. 
  
In summary, we were unable to detect the polymorphisms at Asp299Gly or Thr399Ile of 
TLR4 in the Chinese group. Our results suggested that these two polymorphisms in TLR4 









ASSOCIATION BETWEEN IL-18 POLYMORPHISMS AND ATOPY 
 
 
7.1 Introduction  
 
Allergic asthma is thought to be regulated by Th2 cells. IL-4 is essential for Th2 
development while IL-12 induces Th1 development, both of which can be enhanced by 
IL-18 (Mosmann and Coffman, 1989; Krug and Frew, 1997; Yoshimoto et al., 1997). On 
the other hand, according to hypotheses of hygiene, environmental factors may influence 
the postnatal development of immune systems. As potential stimulus of IL-18 protein 
secretion, LPS mediates IL-18 expression and secretion which was CD14-dependent 
(Manigold et al., 2000). 
 
7.1.1 Role of IL-18  
 
Interleukin-18, a member of the IL-1 family, is a cytokine that was found to be an IFN-γ-
inducing factor (Okamura et al., 1998; Nakanishi et al., 2001). IL-18 was first purified 
from the sera or the extracts of liver tissues of mice (Okamura et al., 1995). IL-18 mRNA 
is expressed in a wide range of cells including Kupffer cells, macrophages, T cells, B 
cells, dendritic cells, osteoblasts, keratinocytes, astrocytes and microglias (Nakanishi et 
al., 2001).  IL-18 is synthesized as an inactive 24-kDa precursor (proIL-18), which is 
cleaved into 18-kDa mature IL-18 by active form caspase-1 (casp1) or casp1-like 
enzymes induced by stimulation with LPS or FasL respectively (Nakanishi et al., 2001). 
After TLR4 is activated by LPS via LPS-binding protein (LBP), casp1 is activated 
independently of MyD88.  In addition, LPS-induced accumulation of pro-caspase-1 and 
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proIL-18 requires MyD88-dependent signaling (Ulevitch, 1999; Nakanishi et al., 2001). 
LPS-induced activation of casp1 leads to secretion of biologically active IL-18 (Gu et al., 
1997; Ghayur et al., 1997). Therefore, the active IL-18 has close relationship with LPS 
and TLR4. 
 
Th1    Th0     Th2 
 
 NK  Th1  B cell      Th2         Basophil &Mast 
  
IFN-γ      IL-4, IL-13 
 
    Virus &Tumor Macrophage  IgG   IgE 
        Basophil&Mast cells 
 
  Defense/ tissue injury           Allergy 
 
Figure 46. The role of IL-18. IL-18 stimulates Th1 and Th2 response depending on its 
cytokine milieu. IL-18, in collaboration with IL-12, strongly induces Th1 cytokines such 
as IFN-γ, while in combination of IL-2, strongly induces Th2 cytokines such as IL-4 and 
IL-13. 
 
The function of IL-18 is very complicated and heterogeneous. It is known that IL-18 
influences the balance of Th1/Th2 immune response. On the one hand, IL-18, in 
collaboration with IL-12, strongly induces type I cytokines such as INF-γ leading to the 
production of molecules destructive to tissues, including nitric oxide, reactive oxygen 
species and TNF-α (Holla, 2003). For example, coadministration of IL-12 and IL-18 is 
IL-18 +IL-2 IL-18+IL-12 
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associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia 
and serum IgE level (Hofstra et al., 1998). On the other hand, without help from IL-12, 
IL-18 induces the production of Th2 cytokines from T cells, NK cells and basophils/mast 
cells (Nakanishi et al., 2001). For example, IL-18 can directly stimulate IL-4 release from 
basophiles (Yoshimotor et al.,  1999), increase IL-13 production from both NK and T 
cells in synergy with IL-2 (Hoshino et al., 1999) and induce IgE expression in B cells 
(Yoshimoto et al.,  2000). Therefore, IL-18 can enhance the IL-12-driven Th1 immune 
responses, and can also stimulate Th2 immune responses. IL-18 is a kind of cytokine that 
stimulates both Th1 and Th2 responses depending on its cytokine milieu and regulates 
both innate immunity and acquired immunity (Nakanishi et al., 2001). Figure 46 
summarizes the role of IL-18 in development of inflammation and allergy. 
 
Some studies have been carried out on the role of IL-18 in atopic disorders recently. 
Hofstra et al. showed that IL-12/IL-18 treatment can inhabit the development of Th2 cells, 
which is associated with decreased IgE levels, inhabitation of airway 
hyperresponsiveness and eosinophilic infiltration in a mouse model of allergic asthma 
(Hofstra et al., 1998). Previous study also demonstrated that IL-18 regulated IgE 
production in vivo in the absence of allergen (Yoshimoto et al., 2000). In addition, it was 
found that daily administration of IL-18 induces a dose-dependent increase in serum IgE 
levels in mice, furthermore, transgenic mice overexpressing IL-18 spontaneously has 
high serum levels of IgE and IL-4 (Hoshino et al., 2001). Collectively, these results 
indicate that IL-18 has the potential to initiate Th2 responses and upregulate IgE 
production. Elevated serum levels of IL-18 were also reported in patients with asthma, 
atopic dermatitis and allergic rhinitis (El-Mezzein et al., 2001; Wong et al., 2001; Tanaka 
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et al., 2001; Verhaeghe et al., 2002). Therefore, it might be plausible that genetic 
variations within the IL-18 gene might influence TH2 responses and predispose to 
exaggerated IgE production to specific allergens.  
 
7.1.2 Current studies on IL-18 polymorphisms  
 
The human IL-18 gene is located on chromosome 11q22.2-22.3 (Locus ID 3606, NCBI) 
close to the marker D11S927. It is composed of six exons and five introns spanning about 
19.5 kb. Importantly, linkage of this marker to the phenotype of sensitization to mite 
allergen’ has been shown recently (Kurz et al., 2000). A genome-wide search for atopy 
susceptibility genes has identified chromosome 11q22 as an important candidate region 
for atopy susceptibility (Koppelman et al., 2002).  In mouse model of allergic disorders, a 
genome-wide screen found evidence for linkage of the allergic phenotypes in 4 loci 
homologous to 5 human regions, including chromosome 11q22 (Zhang et al., 1999). 
Therefore, genetic variations within the IL-18 gene might be responsible for the observed 
linkage between 11q22 and atopy susceptibility. 
 
In 2001, five single nucleotide polymorphisms were first detected in the promoter and in 
the 5’-nontranslated region of the gene and all IL-18 promoter alleles were found to have 
clear promoter activity when inserted into a luciferase reporter vector (Giedraitis et al., 
2001). In 2003,  polymorphisms in exon 1 +113/ T to G, +127/ C to T and in promoter 1 
–137/G to T (GATA3 site) of the IL-18 gene were reported to be significantly associated 
with high IgE levels (P ≤ .005). The polymorphism +127/ G to T in exon 1 was also a 
susceptibility locus for seasonal allergic rhinitis (P =0.008) (Kruse et al., 2003). In 2004, 
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polymorphisms of IL-18 were confirmed to be related with IgE phenotypes (Nieters et al., 
2004). According to these current studies, it seems that polymorphisms of IL-18 have 
association with total IgE levels and atopic phenotypes. However, there have been just a 
few association studies between polymorphisms of IL-18 and atopic diseases, which is 
listed in Table 48. 
 
Table 48. Summary of association studies on IL-18 polymorphisms 
 
 
7.1.3 Objectives  
The objective of this study was to investigate the association of polymorphisms of IL-18 
promoter at position -137, +113 and +127 with the phenotypes of atopy in Singapore 
population, including Chinese, Malays and Asian Indians. In addition, the transcriptional 










-137C   113G   127T Yes 
/No 
Diseases for comparison 
Kruse et al., 
(2003) 
Germany 105 28.3%       27.4%       25.9%    Yes Allergic rhinitis 
Stassen et al., 
(2003) 
USA 66 21% Yes Sepsis. (haplotype of -607  
and -137) 
Nieters et al., 
(2004) 





Yes Elevated IgE phenotype 
Takada et al., 
(2002) 














           Malay: 17-34 
           Indian: 11-12%   
No Rheumatoid Arthritis  
Ide et al., 
(2003) 
Japan 235 11.4% No Diabetes and 
Autoimmune 
Thyroid Disease 
Janssen et al., 
(2004) 
Dutch  133 24.1% No Sarcoidosis 
Heinzmann  
et al., (2004) 
Germany 321 
children 
25-29%   25-29%   25-29% No Asthma and juvenile 
idiopathic arthritis  
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activity of IL-18 promoter polymorphisms was investigated in four cell lines including 
HepG2, THP-1, U937 and Hela. 
7.2 Results 
7.2.1 IL-18 sequences 
Genbank accession numbers of IL-18 are AB015961 and BC007461, and Known 
polymorphisms are showed in bold and position number. The primers were designed 































7.2.2 Sequence analysis of the IL-18 polymorphisms 
 
The polymorphisms of IL-18 promoter at position -137, +113 and +127 were identified 
by sequence analysis in 388 subjects (249 Chinese, 46 Malays and 93 Asian Indians). The 





Figure 47. IL-18 PCR results. M stands for DNA markers. S1-S7 are samples. The size of DNA is 
906bp. 
 
Sequencing reactions were conducted using the standard protocol. Forward primer, 5’- 







-137            
Exon1 Exon 5 Exon 4 Exon 6 
G/G 
+113          
C/T 
+127           
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polymorphisms at position -137, +113 and +127 of IL-18 were identified in our 
population. Figure 48 and 49 show the results of the sequencing.  
 
 
Figure 48. IL-18/-137 sequencing results. A: Homozygote of IL-18/-137GG; B: Heterozygote of 

















 A. Homozygote of 
IL-18/-137GG 
B. Heterozygote of  
IL-18/-137GC 





Figure 49. IL-18/ +113 and IL-18/+127 sequencing results. A: Homozygote of IL-




7.2.3 IL-18 polymorphisms 
 
Using the direct PCR-sequencing method, we detected the 3 known (-137, +113 +127) 
polymorphisms at the IL-18 5’-UTR. The genotype frequencies of all the three 
polymorphisms were in agreement with the Hardy-Weinberg equilibrium. Table 49 
shows that no significant difference in the genotype frequencies of the polymorphisms 




A. Homozygote of 
IL-18/+113TT& 
+127CC 









Table 49. Genotypes distribution of IL-18 polymorphism at amino acid 27 in non-
atopic and atopic subjects and Hardy-Weinberg equilibrium 
 
A perfect linkage disequilibrium (D’=1; r
2
=1) was found among these three loci of IL-18 
5’-UTR (Table 50). That is to say, three polymorphisms were in complete linkage 
disequilibrium with only two haplotypes: <IL-18/-137G, +113T, +127C> and <IL-18/-
137C, +113G, +127T>. Therefore, these three polymorphisms had similar allele 
frequency. The frequency of -137T, +113T and +127C was the same in three ethnic 
groups (Table 51). 
Table 50. Pair-wise linkage disequilibrium of IL-18 
all pairs of loci of 
IL-18 







IL-18/+113   D’=1 
r2=1 
 
Table 51. Comparison of IL-18 allele frequency among three different ethnic groups 










Non-atopy z-test  
    (p-value) 
Atopy z-test 
      (p-value) 
Non-atopy  87.3 12.7% Chinese 
 Atopy 85.5 14.5% 
Non-atopy 82.6 17.4% Malays 
Atopy 87.5 12.5% 
Non-atopy 80.2 19.8% Asian 
Indians Atopy 78.4 21.6% 
Chinese & Malay 
z= 0.632, NS 
Chinese & Indian 
z= 1.140, NS 
Malay & Indian 
z= 0.280, NS 
Chinese & Malay 
z= 0.346, NS 
Chinese & Indian 
z= 1.272, NS 
Malay & Indian 
z= 1.224, NS 
IL-18 polymorphisms Chinese 
Non-atopy   atopy 
71              179 
Malays 
Non-atopy   
atopy 
23              24 
Asian Indians 
Non-atopy   
atopy 
43              51 
–137/GG; +113/TT; +127/CC 53 132 16 19 28 32 
-137/GC; +113/TG;  +127/CT 18 42 6 4 13 16 
–137/CC; +113/GG; +127/TT 0 5 1 1 2 3 












p value 0.356 0.728 0.953 
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7.2.4 Association between IL-18 polymorphisms and tIgE levels 
 
We subdivided the study subjects into atopic and non-atopic groups, and analyzed the 
association between the IL-18 polymorphisms and serum tIgE levels. Our results 
suggested that there was no association between the 3 polymorphisms and tIgE among 
atopic patients or non-atopic controls in three Singapore races (Table 52).  
 
Table 52.  Mean of serum tIgE levels (IU/ml) (95% CI of the mean) by IL-18 
genotypes between atopic and non-atopic groups in three races. 
 
      
 
 
       
*Only one subject in this group 
 
7.2.5 Association between IL-18 polymorphisms and atopic phenotypes 
 
Relationship between IL-18 promoter polymorphisms and atopic phenotypes including 
allergic rhinitis and asthma was analyzed among the three ethnic groups. When the 
association of allele frequency with atopic diseases was analyzed, known confounding 
variables were considered. No significant difference between atopic and non-atopic 
groups was found in any subgroups (Table 53). 











































































p value 0.183 0.559 0.995 0.079 0.327 0.701 
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Table 53. Association between IL-18 polymorphisms and atopic phenotypes 
 










Atopy & non-atopy  
Asthma & non-asthma 
Atopic asthma & non-atopic asthma 












Atopy & non-atopy  
Asthma & non-asthma 
Atopic asthma & non-atopic asthma 













Atopy & non-atopy  
Asthma & non-asthma 
Atopic asthma & non-atopic asthma 










7.2.6 Association between haplotypes and atopic phenotypes 
There was perfect linkage disequilibrium between IL-18 promoter polymorphisms. The 
haplotype was calculated using Phase-Standard analysis (version 2.0.2). A total of 2 
haplotypes were found, i.e., <IL-18/-137G, +113T, +127C> and <IL-18/-137C, +113G, 
+127T>. The former was more frequent than the other one, which constituted up to 
86.2%, 85.4% and 79.4% of the Chinese, Malay and Asian Indian subjects. However, 
there was no association between these two haplotypes and atopic phenotypes including 
tIgE concentrations and atopic diseases (Table 54). 
 





-137 +113 +127 
Frequenc
y 











G       T        C 86.2 124 308 Chinese 
C       G        T 13.8 18 50 
0.868 0.704 0.563 0.783 0.565 
G       T        C 85.4 38 44 Malays 
C       G        T 14.6 8 6 
0.182 0.455 0.244 0.301 0.097 
G       T        C 79.4 69 82 Asian 
Indains C       G        T 20.6 17 22 
0.211 0.814 0.772 0.870 0.883 
 184 
 
P1: haplotypes and tIgE level 
P2: haplotypes between atopy and non-atopy 
P3: haplotypes between asthma and non-asthma 
P4: haplotypes between allergic asthma and non-allergic asthma 
P5: haplotypes between allergic rhinitis and non-rhinitis 
 
7.2.7 Functional study  
 
7.2.7.1 Transcription factor binding sites of IL-18 promoter 
The binding sites for transcription factors of IL-18 promoter were analyzed by Match
TM
 
(http://www.gene-regulation.com/pub/programs.html#match). Table 55 shows the result.  
Table 55. Transcription factor binding sites of IL-18 promoter. Tissue specificity of the 
transcription factors stored in TRANSFAC, position, potential binding sites for transcription factors and the 
name of transcription factors.  
  
   
 
1) Best-selection: 
V$CMYB_01   943 (-)  1.000  0.840  ctgCCAACtctggctgct    c-Myb 
           
2) Muscle No match 
                 
3) Immune cells 
V$CEBPB_02     701 (+)  0.865  0.800  agaTTTCAtgaaaa     C/EBPbeta 
 
4) Liver 
V$HNF3B_01  694 (-)  0.930  0.908  gaagaAAAGAtttca     HNF-3beta 
V$CHOP_01   699 (-)  0.882  0.818  aaagaTTTCAtga       CHOP-C/EBPalpha 
V$GATA3_03  699 (+)  0.968  0.945  aaaGATTTca          GATA-3 
V$CEBPB_02  701 (+)  0.865  0.800  agaTTTCAtgaaaa      C/EBPbeta 
              
V$NF1_Q6   934 (-)  1.000  0.962  ccctcctggctGCCAAct      NF-1 
V$NF1_Q6   937 (+)  0.921  0.902  tcCTGGCtgccaactctg      NF-1 
V$NF1_Q6   950 (+)  0.921  0.886  ctCTGGCtgctaaagcgg      NF-1 
V$NF1_Q6   959 (-)  0.905  0.872  ctaaagcggctGCCACct      NF-1 
 
5)Cell-cycle 
V$NF1_Q6  934 (-)  1.000  0.962  ccctcctggctGCCAAct       NF-1 
V$NF1_Q6  937 (+)  0.921  0.902  tcCTGGCtgccaactctg       NF-1 
V$CMYB_01 943 (-)  1.000  0.840  ctgCCAACtctggctgct       c-Myb 
V$NF1_Q6  950 (+)  0.921  0.886  ctCTGGCtgctaaagcgg       NF-1 
V$NF1_Q6  959 (-)  0.905  0.872  ctaaagcggctGCCACct       NF-1 
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The IL-18/-137 polymorphism is located at the binding site for the transcription factor 
GATA-3 and HNF-3beta in liver cells, and it might affect the transcriptional factor 
binding and the IL-18 expression. 
 
7.2.7.2 Selection of suitable cell line 
Since Match
TM
 results showed that the IL-18/-137 polymorphism was located on the 
transcription factor GATA-3 and HNF-3beta binding site in liver cells, HepG2 was selected 
as transfection cell line. IL-18 expression was found with a high level in macrophages 
(Nakanish et al., 2001), so macrophages should be a good cell line for transfection. But we 
do not have the macrophage cell line. To analyze the transcription activity of IL-18 
promoter polymorphisms in different cell lines and with different stimulation, we chose 
THP-1, U937 and Hela as control for studying the IL-18 promoter activity. The three 
observed alleles of the IL-18 promoter region were cloned and transfected into the four cell 
lines (HepG2, U937, THP-1 and Hela).  
 
7.2.7.3 Amplification of the inserted DNA  
 
The IL-18 promoter fragments from two individuals, whose genotypes were homozygous 
for wild-type (-137/G, +113/T, +127/C) and mutation (-137/C, +113/G, +127/T) 
respectively, were amplified using primers 5’-AGT CTC GAG CTC TTT GCT ATC 
ATT CCA GGA A-3’ and 5’-GTA CTG CTA GCT TTC CTC TTC CCG AAG CTG-3’, 
which incorporated the specific cleaving sequence for restriction endonucleases for Sac-I 
and Nhe-I respectively (Giedraitis et al., 2001). The amplified fragment was 909bp and it 
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included three polymorphisms of IL-18/-138, +117 and +127. Figure 50 shows the PCR 
results for the inserted DNA. 
 
 
Figure 50. PCR results of IL-18 inserted DNA. The size for the inserted DNA is 909bp. 
 
 
7.2.7.4 Gel electrophoresis to confirm the inserted DNA 
 
The amplified fragments with different polymorphisms were inserted into pGL3-Basic 
vector and cloned into competent cells. In order to confirm whether the constructed 
plasmids contained the polymorphisms of IL-18, the DNA of constructed plasmids was 
digested with matched restriction enzymes. Agarose gel electrophoresis was used to 
screen the correct plasmids with inserted DNA and PGL3-Basic vector (Figure 51). 
 
                      
Figure 51. Gel electrophoresis to comfirm the IL-18 inserted DNA. W1 and W2 are wild 
type samples and M1 and M2 are mutation samples. 
     
 





After screening, the forward primer 5’- CCT CTG TGA ACC CTG ATC AC -3’ was 
used for sequence analysis to confirm whether the constructed plasmids contained the 
correctly inserted DNA with polymorphisms of IL-18. Sequencing reactions were 
conducted using the standard protocol. 
 
After sequencing results were acquired, Blast was used to test these plasmids with both 
sequencing of pGl-3 and inserted DNA (http://www.ncbi.nlm.nih.gov/blast/bl2seq). The 
results confirmed that the two constructed plasmids contain the PGL-3 vector and 
fragments of IL-18 promoter with different polymorphisms. Figure 52 shows that the 




Figure 52. Sequencing results of  2 constructed plasmids. 
A: Constructed plasmid with wild type haplotype (IL-18 / -137G, +113T +127C); 
B: Constructed plasmid with mutation haplotype (IL-18 / -137C, +113G, +127T). 
 
   
7.2.7.6 Transcription activity of IL-18 promoter polymorphisms 
HepG2, Hela, THP-1 and U937 were transfected by the constructed plasmids and pGL-3-
Basic respectively and the results were expressed as fold increase in relative luciferase 
activity (RLA) of the IL-18 promoter constructed vectors compared to that of pGL3-




B: Constructed Plasmid (IL-18 / -137C, +113G, +127T) 






and U937 cells were repeated 5 times. The data was analyzed by both Paired Samples 
Test and Wilcoxon Signed Ranks Test, and the p value of Wilcoxon Signed Ranks Test is 
shown in Table 56-59. 
 
7.2.7.6.1 RLA result of HepG2  
HepG2 cells were transiently transfected 8 times with one of the two constructed plasmid 
and a control Renilla luciferase reporter plasmid (pRL-CMV, promega) using 
lipofectamine 2000. The pGL3-Basic vector without DNA insertion was used as negative 
control of transfection. After 6-8 hours of transfection, transfected cells were stimulated 
with/without LPS (100ng/ml; Sigma-Aldrich) or PMA (100ng/ml; Sigma-Aldrich) for 
16-18 hours before measuring the luciferase activity. The results suggested that there be a 
significant difference in promoter activity between wild type (IL-18 / -137G, +113T, 
+127C) and mutation (IL-18 / -137C, +113G, +127T), and the mutation made the RLA 
obviously decrease in all the cases with LPS or PMA stimulation or without any 
stimulation (p=0.036, 0.036, and 0.012, Table 56). However, LPS or PMA stimulation 
did not create any significant difference in RLA in contrast with that without stimulation.  




7.2.7.6.2 RLA result of Hela 














Times 8 8 8 8 8 8 
Mean 114.2  65.3 117.4 58.5 122.6 56.5 
Std. Deviation 49.5 11.7 49.5 19.7 68.9 6.7 
 P value  0.036 0.036                  0.012 
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Hela cells were transiently transfected 8 times with one of the two constructed plasmids. 
The procedure was as the same as that of HepG2 cell line. There was also a significant 
difference in promoter activity between wild type (IL-18 / -137G, +113T, +127C) and 
mutation (IL-18 / -137C, +113G, +127T). Not as in the result of HepG2, mutation made 
the RLA increase in all the cases with or without LPS or PMA stimulation (p=0.036, 
0.036, and 0.017, Table 57). In addition, RLA significantly increased with PMA 
(p=0.012) in wild type, and not in mutation type, while LPS stimulation did not create 
any significant difference in RLA in both wild type and mutation type.  
 




       * Comparison between wild and wild PMA, p=0.012 
  
 
7.2.7.6.3 RLA result of U937  
U937 cells were transiently transfected 5 times with one of the two constructed plasmids and 
a control Renilla luciferase reporter plasmid (pRL-CMV, promega) using electroporation.  
After 6-8 hours of transfection, the transfected cells were stimulated with/without LPS 
(100ng/ml; Sigma-Aldrich) for 16-18 hours before measuring the luciferase activity. Because 
PMA made THP-1 and U937 adhere to flask walls, only LPS was used as stimulator. There 
was no significant difference in the promoter activity between wild type (IL-18/-137G, 
+113T, +127C) and mutation (IL-18 / -137C, +113G, +127T). However, the prompter 














Times 8 8 8 8 8 8 
Mean 39.8 57.8 47.2 58.5 40.9 59.6 
Std. Deviation 5.5 13.3 8.0 18.4 6.8 15.7 
 P value  0.036 0.036 0.017 
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activity for either wild type or mutation decreased with LPS stimulation (p=0.043). It seems 
that the LPS can reduce the promoter activity (Table 58).  
 












* comparison between wild and wild LPS: p=0.043 
# comparison between mutation and mutation LPS: p=0.043 
 
7.2.7.6.4 RLA result of THP-1 
THP-1 was transiently transfected 5 times with one of the two constructed vectors 
respectively. The procedure was as the same as that of U937. The results also suggested that 
there be no significant difference in promoter activity between wild type (IL-18/-137G, 
+113T, +127C) and mutation (IL-18/-137C, +113G, +127T), and that LPS stimulation did 
not create any significant difference if the same transfected cell lines were compared (Table 
59).   





















Times 5 5 5 5 
Mean 110.4 110.0 62.7 74.8 
Std. Deviation 43.5 23.3 24.9 38.1 
 P value  0.893 0.345 










Times 5 5 5 5 
Mean 42.9 39.5 46.8 42.2 
Std. Deviation 15.9 22.1 17.6 23.8 
 P value  0.893 0.686 
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The RLA results in the four cell lines were summarized in Figure 53, and it shows that 
the promoter of IL-18 has strong transcriptional activity. All the luciferase activity of the 
cells transfected by the constructed plasmids including promoter of IL-18 was obviously 
higher than that of the negative control. Some RLA was even 100 times higher than that 
of the negative control. The data demonstrated that the transcriptional activity of IL-18 
polymorphisms was different in different cell lines. With different stimulation, IL-18 





























































































Figure 53. Luciferase reporter assay for human IL-18 promoter region.  The 909 bp 5’ 
flanking fragments with wild type (–137/G, +113/T, +127/C) or mutated (–137/C, +113/G, +127/T) 
human IL-18 genotype were inserted into the luciferase reporter plasmid pGL3-Basic. RLAs were 
normalized by Renilla luciferase activities and compared to the negative pGL3 control vector. The pGL3 
plasmid containing the SV40 promoter and enhancer served as a positive control. All assays were repeated 





Recent studies have suggested the association of genetic polymorphisms of human IL-18 
gene with both Th1- and Th2-mediated chronic inflammatory diseases.  In this aspect, the 
association of genetic polymorphisms of human IL-18 gene with atopic phenotypes, such 
as elevated serum total IgE levels and sensitization to common allergens, has been 
reported. In this study, we screened the genetic polymorphisms of the human IL-18 
promoter region in the subjects with atopic phenotypes and normal controls, and 
identified three common polymorphisms (-137, +113 and +127) within the IL-18 gene 
promoter region. 
 
Furthermore, we investigated the association of the three common polymorphisms within 
the IL-18 promoter region with prevalence of atopic phenotypes and serum total IgE 
levels in Singaporean Chinese, Malays and Indians. In conflict with previous reports 
(Kruse et al., 2003; Higa et al., 2003; Heinzmann et al., 2004), we did not find any 
association of these three polymorphisms with prevalence of atopic phenotypes or serum 
total IgE levels in our population. Such conflicting results are normally observed in 
association studies based on populations with different ethnic backgrounds.   
 
The results suggested that no allele frequency difference be found among the three races 
in Singapore. In our study, the mutation allele frequency (mutation: -137C, 113G, 127T) 
in the non-atopic subgroup was 12.7% in Chinese, 17.4% in Malays and 19.8% in Asian 
Indians. According to previous reports from other ethnic populations, the mutation allele 
frequency of IL-18 was 21% in USA, 23% in Germany, 24.1% in Dutch and 11.4% in 
 195 
Japan (Stassen et al., 2003; Kruse et al., 2003; Janseen et al., 2004; Takada et al., 2002). 
This indicates that there is no significant difference in the mutation allele frequency of 
IL-18 5’-non-trnaslated region between Asian populations and western populations. 
 
Our negative association result cannot exclude that atopic diseases might be just 
influenced by the opposing effects of IL-18.  IL-18 represents a pleiotropic cytokine with 
varying and sometimes opposing effects in the pathogenesis of diseases. For instance, it 
was proposed that IL-18 might initiate bronchial asthma through enhanced serum IgE and 
Th2 cytokine levels. At the same time, IL-18 exhibits some protective roles in 
development of bronchial asthma, especially in conjunction with Th1 cytokine such as 
IL-12. Atopic diseases represent a kind of complex and varying clinical pictures with 
varying cytokine milieus, depending on respective activities of the diseases. Thus, it is 
reasonable to suggest that the opposite effects of IL-18 might be exhibited on the atopic 
phenotypes due to the varying cytokine milieus in the course of atopic diseases. 
Therefore, although the association of IL-18 promoter polymorphisms was negative, 
functional studies for these polymorphisms were conducted in vitro due to the 
complicated roles of IL-18. 
 
Functional studies of the identified IL-18 variants were evaluated using luciferase 
reporter gene assay. RLA was used to quantify the effects of IL-18 promoter 
polymorphisms. HepG2 cell line was chosen since IL-18 is constitutively expressed 
(Okamura et al., 1995). For HepG2 cell line, there was a significant difference in 
promoter activity between wild type (IL-18 / -2137G, +113T, +127C) and mutation (IL-
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18 / -137C, +113G, +127T). With or without stimulation, the plasmid containing the 
wildtype IL-18 genotype yielded significantly higher luciferase activity in HepG2 cells 
(p=0.036, 0.036 and 0.012). The reason might be that the change of G to C especially at 
position -137 affected the transcription factor binding and made the promoter 
transcription activity decrease. The result of HepG2 confirmed that polymorphisms in the 
IL-18 promoter region might affect its expression. This result was in agreement with 
previous studies in that the common IL-18 promoter polymorphisms influenced the 
expression of IL-18 (Giedraitis et al., 2001).  
 
However, similar result could not be found for Hela, U937 and THP-1. There was no 
significant difference in promoter activity between the polymorphisms of IL-18 promoter 
in U937 or THP-1 and the result of Hela cell line was even the contrary. The reason for 
the inconsistency in the cell lines may lie in the fact that the effect of the polymorphisms 
on transcription activity might be highly tissue or cell specific and it might require a 
highly specific stimulus. This concept has been demonstrated by Kroeger KM and his 
colleagues when they studied the polymorphisms of the tumour necrosis factor at position 
-308G/A (Kroeger et al., 2000). HepG2 cell line was considered as the most suitable for 
studying the promoter activity of IL-18 as IL-18 is constitutively expressed in liver cells 
(Okamura et al., 1995). Furthermore, IL-18 promoter was analyzed by Match
TM
, which is 
designed for searching potential binding sites for transcription factors (TF binding sites) 
including the tissue specificity of the transcription factors stored. The results showed that 
the polymorphism of IL-18/-137 is located exactly at the two transcription factor binding 
sites in liver cells, one is HNF-3beta (AAAGA) and the other is GATA-3 (GATTT). 
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Therefore, when we studied the effect of the promoter polymorphism by reporter gene 
assay, the first and the most important thing was to choose the suitable cell line for 
transfection. In addition, the interaction between the promoter and the 3’ untranslated 
region might affect the level of transcription. In a study of the promoter polymorphism of 
tumor necrosis factor alpha gene, -308A allelic form gave a two-fold greater level of 
transcription than the -308G form only in the presence of the tumor necrosis factor, i.e., 
alpha 3’ untranslated region (Kroeger et al., 1997). The role of 3’ untranslated region of 
IL-18 was not addressed in this study, which might also contribute to the different results 
in the different cell lines. 
 
Recent studies have elucidated the functional regulation of the IL-18 gene in human cell 
lines. Human IL-18 possesses only a single promoter 5’ upstream of the first exon.  
Within the promoter region, two regulatory sites, a consensus PU.1 binding site and a 
GC-rich site are required for basal IL-18 promoter activity in human cell lines (Koyama 
et al., 2004). In addition, a 108 bp of the promoter region is sufficient for constitutive 
promoter activity in the human cell lines. Subsequently, DNA protein binding 
experiments revealed specific binding of STAT 5 to three consensus sequences upstream 
in the promoter region (Kalina et al., 2000).  Taken together, these data indicate that IL-
18 promoter polymorphisms may influence the expression of IL-18 and potentially STAT 
signaling pathway.  
 
Although we found the polymorphisms of the IL-18 promoter could make a difference in 
transcription activity, there was no relationship found between these polymorphisms and 
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atopy-related phenotypes. It is known that atopy may be regulated by interaction of 
multiple genes and multiple environmental factors, and the difference of ethnicity, 
environment and age may affect the results. According to hypothesis of endotoxin switch, 
a dose-dependent relationship exists between environmental exposure to bacterial 
products and the outcome of the immune responses (Vercelli, 2003). Quantity of 
environmental endotoxin may also affect the balance of Th1/Th2 cytokine levels. Even if 
IL-18 may play an important role in the allergic procedure, other genes, such as CD14, 
IL-4, IL-12 and IL-13 and so on, may be also involved in this complex pathophysiology 
stage. Therefore, one or two genetic variations might not be sufficient to cause diseases 
when taken individually. On the other hand, we could not exclude that the other 
polymorphisms of IL-18 might relate with atopic-related phenotypes. For example: the 
IL-18 polymorphism 105A/C was reported to be associated with asthma in Japan a 
population (Higa et al., 2003). 
 
The discordant results between our association and function study could be due to the 
following two reasons:  i) the effects of the functional sites could have been masked by 
other genes and environmental factors in vivo as atopy and asthma are polygenic traits 
with multifactorial etiology; ii) heterogeneous outbred populations were used in the 
association study and it may be difficult to detect the effects of the functional sites from 
individuals with different genetic and environmental background. 
 
In conclusion, herein we reported the identification of the three polymorphisms in the 
human IL-18 promoter region in our subjects, patients with atopic phenotypes and 
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controls. Although these polymorphisms appeared to have no association with atopic 
phenotypes in our population, subsequent functional studies suggested that 
polymorphisms in the IL-18 promoter region could significantly affect its activity. The 
effect of the IL-18 polymorphisms within the promoter region in the immunologic 
context of diseases such as atopic disorders might be too complex to be reflected in a 
simple one-way association study. In addition, it was confirmed that the polymorphisms 

























The association study has been used widely to identify regions of the genome and 
susceptibility genes that contribute to atopic diseases. In this study, we investigated the 
association between the candidate genes and atopy-related phenotypes in the Singapore 
population, and no significant association could be found among them. However, in our 
functional study, we found the polymorphisms of IL-18 could affect the transcriptional 
activity in in vitro experiments although no significant effect was observed in our 
association study. Because predisposition to atopy is influenced by a complex immune 
procedure, the effect of one gene or one polymorphism might be not strong enough to be 
reflected in the association study.  
 
Because the true effect could be masked by other genetic factors, gene-gene interaction 
was evaluated in many studies recently. For example: the interaction between CTLA4 
and FCER1B was reported to influence total serum IgE levels in patients with asthma. 
The analysis of -318C/T (at CTLA4) and -109C/T (at FCER1B) promoter 
polymorphisms showed a significant correlation between the combined genotypes and 
increased levels of total IgE in patients with asthma (P =0.000014) (Hizawa et al., 2001). 
In 2002, the interaction between IL4RA and IL13 was demonstrated to markedly increase 
the susceptibility to asthma (Howard et al., 2002). In 2004, the association between 
specific serum IgE response and 6 variants within the genes IL4, IL13 and IL4RA was 
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performed in German children (Liu et al., 2004). In 2005, the interaction between IL-5 
and TBXA2R genes was suggested to contribute to the severity of asthma, especially 
atopic asthma in Korean children (Hong et al., 2005).  All these studies indicate that 
different combinations of susceptibility genes may play a role in development of atopic 
diseases. Therefore, a strategy for searching multiple susceptibility genes for atopic 
diseases should be considered. In this chapter, possible interaction among the genes 
studied in this project and atopic phenotypes were analyzed by Standard tools for 
haplotypes, Chi-square and ANOVA.  
 
The use of haplotypes in association study is increasingly important, especially when 
there are multiple genetic markers within a candidate gene (Horvath et al., 2004). The 
three primary reasons for considering haplotype organization of polymorphisms are: 1) 
that the unit of biological function, the protein-coding gene, produces proteins whose 
sequences correspond to maternal and paternal haplotypes; 2) that variation in a 
population is in fact structured into haplotypes that are likely to be transmitted as an unit; 
3) that regardless of the population genetic reasons, haplotypes serve to reduce the 
dimensionality of the problem of testing association, and so they may increase the power 
of those tests (Clark, 2004). So it is necessary to consider the haplotypes of the 
polymorphisms in candidate genes for atopic diseases, especially when there is no 
association found in the one-polymorphism study.  
 
In this study, we would like to extend the concept of haplotype and assume that all 
polymorphisms were on the same chromosome. The haplotypes were calculated not only 
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in one candidate genes but also in different genes. We grouped all the candidate 
polymorphisms in this study into three groups:  
       (1) The first group, based on the positions, contained all the polymorphisms on 
chromosome 5q31-33, e.g. polymorphisms of CD14, IL-4 and B2AR. In this group, there 
were 7 polymorphisms in Chinese population and 6 polymorphisms in Malay and Asian 
Indian populations (CD14/-550 was only in Chinese population). The number of the 


































) in Malay and Asian Indian groups.  
(2) The second group, based on their biological functions, contained the 
polymorphisms of CD14, IL-4 and IL-18, etc. All of them might play a role in balancing 
of Th1 and Th2. In this group, there were 8 polymorphisms in Chinese population and 7 
polymorphisms in Malays and Asian Indians (CD14/-550 was only in Chinese 









































Malay and Asian Indian groups.  
(3) The third group has only one haplotype containing all the 10 polymorphisms in 
Chinese population and 9 polymorphisms in Malay and Asian Indian populations, and the 
number is 1.  
 
The goal of this chapter was to investigate the association between any polymorphism 
combinations of the candidate genes, such as: CD14/-159, 550, -1145, 1359, IL-4/-590, 
B2AR at amino acid 16 and 27, and IL-18/-137, +113, +127 and the risk of atopy-related 
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phenotypes. The haplotypes in group 1, 2 and 3 were analyzed by Phase-Standard 
analysis (version 2.0.2, http://archimedes.well.ox.ac.uk/pise/) (Stephens et al., 2001), and 
then the association between haplotypes and atopy-related phenotypes including tIgE 
levels, atopic asthma and allergic rhinitis were determined.  
 
8.2 Results 
8.2.1 Association between haplotypes and tIgE levels 
Table 60 lists the haplotypes, each of which is associated with the tIgE levels with a p- 
value less than 0.05. Notice that for each ethnic group, there is a full haplotype containing 
all the polymorphisms in the race. Table 60 shows that there is no association between 
the full haplotypes and the tIgE levels. For Chinese group, we could find that the 
polymorphism of CD14/-550 seemed to play an important role in IgE levels. The smallest 
p-value is 0.007 for the haplotype, <CD14/-550, IL-4/-590, IL-18>, among all those 
containing CD14/-550. The results also demonstrated that haplotypes with CD14, IL-4, 
IL-18 and B2AR could affect tIgE levels. For Malay group, the haplotypes with CD14 
and B2AR in the position subgroup could affect tIgE levels, with the p-values ranging at 
0.035-0.047, and the haplotypes with CD14/-1145 and IL-18 in the function subgroup 
could affect tIgE levels with the p-values as 0.036. For Asian Indians, only haplotypes 






Table 60. Association between haplotypes and tIgE levels (significant results) 
 



































































































































Full haplotype 159_1145_1359_590_16_27_137_113_127 NS 
   
* NS stands for no significant association. 
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8.2.2 Association between haplotypes and atopic diseases 
 
 
Table 61 shows the association between haplotypes and atopic diseases. In all races, no 
association could be found between the haplotypes and allergic rhinitis. On the other 
hand, all the full haplotypes had no association with atopic diseases. In Chinese and 
Malay groups, some haplotypes could be related with atopy, asthma and allergic asthma, 
while for Asian Indians, only atopy and allergic asthma could be associated with some 
haplotypes. 




Diseases Gene combination haplotype p-value 










































































































































































































































































































atopy 1359_590_16 0.048 












atopy NS NS 































The candidate gene approach has been widely used for searching susceptibility genes for 
atopic diseases. But until now, the genes related with the risk of atopic diseases are still 
unknown. The strategy for candidate gene identification of complex diseases should 
consider multipoint polymorphisms. In this study, we extended the concept of haplotype 
and assumed that all the polymorphisms which we had studied were on the same 
chromosome. The objective of this chapter was to investigate the association between the 
haplotypes and atopy-related phenotypes in the three races of Singapore population. 
 
The results showed that haplotype analysis seemed helpful to detect the role of 
susceptibility genes for atopic diseases. The results may suggest: (1) Polymorphisms of 
CD14, IL-4, IL-18 and B2AR might be not susceptibility genes for allergic rhinitis. (2) All 
these polymorphisms might have association with IgE levels, atopy, asthma and allergic 
asthma. (3) Susceptibility genes for atopic diseases in different races might be different. 
(4) Some kinds of gene-gene interactions might be related with atopic phenotypes.   
 
One problem worth considering is the sample size. A simulation study suggested that 
genes with minor effects were not likely to be detectable by association studies in sample 
size of less than 500 (Long and Langley, 1999; Palmer and Cookson 2001). Sample size 
might be a limitation in this study. In addition, the gene-gene interaction should be 
considerated. The combinations of alleles at a variety of candidate loci might be more 
important than the variants that are found at any single locus in conferring the risk of 
having atopic diseases. However, the objective of this chapter was only to test a new 
method to analyze the association data. We suggested that the polymorphisms could be 
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combined not only within the same chromosome region but also by similar biologic 
functions. The haplotype analysis based on these combinations may be helpful to find 
susceptibility genes for atopic diseases.  
 
In summary, although individual genes may appear unrelated with atopic phenotypes, 
haplotypes with combinations of genes may be associated with them, which suggests that 
gene-gene interaction is very important for uncovering the genetic background of atopy 
and atopic diseases.  
 































            
CONCLUSIONS 
 
Because of the complex mode of inheritance, the genetic predisposition of atopy and 
atopic diseases is still not completely understood. This study investigated the relationship 
between the 12 candidate gene polymorphisms (CD14/-159,-550,-1145 and -1359; IL-
18/-137, +113 and +127; B2AR at the amino acid position 16 and 27, IL-4/-590 and TLR-
4 at the amino acid position 299 and 399) and atopic phenotypes in Singapore population, 
including Chinese, Malays and Asian Indians, and determined whether CD14 and IL-18 
promoter polymorphisms affected transcriptional activity using in vitro experiments. The 
conclusion for this study includes the following. 
 
1. Genetic susceptibility to atopy and atopic diseases might be different in various 
populations. 
 
In this work, polymorphisms we studied include CD14 at position -159, -1145, -1359, -
1619; IL-4 at -590; polymorphisms of IL-18 at position -137, +113 and +127; 
polymorphisms of the B2AR at the amino acid position 16 and 27 and TLR-4 at the amino 
acid position 299 and 399. A novel polymorphism of CD14/-550 was identified in our 
Singapore population. There existed ethnic difference in the distribution of allele 
frequency especially in polymorphisms of TLR-4, IL-4 and B2AR genes. We could not 
detect any polymorphisms of TLR-4 at the amino acid position 299 and 399 in Singapore 
Chinese population although they were reported in other populations. In view of the 
conflicting evidences, further studies are needed to identify the key genes for atopic 
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phenotypes and to investigate the interactions between genetic and environmental factors 
influencing the complex traits of allergic diseases in different populations. 
 
2. No association between these polymorphisms of candidate genes (CD14, IL-4, IL-18 
B2AR and TLR-4) and atopy-related phenotypes, e.g. tIgE level, asthma and allergic 
rhinitis, was found in this study. 
 
Although all the polymorphisms studied in this work were reported to be associated with 
atopic-related phenotypes, the association could not be confirmed in our subject group, 
except the association between CD14 polymorphisms and allergic asthma in Malay. This 
may be because that predisposition to atopy is influenced by a complex immune 
procedure, including interaction of multiple genes, interaction of environmental, genetic 
factors and population heterogeneity, the effect of susceptibility genes in the 
immunologic context of atopic-related phenotypes including serum tIgE level, asthma 
and allergic rhinitis might be very complicated and could not be reflected in our 
association study. 
 
3. The promoter polymorphisms might affect the transcription activity and have cell or 
stimulus specificity. 
 
In in vitro experiments, the polymorphisms of CD14 promoter and IL-18 promoter were 
investigated by reporter gene assay. CD14 polymorphisms seemed to have no obvious 
effects on the transcriptional efficiency. But the polymorphisms in the IL-18 5’ non-
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transcription region were found to have some influence on the transcription activity, and 
it was confirmed that the IL-18 promoter polymorphisms had cell or stimulus specificity.  
 
4. The association between haplotypes of the same gene or even different but 
pathphysiologically related genes and atopic diseases should be considered.  
 
We could find the effect of IL-18 polymorphisms in in vitro experiments but not in the 
association study. The results highlighted the necessity of investigation of gene and gene 
interactions in uncovering the genetic background of atopic diseases.  
 
In this study, we explored the candidate genes for atopy one by one. However, atopy and 
atopic diseases appear to have a heterogeneous etiology. The atopy and atopic diseases 
may be caused by different genetic loci working together, or a predisposing gene may be 
manifest only in the presence of a particular environmental expose. Therefore, identifying 
genetic factors for atopy is quite a challenge.  
 
In recent years, the technology of microarry is developing very fast. DNA microarray 
technology may be defined as a high-throughput and versatile technology used for 
parallel gene expression analysis for thousands of genes of known and unknown 
functions, or DNA homology analysis for detecting polymorphisms and mutations in 
genomic DNA. An array is an orderly arrangement of samples where matching of known 
and unknown DNA samples is done based on base pairing rules 
(http://en.wikipedia.org/wiki/DNA_microarray).  
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On the other hand, the International HapMap Project was launched in Oct. 2002. The 
HapMap is a catalog of common genetic variants that occur in human beings. It describes 
what these variants are, where they occur in our DNA, and how they are distributed 
among people within populations and among populations in different parts of the world. 
All these data document the generality of recombination hotspots, a block-like structure 
of linkage disequilibrium and low haplotype diversity, leading to substantial correlations 
of SNPs with many of their neighbors. An important application of the HapMap data is to 
help make possible comprehensive, genome-wide association studies 
(http://www.hapmap.org; the international HapMap consortium, 2005). This is useful to 
determine the allele frequency in various populations and identify regions of the genome 
associated with atopy.  
 
At present, there are mainly three kinds of microarraies available: (1) expression analysis 
microarray; (2) mutation analysis microarray, and (3) whole-genome analysis microarray. 
All the three microarraies are useful to identify the disease susceptibility genes for atopy. 
For example: firstly, we can use whole gnome analysis microarray to identify the 
susceptibility polymorphisms or genes for atopy; secondly, we can use SNPs microarray 
to confirm the susceptibility polymorphisms or genes by case-control samples, thirdly, 
we can confirm the role of polymorphisms from the cDNA level using expression 
analysis microarray. 
 
Of course, bioinformatics methods might allow prediction of key plausible genes for 
atopy more accurately. Better statistical methods for evaluating the effect of combination 
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of different susceptibility genes should be developed. Eventually, functional study in 
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